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Obesity is one of the biggest public health problemstoday, leading to type II diabetes, 
coronary heart disease, hypertension, sterility and cancer (Hashmi et al., 2013). 
C.eleganshas been used extensively in obesity research to dissect the underlying 
principles. The overarching goal of my thesis has been to identify molecular signatures 
linking phenotypic and molecular responses of the nematode C.elegans to a number of 
experimental conditions that induce alteration in lipid metabolism. More specifically, I 
developed experimental procedures in C.elegans to studythe effects of exercise, diet and 
a C.elegans antiageing drug valproate. Using a modified lipid assay, I found for the first 
time that valproate induce lipid accumulation in C.elegans in a dose dependent manner. 
In this study obesity is induced in C.elegans by treating with either cholesterol or 
sodium valproate. Using microarray technology, expression profiles associated with the 
induction of obesity are studied. In addition, C.eleganswere treated with monosodium 
glutamate which is found to decrease lipid mass. Exercise is a recommendation for 
obese people and hence a C.elegans model system is developed to study effect of 
exercise. Effects of valproate on C.elegans with respect to lipid quantity are studied in 
detail, with emphasis on insulin signalling pathway. Expression changes associated with 
insulin mutants are compared with the valproate exposure expression profile to 
understand how much of the valproate exposure could be explained by insulin 
signalling. I also found for the first time that valproate cause a global down regulation 
of nuclear components. A hypothesis on lipid accumulation on valproate exposure is 
presented. TGF-β pathway is also found to be involved in fat metabolism. Finally I 
report an interesting phenotype  for the first time in which the TGF-β pathway receptor 
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1.0  INTRODUCTION 
 
1.1C.elegans as a model system 
 
C.elegans is a free living nematode found in many countries of the world. It has been 
first adopted as a laboratory strain by Sydney Brenner in 1974(Brenner, 1974)leading to 
the Nobel Prize for Physiology or Medicine in 2002. During the last forty years 
C.elegans has been extensively used in research and some important findings were on 
C.elegans.  
C.elegans can be grown in laboratory conditions with Escherichia coli OP50 strain, a 
uracil auxotroph, as the food source. The population is dominated by hermaphrodites 
(XX) and seldom get males (X0) characterized by the presence of male tail and lack of 
eggs and vulva which are found in the self-fertilizing hermaphrodite. There are four 
larval stages in its life cycle, L1 larva, L2 larva, L3 larva and L4 larva. Eggs hatch into 
LI larva which goes through L1, L2, L3 and L4 larval stages to adult in four days which 
is 1mm long. During food deprivation, presence of dauer hormone, high temperature or 
overcrowding allows this nematode to enter into a third larval arrest stage called dauer 
larva. This larval stage is long lived compared to the normal lifespan of three weeks at 
20
o
C and is resistant to stress. When conditions become good they complete the life 
cycle (Ren et al., 1996). 
C.elegans is genetically tractable and a lot of phenotypic and genotypic data is available 
for these organisms(Hodgkin, 2005). Its genome is known and it is estimated to contain 
~ 19000 genes in five pairs of autosomes and a single pair of X chromosomes in the 
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hermaphrodite (Fraser et al., 2000). The ease of making mutants by chemical (ethyl 
methane sulfonate), physical (ionizing radiation) or RNAi methods and the ability to 
store these mutants as frozen stock for years makes it a good model system to study 
gene functions and genetic interactions(Liu et al., 1999). It is also ethically more 
acceptable to use a lower level animal like C.elegans for the initial stages of research 
rather than using higher-level animals such as monkeys or mouse models. C.elegans 
provides a simple system to study complex gene functions in a multi-cellular organism 
level, which can be extended to understand the homologous mechanisms in human 
system.  
 
1.2 Exercise and diet are well known factors affecting ageing and metabolism in 
living organisms across the tree of life 
 
Food restriction is known to prolong life in yeast, C.elegans, mice and monkey (Young, 
1979). Different dietary restriction methods in C.elegans involve different genetic 
mechanisms and result in varying degrees of life span extensions. These mechanisms 
include genes such as sir-2, TOR, skn-1, hsf-1, eat-2, clk-1, aak-2 and daf-16 (Greer and 
Brunet, 2009). Clinical and epidemiological studies suggest an antiageing and age 
related disease preventive effect of dietary restriction on humans(Kagawa, 1978). 
Several dietary factors are known to reduce age related decline of health. Folic acid and 
antioxidants are known to have a neuroprotective effect(Yu et al., 2009). For example, 
vitamin E reduces lipid peroxidation and protects cells from oxidative 
damage(Suleiman et al., 1996). Creatine increases energetics in muscles and nervous 
system(Andres et al., 2008).Ginkgo biloba extracts improved memory and learning in 
aged mice(Wesnes et al., 2000). Carotenoids such as lycopene and β-carotenes improve 
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memory and reduce risk of heart diseases, cancer and stroke which are implicated in 
ageing (Tapiero et al., 2004).  Methionine restricted diets are found to cause decreased 
insulin and fasting blood glucose levels and increase lifespan of rats (Miller et al., 
2005). Cholesterol synthesis increases with obesity  (MIETTINEN, 1971) and weight 
reduction on a 1000cal diet resulted in lower levels of cholesterol synthesis and 
excretion in human (Bennion and Grundy, 1975). Increase in dietary leucine, which 
activates mTOR (mammalian target of rapamycin) decrease diet induced obesity, 
hyperglycemia and hypercholesterolemia in mice fed with a high fat diet. This is due to 
increased insulin sensitivity, decreased plasma glucogon and glucogenic amino acids 
and down regulation of hepatic glucose-6-phosphatase (Zhang et al., 2007). Several 
dietary factors are associated with age related decline of health. Cholesterol and 
saturated fat impair cognitive function in middle aged people ((Kalmijn et al., 2004). 
Dietary monosodium glutamate increases palatability and neonatal administration 
causes obesity in mice due to diminished energy expenditure (Poon and Cameron, 
1978).  Exercise is also known to improve age related decline of cognitive function 
(Mattson et al., 2002). But exercising of rats did not increase lifespan despite of caloric 
deficit even though dietary restriction of sedentary rats to get the same caloric deficit 
extends lifespan (Holloszy, 1998). Both caloric restriction and exercise have an anti-
inflammatory effect measured by C-reactive protein levels (Kalani et al., 2006). 






1.3C. elegans is a well established model in ageing research 
 
Ageing is an endogenous, progressive, irreversible and deleterious process. Availability 
of assay methods and genetic amenability to produce C.elegans with extended or 
shortened lifespans has made this nematode a good model system to elucidate 
mechanisms underlying ageing. Long lived dauer larval stage provides a simple system 
to study life extending factors (Fielenbach and Antebi, 2008).  
Much research has been carried out in attempting to understand ageing using C.elegans 
as a model system. Involvement of the insulin signalling pathway on lifespan was first 
demonstrated in C.elegans(Kenyon et al., 1993). Insulin signalling pathway mutants 
daf-2 and age-1 are known to have extended lifespans and insulin like signalling in 
neurones alone would restore wild type life span in these mutants (Wolkow et al., 
2000). These mutants require HSF-1((Hsu et al., 2003), DAF-16  activity(Lin et al., 
1997) and autophagy (Hansen et al., 2008)for the extension of life span. Over 
expression of sir-2 also increases lifespan in a DAF-16 dependent manner(Kenyon, 
2005). Accumulation of protein similar to the proteins involved in human 
neurodegeneration is found in ageing C.elegans. The occurrence of insoluble proteins 
and their aggregation is decreased on suppression of insulin signalling (David et al., 
2010). Valproate, which I studied in the present study is a fatty acid which is known to 
extend lifespan via the insulin signalling pathway(Evason et al., 2008). Supporting this 
hypothesis, length of fatty acids in C.elegans and their susceptibility to oxidation are 
found to be negatively correlated with lifespan in insulin pathway mutants (Reis et al., 
2011).  In addition to acting on lifespan, the insulin pathway is implicated in lipid 
metabolism but how valproate affects lipid metabolism is not known. The present study 
aims to fill this gap.  
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Transcriptional response to ageing is studied using C.elegans as a model system (Lund 
et al., 2002). Loss of VHL-1 and HIF-1 activity in C.elegans prolong lifespan in a 
mechanism different from dietary restriction and insulin signalling (Mehta et al., 2009).  
In addition a reduction of ATPsynthase activity and electron transport chain also results 
in longer lifespan (Dillin et al., 2002).  
Insulin resistance is known to play a role in human ageing(Dechenes et al., 1998).  
Reduction in TOR decrease senescence in cultured human cells (Kapahi et al., 2010). 




Obesity is a leading cause for several diseases including cancer, type II diabetes, 
hypertension and coronary heart disease(Chan et al., 1994). In human, there is a 40-70% 
genetic contribution to obesity(Comuzzie and Allison, 1998). Obesity results in when 
the energy expenditure is exceeded by food consumption. Unspent energy is stored as 
glycogen and fat, mainly triglycerides. In humans fat is stored in adipocytes in white 
adipose tissue which also has an endocrine function. White adipose tissue secretes leptin 
and pancreas secrets insulin. Both insulin and leptin secretion increases with increasing 
fat mass and acts on hypothalamus to decrease food consumption and increase energy 
expenditure(Ashrafi, 2007). C.elegans does not have any leptin homologue(Mullaney 
and Ashrafi, 2009a). Central nervous system also sense carbohydrate and lipid levels 
directly and is also stimulated by presence of food in the gut. A lipid sensing pathway in 
the brain has emerged that limits endogenous output of glucose into circulation by the 
liver(Yue and Lam, 2012).The brain also has glucose responsive and glucose sensitive 
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neurones which fire or get inactivated depending on glucose concentration(Levin et al., 
1999). 
Though C.elegans does not have adipocytes, they do share a lot of information on 
energy uptake and expenditure at the pathway level with human(Mullaney and Ashrafi, 
2009b). Therefore C.elegans provides a valuable system to study lipid metabolism at a 
whole organism level.  Unlike mammals, C.elegans are cholesterol 
auxotrophs(Mullaney and Ashrafi, 2009a). Linolenic acid and Linoleic acid are not 
essential fatty acids for C.elegans as they have all desaturases and PUFAelongases 
found in both animals and plants.  Figure 1( page  8) and Figure 2 (page 9) show lipid 
synthesis and breakdown pathways found in both C.elegans and mammals.  
There are several metabolic pathways that are interconnected which regulate energy 
balance in an organism. Glycolysis is the central to all which converts glucose into 
pyruvate to produce NADH and ATP during the process(Dukes et al., 1994). This 
pyruvate is converted to acetyl CoA by pyruvate dehydrogenase complex(Reed, 1969). 
Acetyl CoA enters the citric acid cycle where it combines with oxaloacetate to form 
several metabolites(Williamson and Corkey, 1969). During this process NADH, 
FADH2 and high energy GTP is produced. These NADH and FADH2 produced 
undergo oxidative phosphorylation where ATP is produced by ATPsynthase. Glucose-
6-phosphate produced in glycolysis can either undergo glycolysis to produce ATP due 
to the action of phosphoglucose isomerise or it can be converted to 6-phospho-
gluconolactone by Glucose-6-phosphate dehydrogenase where it will enter the pentose 
phosphate pathway to produce metabolites and reducing power in the form of NADPH. 
Pentose phosphate pathway makes NADPH required for biosynthesis (fatty acid 
biosynthesis, cholesterol biosynthesis, neurotransmitter biosynthesis and nucleotide 
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biosynthesis) and detoxification (reduction of oxidized glutathione and Cytochrome 
P450 monooxygenases). It also produces three, four, five, six and seven carbon 
sugars(Huck et al., 2003). During starvation glycolysis ceases and gluconeogenesis 
predominates (Moon and Johnston, 1980). In gluconeogenesis, noncarbohydrate 
precursors such as pyruvate, glycerol, lactate and amino acids are converted to glucose 
using up NADH, GTP and ATP in the process. Excess energy in animal tissue is stored 
either as glycogen or fat. Glycogen is synthesized from glucose by glycogen synthase. 
When cells need glucose, glycogen is converted to glucose-1-phosphate by glycogen 
phosphorylase. This is converted to glucose-6-phosphate by phosphoglucomutase, 
which can be used directly for glycolysis or pentose phosphate pathway to produce 
either energy or biosynthetic precursors. It can also be converted to glucose in liver 
where it is transported and used as an energy source by other tissues.  For long term 
storage energy is stored as fat. Acetyl CoA is converted to malonylCoA by AcetylCoA 
carboxylase. Fatty acid synthase converts them into saturated fatty acids of different 
lengths. Fatty acid desaturases converts them into unsaturated fatty acids. Phospholipids 
and triglycerides are produced by combining fatty acylCoA with glycerol. When cell 
needs energy, triglycerides release fatty acids due to action of lipases. These fatty acids 
are converted to acetylCoA units via β-oxidation which can enter citric acid cycle to 
produce energy in the form of ATP. For more details on metabolic pathways refer 
Biochemistry by L. Stryer (Stryer, 1995). α-oxidation is used to degrade some fatty 
acids to remove one carbon unit at a time by dioxygenases (Wanders et al., 2001).  
Insulin signalling pathway, TGF-β pathway, TOR pathway, AMP kinase and serotonine 
are implicated in C.elegans lipid metabolism. These pathways are interconnected via 
insulin signalling pathway.  
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This conservation of lipid metabolism pathways in C.elegans and human is exploited in 
the current study to develop a model system which is more ethically accepted than using 
higher organisms for such studies. How valproate increases lipid level is not known. 
Current study aims to fill this gap by looking at changes in gene expression profiles 
induced by valproate exposure. Depending on the tissue requirement lipid metabolism 
and other pathways which are interconnected to it are regulated to obtain a balance in 
energy level. Therefore it is important to look at the whole system as an entity rather 
than on its isolated features to get a clear understanding of the whole system and this is 
achieved by expression profiling.  
 
 





Figure 2 Lipid and glycogen breakdown pathways 
 
1.5 Egg laying 
 
Egg laying is another phenotype that is related to lipid metabolism and ageing. Aged 
C.elegans lay fewer eggs and high lipid content negatively correlates with egg 
laying(Sze et al., 2000). It is also known that high lipid content and ageing decrease 
fertility in human as well(Balen and Anderson, 2007). C.elegans hermaphrodites are 
self-fertile and produce sperm, which are stored in spermatheca and then produce 
oocytes. Fertilized eggs are stored in the uterus and are layed through the vulva when 
sex specific muscles contract. An adult animal would lay around 300 eggs during its 
lifetime. Egg laying is controlled by sensory cues. Vibration of culture medium, 
hypertonic salt solutions and food scarcity inhibit egg laying. Mutation of egl-4 make 
nematodes insensitive to food induced egg laying and this phenotype is suppressed by 
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mutations in TGF-β pathway antagonistic transcription factor genes daf-3 and daf-
5(Daniels et al., 2000).Other TGF-β dauer pathway receptor mutantsdaf-1 and daf-4, 
daf-7 ligand mutants, daf-8 and daf-14smads, which transduce the signal are all egg 
laying defective(Schafer, 2006). Serotonin is thought to act as a neuromodulator of egg 
laying and serotonin deficient mutant tph-1 show egg laying defects, extended 
reproductive lifespan, arrest at dauer stage and lipid accumulation. These phenotypes 
are partly due to down regulation of the TGF-β and insulin signalling pathways(Sze et 
al., 2000). In the present study valproate is shown to down regulate tph-1 activity, 
which could partly explain these three phenotypes observed on valproate exposure.  
 
1.6 Sodium valproate 
 
Valproate is a first line drug with antiepileptic, antipsychotic and anticancer activity. It 
was recently identified as a treatment for migraine(Sze et al., 2000). It is a histone 
deacetylase inhibitor(Göttlicher et al., 2001).Sodium valproate extends lifespan and 
decrease egg laying in C.elegans and cause obesity in human(Tokuoka et al., 2008, 
Isojärvi et al., 1996). It extends the lifespan of C.elegans in a dose dependent manner 
upto18mM, but reduce lifespan on higher concentrations(Evason et al., 2008). 
Valproate may exert this effect on life span by modulating the insulin signalling 
pathway because valproate causes dauer larva formation and cause nuclear localization 
of DAF-16 (Evason et al., 2008). Valproate inhibits egg laying by inhibiting 
diacylglycerol (DAG) production (Tokuoka et al., 2008). Even though valproate is 
reported to cause obesity in patients, the mechanism is not known. But high serum 
insulin levels are found in valproate treated patients compared to the control and insulin 
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resistance is thought to cause obesity on valproate treatment (Pylvänen et al., 2002). 
Some of the research done so far on valproate exposure is shown in Table 1.  
 
Table 1 Research done on valproate up to 2012. The results of the respective reference article given is quoted 
or paraphrased to give an understanding of the work that has been done on Valproate by others before and 




 Prescribing controlled release 
valproate or multiple daily 
administrations in pregnancy did not 
reduce the risk for malformations. 
Higher malformation rates observed 
with in utero exposure to valproate 
are more likely related to total daily 
dose, rather than peak serum levels. 
 Human pregnant 
women on VPA 
monotherapy 
(Mawhinney et al., 2012) 
VPA reduced the expression 
of Homer1b/c in cortical regions 
critical to motor control (medial 
agranular and motor cortices) and to 
cognitive and behavioural aspects of 
emotion (cingulate and insular 
cortices). The cortical premotor and 
motor areas project specifically to 
the dorsolateral regions of the 
striatum, which specifically control 












Rat brain (de Bartolomeis et al., 2012) 
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insular cortices project to the ventral 
striatum, which is mostly implicated 
in behavioural control. 
Shank expression was mildly 
impacted by chronic lithium in the 
cortex, while VPA significantly 
down-regulated gene expression in 
motor and insular cortices. 
both mood stabilizers 
promoted IP3R cortical down-
regulation, only lithium treatment 
significantly 
decreased IP3Rexpression in almost 
all cortical sub regions. In contrast, 
in the dorsolateral caudate-
putamen, IP3R was down-regulated 




Serum ammonia levels were 
elevated without clinical or 
laboratory evidence of 
hepatotoxicity. This lead to 
Valproate induced hyperammonemic 
encephalopathy.  
 7 patients treated 
with VPA  




(VHE) is a serious drug-related 







(Chopra et al., 2012) 
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lethargy, vomiting, cognitive 
slowing, focal neurological deficits 
and decreased levels of 
consciousness ranging from 












Embryos developmentally exposed 
to valproate show concentration 
dependent alterations in locomoter 
activity. These data demonstrate that 
exposure to valproate during 
development affected locomoter 
activity at a concentration that did 
not cause malformations.  
The malformations include lordosis, 
stunted skeletal growth in the spinal 
region, stunted fins, distended 
abdominal and thoracic regions, 
microencephaly and 
microophthalmia. 
Also it caused decreases in the 










Short-term social recognition ability 
of adult rats was improved with 
VPA.  
 
No effect on VPA on olfactory 
discrimination, short and long term 
memory, locomoter activity.  
 
In forced swimming test, climbing 
time increased and immobility time 
decreased indicating antidepressant 
like effect of VPA. 
VPA increased dopamine levels in 
striatum but not in the olfactory 
bulb.  
 
Pre-treatment with VPA can reduce 
the effects of MPTP on olfactory 
discrimination and short-term 
memory impairments and prevent 
dopamine depletion in the olfactory 
bulb of MPTP-treated rats. 
 
 
 rat (Castro et al., 2012) 
VPA induced a lower fertility rate 
(this effect is reduced by 
coadministration of folinic acid (FA) 
or S-adenosylmethionine (SAM). 
Foetal weight and length were 
unaffected by VPA treatment.  
Hepatic injury was observed in 
foetuses treated with VPA. FA and 
 Wistar rats (Ubeda et al., 2013) 
15 
 
SAM were able to reverse the 
decrease in VPA-induced foetal liver 
T-lymphocyte cells 
 
VPA treatment resulted in skeletal 
modifications in the skull, 
appendicular bones, vertebrae and 
ribs. Only FA was able to reverse the 




VPA decrease DAG (diacylglycerol) 
production and inhibit egg laying. 
VPA disrupt ovulation and 
defecation by decreasing production 
of inositol-1,4,5-triphosphate (IP3).  
VPA may inhibit phospholipase-C 
mediated hydrolysis of 
Phosphatidylinositol-4,5-
bisphosphate (PIP2) to form DAG 
and IP3.  
 
 C.elegans (Tokuoka et al., 2008) 
VPA increase lifespan of C.elegans  C.elegans (Evason et al., 2008) 
VPA Decrease apoptosis due to 
histone deacetylase inhibitor activity 
of VPA 
 Rat Cerebral 
cortical neurones 
(Jeong et al., 2003) 
Increase of G0-G1 and a decreased 
G2/M and S-phase following VPA 
treatment, indicating in vivo effects 
of VPA on cell cycle regulation. 
VPA inhibited cell proliferation in a 
 Multiple myeloma 
cells 
(Neri et al., 2008) 
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time and dose dependent manner and 
induced apoptosis. 





(Neri et al., 2008) 
 
 
1.7 Insulin signalling pathway 
 
DAF-2 acts as the C.elegans’ sole homologue of insulin receptor. There are 40 insulin 
homologs in C.elegans compared to the 10 insulin/insulin homolog genes in human 
which may have redundant functions (Ritter et al., 2013). Activated DAF-2 causes 
phosphorylation of the DAF-16 C.elegans FOXO transcription factor and prevents it 
from being transported to the nucleus and prevents transcription of downstream target 
genes. FKHR and AFX are the human orthologues of DAF-16(Lee et al., 2001). When 
ligand is bound, DAF-2 activates theAAP-1; AGE-1(PI3K) complex(Paradis and 
Ruvkun, 1998).This complex when activated activates PDK-1, which in turn activates 
both AKT-1 and AKT-2. Activated AKT-1 and AKT-2 prevent nuclear localization of 
DAF-16. DAF-18(PTEN) inhibits AGE-1. Genes of insulin like signalling pathway and 
associated pathways, which cause phenotypic changes associated with valproate 




Table2 C. elegans genes of the insulin signalling or associated pathways and their nul-phenotypes. These 
phenotypes are also observed on valproate exposure. 
Phenotype Gene mutated Acts via Reference 
dauer daf-2 DAF-16 (Ogg et al., 1997) 
 daf-1  (Ogg et al., 1997) 
 daf-4  (Ogg et al., 1997) 
 age-1 DAF-16 (Ogg et al., 1997) 
 daf-7 Not via DAF-16 (Ogg et al., 1997) 
 daf-8 DAF-3 (Ogg et al., 1997) 
 daf-14 DAF-3 (Ogg et al., 1997) 
Longer lifespan daf-2 DAF-16 (Ogg et al., 1997) 
 sir-2.1  (Tissenbaum and 
Guarente, 2001) 
 age-1 DAF-16 (Ogg et al., 1997) 
 AAK-2 In parallel to DAF-
16 
(Apfeld et al., 2004) 
Lipid accumulation  daf-2 DAF-16 (Ogg et al., 1997) 
 daf-7 DAF-3 
(Not via DAF-16) 
 
(Ogg et al., 1997) 
 daf-14 DAF-3 (Ogg et al., 1997) 
 daf-8 DAF-3 (Ogg et al., 1997) 
 daf-1 DAF-3 (Greer et al., 2008) 





daf-7 DAF-3  




1.8 Non insulin pathways that could be involved in lipid metabolism 
 
Transforming growth factor –β (TGF-β) pathway is another pathway that works in 
parallel to insulin signalling pathway, which is thought to bring metabolic changes in 
C.elegans(Figure3 page20). There are two TGF-β pathways. One pathway (Figure 3B) is 
where a ligand DAF-7 binds to the receptor DAF-1 and DAF-4 inactivates the DAF-3 
smad (Georgi et al., 1990). Mutants of daf-7,daf-1and daf-4 are dauer constitutive 
(Schackwitz et al., 1996, Georgi et al., 1990, Estevez et al., 1993). This pathway is also 
implicated in lipid metabolism asdaf-1, daf-4 and daf-7 mutants all show lipid 
accumulation(Hellerer et al., 2007). This lipid accumulation occurs via DAF-3. Excess 
fat indaf-7 mutants is due to activation of specific glutamergic receptors (mgl-1 and 
mgl-3), and this lipid accumulation is found to be due to increased fat synthesis by the 
activation of the fatty acid synthase gene, fasn-1(Greer et al., 2008).  This lipid 
accumulation via DAF-3 does not depend on DAF-12, which is found downstream of 
DAF-3 in dauer formation.  
In the other TGF-β pathway(Figure 3C) DBL-1 binds to a receptor composed of SMA-6 
which phosphorylates the type II receptor DAF-4 and this signal is transduced to SMA-
9 in the nucleus via SMA-2, SMA-3 and SMA-4 through phosphorylation events 
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(Savage et al., 1996), (Savage-Dunn, 2005). SMA-6 is not associated with fat 
accumulation (Greer et al., 2008).  
SIR-2 is a histone deacetylase that is reported to activate DAF-16 (Tissenbaum and 
Guarente, 2001). Its over expression is  reported to cause lifespan extension in 
C.elegans and drosophila(Tissenbaum and Guarente, 2001, Rogina and Helfand, 
2004,Viswanathan and Guarente, 2011). But this is doubtful as Buerrnet et al have 
found no effect of over expression of SIR-2 on lifespan of these two organisms (Burnett 
et al., 2011). Rizki et al have shown that HCF-1 probably represses DAF-16 by forming 
a complex with SIR-2.1 and antagonizing their abilities to stimulate DAF-16 (Rizki et 
al., 2011).  
AMP activated protein kinase (AMPK) also activates DAF-16 by direct 
phosphorylation (Greer et al., 2007). aak-1 and aak-2 codes for the catalytic α-subunits 
of AMPK. aakb-1 and aakb-2 code for the two regulatory subunits of AMPK 
(Narbonne and Roy, 2008).  Narbonne and Roy have shown that AMPK signalling 
helps the slow release of fat deposits during dauer stage and lack of this pathway causes 





Figure3Insulin and TGF-β pathways in C.elegans. (A) C.elegans insulin signalling pathway. Insulin 
homologues in C.elegans bind to its sole insulin receptor DAF-2. Ligand bound DAF-2 inactivates the FOXO 
transcription factor, DFA-16 and prevents activation of downstream target genes. (B) C elegans TGF-β deaur 
pathway. Ligand DAF-7 binds to receptor made up of DAF-1 and DAF-4 and activates DAF-8  and DAF-14 
which would inhibit the downstream transcription factors DAF-3 and DAF-5. (C) C.elegans TGF-β sma/mad 
pathway. The ligand DBL-1 binds to the receptors SMA-6 and DAF-4 , which activates SMA-9 transcription 




1.9 The general challenge of using non vertebrate species to understand drug mode 
of action 
 
The activity of a drug depends on its successful uptake by the organism, interaction of 
the drug with its primary targets, metabolism of the drug and its resulting metabolites. 
These metabolites can act on specific or general targets bringing out secondary 
responses and finally the elimination of the drug and its metabolites from thebody, 
which determines the duration of the activity of drug, which cause transcriptomic or 
metabolomic changes. C.elegans, being a nematode, cannot be used to model the more 
complicated human disease processes or whole pathology to understand the mode of 
drug action. C.elegans also lacks certain pathways found in humans. For example 
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C.elegans does not have de-novo cholesterol synthesis pathways (Crowder et al., 2001) 
making it impossible to use as a study model to look into this pathway or to understand 
the drug mode of action which acts via this pathway. There are no orthologs for certain 
human genes in C.elegans. Understanding the drug activity on complex human organs, 
such as the pituitary is also not possible in C.elegans, as it does not have these complex 
organs. This also makes it difficult to understand the adverse effects of drugs and limits 
its use in testing drug suitability for clinical trials.   
Though there are drawbacks in the use of C.elegans to model human systems, several 
studies reveal this nematode to be a good model system to understand drug mode of 
action in several ways. For example, C.elegans has been used successfully to study the 
mode of drug action of the antidepressant fluoxetine.  Even though depression is a 
complex phenotype, which cannot be directly observed in C.elegans, fluoxetine changes 
feeding behaviour of C.elegans. Mutants of serotonin reuptake transporter MOD-5 are 
resistant to fluoxetine for this behaviour. This leads to the recognition of fluoxetine 
action where inhibition of MOD-5 is found to be the main mechanism by which this 
drug brings its antidepressant activity. MOD-5 homologue SERT is found to be the 
main target of fluoxetine in mammalian system (Ranganathan et al., 2001).   Also 
C.elegans homologues have been identified for 60-80% of human genes.  According to 
Kaletta and Hengartner (Kaletta and Hengartner, 2006) , out of  the animal models, C. 
elegans is the fastest and most amenable to cost effective medium/ high-throughput 
technologies. Thus, C.elegans has been used in this study to model the effect of 




1.10C.elegans in neuronal studies 
 
C.elegans is a model organism widely used in neuronal studies. It has two almost 
independent nervous systems, the pharyngeal nervous system and the extra-pharyngeal 
nervous system. In hermaphrodite, the pharyngeal nervous system is composed of 20 
neurones with the extra-pharyngeal nervous system having 282 neurones (Dent et al., 
2000). But pharyngeal pumping is independent of the pharyngeal nervous system 
(Avery and Horvitzt, 1989).  
C.elegans hasexcitatory neurotransmission via acetylcholine.Its acetylcholine receptors 
a homo or heteropentamers made up of α and nonα subunits. unc-38 codes for the α 
subunit (Almedom et al., 2009) and levamisole is an agonist of this receptor. Aldicarb is 
an acetylcholine esterase inhibitor which prevents hydrolysis of acetylcholine in the 
synaptic cleft(Hu et al., 2009).  
C.elegans also has an inhibitory neurotransmission via γ-amino beutric acid (GABA). 
unc-25 codes for glutamic acid decarboxylase, the enzyme which syntheses GABA 
from glutamic acid and is involved in this inhibitory neurotransmission (Jorgensen, 
2005). 
 
1.11Why an “omics” approach 
 
The central dogma of Molecular Biology explains the flow of information in biological 
systems to be unidirectional, which is from genes to RNA to protein. But the 
identification of several complex interactions between proteins, RNA and DNA with 
their further complicated regulatory mechanisms has lead to the realization that the flow 
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of information is not in one direction. This made it important to get a holistic view of 
the system rather than looking at its individual components in isolation. To obtain 
ahigh-throughput, data driven holistic view of valproate exposure, gene expression 
profiling was performed on C.elegans treated with different concentrations of valproate.  
Analysis of valproate exposure revealed the down regulation of nuclear components to 
be a key feature of valproate exposure. It also revealed that the lipid accumulation 
observed on valproate exposure could be the net effect of the concomitant activation of 















2.0  MATERIALS AND METHODS 
 
 
2.1C.elegans strains used 
 
All the experiments were based on C.elegans strains provided by Caenorhabditis 
Genetics Centre (CGC) which is funded by NIH Office of Research Infrastructure 
Programs (P40 OD010440). N2(C. elegans wild type; Bristol isolate),CF1038 daf-
16(mu86)I(a null mutant where most of the coding region including the whole forkhead 
domain is deleated), LT186sma-6(wk7)II( a null mutant), DR40daf-1(m40)IV (a 
substitution mutant), CB1370daf-2(a substitution mutant), daf-4(ok827)III(provided by 
the C. elegans Reverse Genetics Core Facility at UBC, which is part of the International 
C. elegans Gene Knockout Consortium), unc-38(e264)I(recessive), unc-25(n2569)III 
were used in the experiments. 
 
2.2 Culture conditions 
 
C.elegans were grown as described previously ((Brenner, 1974). Briefly, animals were 
maintained on 90mm petri dishes with nematode growth medium  (NGM; 1.7% agar, 
0.25% peptone, 0.3% NaCl, 5μg/ml Cholesterol, with the addition of 1mM CaCl2, 1mM 
MgSO4 and 25mM KPO4, pH6, after autoclaving). These plates were seeded with a 
lawn of Escherichia coli OP50, a natural uracil mutant strain and the standard food 





2.3 C. elegans bleaching protocol 
 
This protocol was used to generate staged animal cultures and to remove any 
contamination from C. elegans stock plates.  Animals were washed off from newly 
starved stock plates (9cm) in 3ml M9 buffer (22mM KH2PO4, 42mM Na2HPO4, 80mM 
NaCl, 1mM MgSO4) and the suspension was transferred into 1.5ml centrifuge tubes and 
centrifuged at 6,500g for 30s.  The supernatant was removed to leave 0.5ml in the tube.  
80μl 5M NaOH and 160μl Sodium hypochlorite was added and the tubes were shaken 
vigorously for 2 min.  The tubes were then filled with M9, centrifuged as above and the 
supernatant removed; this washing step was repeated twice and on the 2nd time 200-
400μl M9 buffer was added to the tube.  The tubes were rolled overnight to keep the 
animals oxygenated and transferred onto OP50 plates the following day, where the 
cultures developed synchronously. 
 
2.4 Lipid assay 
 
Lipid assay was performed on 1 day adult nematodes with modifications of the method  
described previously (O'Rourke et al., 2009). Assay was performed by collecting 
C.elegans into 1.5ml tubes with 1mL M9 buffer and removing supernatant by 
centrifuging at 4000rpm. Added 1mL dis.H2O and 50µL of freshly prepared 10% 
formaldehyde into the tube and freeze thawed in liquid nitrogen twice without thawing 
completely. The worms were allowed to settle and formaldehyde solution was removed. 
Then 1ml of 1µg/mL Nile red solution prepared in M9 buffer was added and incubate at 
room temperature rolling for 20min in a rotator. Worms were allowed to settle, the 
supernatant was removed and the nematodes were washed with 1mL disH2O.  Once 
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again the nematodes were allowed to settle and the supernatant was removed leaving 
100μl from which15μlwas added per well to 96 well plates. Fluorescent images were 
taken at λex 553nm, λem 637 using Q Capture Pro programme with Q Imaging Digital 
Camera with 2(s) exposure time. Images were analysed using Image J software 
(Abràmoff et al., 2004). Around 120 nematode images were analysed per sample and t 
test is performed to identify significant changes.  
 
2.5 Exercise assay 
 
C.elegans were forced to exercise by culturing them on agar plates with different agar 
concentrations. Synchronized cultures of L4 larva were transferred to 90mm NGM agar 
OP50 bacterial plates containing drug or solvent and total lipid was measured after 24hr 
at one day adult stage. Sodium valproate and monosodium glutamate were dissolved in 
water to get stock concentrations of 1000mM and added to melted NGM agar cooled to 
50
o
C at a final concentration of 15mM and 24mM respectively. A 12mM stock solution 
of cholesterol was prepared in ethanol and added to NGM agar cooled to 50
o
C to get a 
working concentration of 24µM.  Agar plates were prepared as described previously 







2.6 Egg laying assay 
 
One day adult C.elegans were transferred to valproate plates and removed after two 
hours. Number of L2 larva on each plate is counted. Sodium valproate concentrations 
tested were 0, 6, 12, 15, 18 and 24mM. Measurements were taken for 3 nematodes per 
plate with 5 replicates for each drug concentration.  
 
2.7 Development of a paralysis assay 
 
Previous studies have performed this assay by transferring nematodes to relevant drug 
plates or control plates with a hook. This method has several drawbacks. Picking 
C.elegans with a hook can damage their skin affecting drug absorption and sometimes 
cause death. It is also time consuming limiting the number of animals that can be 
assayed and the number of treatments that can be tested. The method developed during 
this study replaces this step by transferring C.elegans directly on to drug or control 
plates with a pipette, which saves time and does not cause any physical damage to 
nematode body.  It makes the test much simple and easy to perform and allows the 
analysis of a number of treatments simultaneously. It also allows the analysis of a large 
number of nematodes per sample increasing statistical significance of the results. There 
is also less variation between samples. Also it does not require the expertise of 
nematode picking and can be performed by an armature. The only drawback of this 
method is the small volume of M9 buffer, which is transferred with the nematodes to 
the drug plates decreasing the drug concentration. But any liquid transferred get 
absorbed in to the agar and the volume transferred is negligible compared to the size of 
the plate.  
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In the method developed during this study, C.elegans at L4 stage were collected into 
1.5mL tubes with M9 buffer, spun at 6000rpm for 30s , the supernatant was removed 
and C.elegans collected at the bottom of the tube were transferred to the relevant drug 
plates or control plates with a pipette. These drug or control plates had OP50 seeded and 
dried under laminar flow 2hrs before the experiment. Then nematodes were observed 
under a light microscope with x 10 magnification and the number of nematodes in a 
given visual field was counted. At each time point, the number of paralysed nematodes 
was calculated, which were not moving and was shorter as a result of muscle 
contraction, as a percentage of the number of total C.elegans in that visual field. Due to 
lack of time, this method could not used to compare with the existing methods. 
 
 
2.8 Preparation of samples for microarray 
 
Staged C. elegans N2 Bristol strain was grown at 20
o
C as explained in chapter 2. They 
were transferred to drug plates containing sodium valproate dissolved in MilliQ H2O at 
L4 stage for 24hrs. Drug concentrations 3, 6, 9, 15, 18, and 24mM in nematode agar 
were prepared from a 1000mM stock solution in MilliQ H2O. After 24hrs on drug 
plates, nematodes were collected with MilliQ H2O by washing each plate twice with 
1ml MilliQ H2O. After nematodes collect to the bottom of the tube, supernatant 
wasremoved and transferred ~ 30mg of nematode pellet into 2ml VK05 Precellys tubes 
containing 600µl RLT buffer. They were homogenized twice at 6400rpm for 10s in 
Precellys24 homogenizer. These tubes were dipped in liqN2 for 5min and transferred to 
-80oC freezer till RNA isolation. All the steps in the collection of nematodes from drug 
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Total RNA was isolated from each frozensample prepared in chapter 2.8 using 
RNAeasy Mini Kit from QIAGEN according to the procedure of total RNA isolation 
from animal tissue with DNAase digestion. The procedure followed is as given below. 
Thawed homogenized samples stored in RLT buffer and centrifuged lysate at full speed 
in a microcentrifuge for 3min. Carefully transferred the supernatant into a new 
microcentrifuge tube with a pipette. One volume of freshly prepared 70% ethanol was 
added into this and mixed by pipetting. Transferred 700µL of this including any 
precipitate formed to an RNeasy spin column kept in a 2mL collection tube. The lid was 
closed gently and centrifuged at 10000rpm for 15s. If there was more than 700 µL, 
repeated the step using the same column. A volume of 350 µL of buffer RW1 was 
added to the spin column, closed the lid gently and centrifuged at 10000rpm for 15s. 
The flowthrough was discarded. Ten µL DNAase 1 stock solution was added into 70 µL 
buffer RDD to prepare the DNAase working solution, mixed this DNAase working 
solution gently by inverting the tube and spun to collect any residual solution left on the 
sides of the tube. Forty µL of this DNAase working solution was added to the 
membrane of the spin column and left at room temperature for 15min.  Added 350 µL 
of buffer RW1into the spin column and centrifuged at 10000rpm for 15s. The 
flowthrough was discarded. The column was washed by adding 500 µL  buffer RPE into 
the spin column and centrifuged at 10000rpm for 2min. Then the spin column was 
placed ina new collection tube and centrifuged at 14000rpm for 1min to remove any 
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residual liquid remaining in the column. The spin column was placed in a new 1.5mL 
microcentrifuge tube, 40 µLof RNAase free water was added and centrifuged at 
10000rpm for 1min to elute the RNA. This elution step was repeated to obtain a higher 
concentration of total RNA. RNA quality was assessed using 2100 Bioanalyzer from 
Agilent Technologies. RNA quantification was performed with NanoDrop from Thermo 
Scientific, UK. Amplified and labelled target RNA using Agilent Low Input Quick 
Amp kit, One Colour according to manufacturer‘s instructions. The following procedure 
was followed to produce labelled cRNA. Spike mix was prepared by vortexing and 
heating spike mix solution to 37
o
C for 5min. Mixed again by vortexing, spun down and 
diluted four times (first dilution 1:20, second dilution 1:25, third dilution 1:20, fourth 
dilution 1:2) in the dilution buffer. Added 2µL of this diluted spike mix in to 50ng of 
total RNA in a volume of 1.5 µL to get a total volume of 3.5 µL. The T7 primer mix 
was prepared by adding 1 µL of nuclease free water into 0.8 µL of T7 primer. Added 
1.7 µL of this into the tube containing total RNA and spike mix. The primer and the 
template were denatured by heating it to 65
o
C  for 10min in a circulating waterbath and 
then placed this labelling reaction tube on ice for 5min. The cDNA master mix was 
prepared by adding 2 µL of 5x first strand buffer, 1 µL of 0.1M DTT, 0.5 µL of 10mM 
dNTP mix and1.2 µL of RNase Affinity Script Block mix and then 4.7 µL of this cDNA 
master mix was added into the labelling reaction. The samples were first incubated at 
40
o
C for 2hrs, and then at 70
o
C for 15min followed by incubation on ice for 5min. The 
samples were stored at -80
o
C until the next step. Thetranscription master mix was 
prepared by adding 0.75 µL nuclease free water, 3.2 µL 5x transcription buffer, 0.6 µL 
0.1M DTT, 1 µL NTP mix, 0.21 µL T7 RNA polymerase blend and 0.24 µL Cyanine 3-
CTP. Six µL of this transcription mater mix was added into the labelling reaction tube 
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and incubated at 40
o
C for 2hrs. Then to purify the labelled cRNA, add 84 µL nuclease 
free water and 350 µL  buffer RLT into the reaction tube. An aliquot of  250 µL of 
100% ethanol was added, mixed by pipetting and transferred  into RNeasy mini spin 
column in a collection tube. The tube was then spun at 13000rpm 30s at 4
o
C. A volume 
of 500 µL buffer RPE was added and spun at 13000rpm for 60s at 4
o
C. Transferred the 
column to a new collection tube and spun at 13000rpm for 30s to remove any remaining 
residual buffer. Purified cRNA was eluted into a new 1.5mL collection tube by adding 
30 µL RNase free water, incubating at room temperature for 1min and centrifuging at 
13000rpm for 30s. cRNA was quantified with NanoDrop. Cyanine 3 dye concentration, 
RNA absorbance ratio at 260nm/ 280nm and cRNA concentration were recorded. The 
yield and the specific activity of each reaction were calculated. After purification of 
cRNA, the hybridization was done as follows. The blocking agent is prepared by adding 
500 µL of nuclease free water into 10x Gene Expression Blocking Agent (GEBA) and 
warmed it at 37
o
C for 5 min. Then 11 µL of GEBA was added to 1.65 µg labelled 
cRNA and made the total volume up to 52.8 µL with nuclease free water. After adding 
2.2 µL 25x Fragmentation  Buffer into this mixture it was incubated at 60
o
C for 
30minfor fragmentation. The fragmentation was stopped by keeping on ice for 1min and 
adding 55 µL of 2x Hi RPM Hybridization Buffer to 55 µL of cRNA fragmentation 
mix. Then carefully mixed by pipetting to avoid bubble formation. Then spun at 
13000rpm for 1min at room temperature, placed the samples on ice and 100 µL loaded 
into C.elegans (V2) Gene Expression Microarray, 4x44K slides from Agilent 
Technologies, UK. Slides were hybridized at 65
o
C for 17hrs. After hybridization, arrays 
were washed as follows.  Two mL of Triton X 102 was added to wash buffer 1and 2 
each in cubitainers to get a final concentration of 0.005%.  One thousand mL of wash 
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buffer 2 was warmed to 37
o
C overnight prior to use. Axon 4000 scanner equipped with 
GenePix 3.0 analysis software was used for initial analysis of microarray data.  
 
2.10 Microarray data analysis 
 
Raw image files are automatically loaded and processed by Agilent Feature Extraction 
software to generate Feature Level Extraction Output (FLEO), GenePix Results (GPR 
files).  Expression values generated are log2 transformed to increase signal : noise ratio 
and Quantile normalized to remove any systematic bias such as bias due to different 
starting RNA quantities, strengths in dye concentration etc.  Significant expression 
profiles are identified by Significance Analysis of Microarray (SAM). Correlation is 
used as a measure linking the two variables lipid level and valproate concentration. 
Expression profile with a threshold value of 1% BH(Bengamini Hochberg correction) 
corrected p value are identified and compared with the significant expression profile 
identified by SAM with a false discovery rate (FDR) less than 1%. Probe IDs of the 
union of the two expression profiles are chosen and after converting to Official Gene 
Symbols, SOTA and CAST clustering were performed for class discovery in TMev 
(Herrero et al., 2001, Dopazo and Carazo, 1997, Ben-Dor et al., 1999). Functional 
annotation was carried out with Database for Annotation, Visualization and Integrated 
Discovery  (DAVID) (Da Wei Huang and Lempicki, 2008, Sherman and Lempicki, 





Figure 4The rational used in generating biological information from microarray. FLEO = Feature level 
extraction output, SAM = Significance analysis of Microarray, ANOVA= Analysis of variance 
 
 
2.11 Ingenuity Systems Pathway Analysis 
 
The Ingenuity platform is comprised of three main components, content acquisition, 
knowledgebase and applications. In content acquisition, information is gathered from 
original research articles, databases etc. and after quality control is integrated into 
Ingenuity ontology. These ontologies provide the scaffolding for the Ingenuity 
Knowledge Base. Research data can be overlaid onto this Knowledge Base and 
Applications layer provides a web based applications for data analysis and 
interpretation. For example, overlaying microarray data on to Knowledge Base will help 
to define pathways activated or inactivated under a treatment. This will lead to the 
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identification of transcription factors associated including ones which were not present 
in the data set submitted and help in identification of upstream master regulators. 
In this study IPA Core Analysis (Ingenuity Systems) was performed on the significant 
expression profile of valproate exposure identified by SAM with less than a 1% false 
discovery rate  pooled together with the genes from the correlation analysis with a 
threshold of BH corrected  p value < 1%. Significant expression profile of valproate 
exposure is overlaid on Ingenuity Knowledge Base and networks were generated with 
each having 35 focus molecules. This included both focus molecules from dataset 
provided and focus molecules identified by Ingenuity Systems as associated with the 
networks generated. Predictions were made on phenotypes that could be observed as a 
result of the given gene expression profiles. Upstream regulators in the data set 
provided and predicted to be associated with which could bring the observed expression 
changes were predicted.  
 
 
2.12 Identification of insulin dependent and insulin independent expression 
profilesfollowing valproate exposure 
 
Inactivation of the receptor DAF-2 causes dephosphorylation of cytoplasmic DAF-16, 
which results in the nuclear translocation of DAF-16 and affects transcription of 
downstream targets. In literature, cytoplasmic DAF-16 is presumed to be inactive, but 
there is no evidence for this. Therefore there are two possibilities when compare gene 





Figure5 Two different models that is used in this study to explain the gene expression profiles of daf-2 and daf-
16 mutants. Panels A, B and C explains the gene expressions assuming cytoplasmic DAF-16 is active. Panels D, 
E and F shows the possibilities assuming cytoplasmic DAF-16 is inactive.  Panel A and D : Pathways affected 
by daf-2. Panel B and E: Pathways affected by nuclear DAF-16. Panel C: Pathways affected by both DAF-2 
and cytoplasmic DAF-16. Panel F: Pathways affected by DAF-2 independent of DAF-16. 
 
Comparison of the microarray data of C.elegans exposed to sodium valproate with 
microarray Data of  time course study done on RNAinterference inactivation of daf-2 
and daf-2;daf-16 double mutants compared to a wild type mixed population as reference 
(Murphy et al., 2003)was used to identify pathways affected by sodium valproate 
dependent on insulin and independent of insulin (Figure 6 page 36). Only 13% of the 
expression profiles associated with valproate exposure was dependent on insulin.  
DAF-16 and DAF-2 dependent expression profiles of valproate exposure were 
identified by comparing DAF-16 dependent and DAF-2 dependent expression profiles 
Wild type daf-2 
daf-2;daf16 daf-2 
Wild type daf-2; daf-16 
Wild type daf-2 
daf-2: daf-16 daf-2 









with the expression profile of valproate exposure (Figure 7 page 37). From these the 
DAF-16 dependent positively and negatively correlated expression profile of valproate 
exposure were identified by comparing nuclear DAF-16 dependent expression profile 
with the positively correlated expression profile of valproate exposure (Figure 8 page 
38). In a similar manner identified the DAF-2 dependent negative, DAF-2 dependent 
positive, DAF-16 independent of DAF-2 dependent positive and DAF-16 independent 




Figure 6 Insulin independent component of valproate exposure associated gene expression profile.  Expression 
profiles of RNAinterference inactivated daf-2 and daf-2;daf16 double mutant (Murphy et al., 2003)were 
compared in Venn diagrams to identify the expression profile affected by valproate exposure independent of 
DAF-2 and DAF-16. There were 1460 expression profiles associated with the insulin independent component 
marked in purple.Sodium valproate indicates the expression profile of wild type C.elegans exposed to 
valproate for 24hrs at L4 stage. Expression profile with a threshold value of 1% BH (Bengamini Hochberg 







97 1460 101 
Sodium valproate Wild type vs daf-2;daf-16 
 
Sodium valproate Wild type vs daf-2 
p value < 
0.0001 
p value < 0.0001 
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correction) corrected p value are identified and compared with the significant expression profile identified by 
SAM with a false discovery rate (FDR) less than 1%. Probe IDs of the union of the two expression profiles are 




Figure 7 DAF-2 and DAF-16 dependent expression profiles were compared in a Venn diagram with the 
expression profile associated with valproate exposure to identify the DAF-16 dependent and DAF-2 dependent 
expression profiles of valproate exposure.Expression profiles of RNAinterference inactivated daf-2 and daf-
2;daf16 double mutant (Murphy et al., 2003)were compared in Venn diagrams with the expression profile of 
wild type C.elegansexposed to sodium valproate. Sodium valproate indicates the expression profile of wild type 
C.elegans exposed to valproate for 24hrs at L4 stage. Expression profile with a threshold value of 1% BH 
(Bengamini Hochberg correction) corrected p value are identified and compared with the significant 
expression profile identified by SAM with a false discovery rate (FDR) less than 1%. Probe IDs of the union of 









Figure 8 Nuclear DAF-16 dependent expression profile of valproate exposure is compared in a Venn diagram 
with the expression profile positively correlated with valproate exposure to identify the positively and 
negatively correlated expression profiles of valproate exposure dependent on nuclear DAF-16."VPA 24hrs 
positive" indicates the expression profile of wild type C.elegans exposed to valproate for 24hrs at L4 stage. 
Expression profile with a threshold value of 1% BH (Bengamini Hochberg correction) corrected p value are 
identified and compared with the significant expression profile identified by SAM with a false discovery rate 
(FDR) less than 1%. Probe IDs of the union of the two expression profiles are taken as the expression profile 
associated with sodium valproate. Positively correlated expression profiles are compared with nuclear DAF-16 
dependent expression profile identified from RNA interference inactivated mutants of the study done by 




2.13 Identification of the TGF-β dependent and TGF-β independent expression 
profiles on valproate exposur 
 
Expression profile associated with valproate exposure that depends on TGF-β pathway 
was identified by comparing the data set on valproate exposure with a microarray data 
set available in GEO database (accession number GSE15527) on TGF - β pathway 
mutant sma-6(wk7) and DBL over expressing strain. The raw data downloaded were 
Nulear DAF-16 dependent 
negative 




RMA normalized together and Affimetrix gene IDs were converted to Agilent IDs by 
the gene ID conversion tool available in DAVID. Genes with less than 20% NAs were 
chosen and the significant expression profile was selected by two class (unpaired) SAM 
for one colour. A threshold value of 1% FDR with 1fold change was used to select the 
significant expression profile. 
 




















3.0 PHENOTYPIC EFFECTS OF DIET, PHYSICAL EXERCISE AND 





Here the phenotypic effects of different feeding regimes, different levels of physical 
activity and different concentrations of sodium valproate in wild type and mutant strains 
in the insulin pathway is tested. To perform these studies we first had to devise an 
effective methodology for lipid quantification. Then a method to manipulate activity 
levels of C.elegans (level of exercise) was designed.  After that the effect of diet, 
specifically cholesterol and monosodium glutamate, on the lipid levels in the nematode 
was tested and the relationship between exercise and diet was analysed.  Finally the 
effect of valproate on lipid content and egg laying was measured and effects of 
valproate on components of insulin signalling pathway was investigated.  
This initial study reveals cholesterol to increase lipid level in C.elegans while exercise 
and decreased lipid accumulation. In addition, the antiageing drug valproate was found 
to increase lipid accumulation in C.elegans in a dose dependent manner (Figure 9 page 
41). This increase of lipid mass by valproate was found to be dependent on DAF-2 but 
independent of DAF-16. Comparison of insulin and TGFβ pathway mutants show an 
inhibitory effect of DAF-16 and DAF-1 on valproate induced lipid accumulation. This 




Figure 9 Summary of the methodology and conclusions. Lipid level was quantified in C.elegans treated with 
cholesterol, MSG, exercise or sodium valproate.  Red arrows indicate an increase in lipid level and green 
arrows indicate a decrease in lipid level on each treatment. Increase in lipid due to valproate is further tested 
and it was found to depend on DAF-2 and SMA-6. DAF-1 and DAF-16 has an inhibitory effect on valproate 





3.2.1 Nilered staining of formalin fixed C.elegans can be used for lipid 
quantification 
 
Since the overall objective of my work was the identification of molecular mechanisms 
underlying obesity in C.elegans, I first needed to develop a reliable assay to quantify 
lipid content in C.elegans. At the time I started this work, the gold standard 
methodology was Nile red staining of live C.elegans. This method has been used for 
several decades but recently its ability to provide reliable measurement in live worms 
has been questioned. As Nile red fails to stain major fat stores in live C.elegans and is 
rapidly degraded.  Therefore, Nile red staining of fixed worms has been suggested to be 
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a more reliable method(O'Rourke et al., 2009).The possibility of using this novel 
technique for lipid quantification was tested in C.elegans with some 
modifications(Chapter 2.4). To validate this technique we used mutants and dietary 
compounds that are known to increase lipid levels.  
As expecteddaf-2; the C.elegans insulin receptor mutant and a mutant of NHR-
80;(which  is required for the expression of the C.elegans ∆9 desaturases FAT-5, FAT-6 
and FAT-7)had higher amounts of total lipid, compared to wild type (Figure 10). unc-22 
is a twitching mutant, which resembled exercising worms and had similar lipid levels as 
wild type worms. Though twitching, unc-22 moved slowly compared to wild type 
where net level of exercising may be similar to the wild type (data not shown).  
 
 
Figure 10Comparison of total lipid mass in mutants stained for lipid by Nile red staining of fixed 
C.elegans. C.elegans mutants and wild type were fixed with formalin and stained with Nile Red for 
total lipids at one day adult stage. nhr-80 is defective in lipid metabolism and unc-22 is a twitching 
mutant which mimics exercising and daf-2 is an insulin receptor mutant. Error bars = ± SEM. *** = 












































Eggs are rich in lipids. To validate our lipid quantification method, lipid levels were 
quantified in both the nematode body where there are eggs and the area of the body 
without eggs (Figure11) using Nile red staining of fixed nematodes. Validating our 
methodology, it showed higher lipid content on eggs compared to the rest of the body 
when tested with t test at a p value < 0.001.  
 
Figure11. Lipid mass detected by Nile red staining of fixed C.elegans at one day adult stage on areas with eggs 
and the rest of the body. Error bars = ± SEM. *** = p  value< 0.001 
 
 
3.2.2 Exercise drastically affect lipid levels in wt C elegans 
 
Having shown the efficacy of the lipid quantification methodology, we then set to 
assess whether different levels of exercise can affect lipid content in C.elegans. In order 
to achieve this, increasing concentrations of agar were used to force the worms to use 







































decreased when nematodes were grown in concentrations of agar ranging between 5g/l 
to 10g/l (Figure 12, page 43). However, lipid content increased when agar concentration 
was raised to17g/l. At agar concentrations≥17g/l movement can be assessed by analysis 
of groves left on the surface of the agar when worms crawl. With increasing agar 
concentration above 17g/l, worms have a lower amount of total lipid.  
 
Figure 12Effect of agar concentration on the lipid mass of C.elegans. Wild type C.elegans was grown from L4 
to one day adult stage on petridishes with different agar concentrations to mimic exercising. Lipid mass is 
measured with Nile red staining of fixed C.elegans at one day adult stage. Error bars = ±SEM, *** = p value < 
0.001, ** = p value<0.005 
 
 
3.2.3 Effects of cholesterol and MSG on lipid accumulation in wtC.elegans 
 
Having demonstrated that exercise influences the amount of lipids, I then assessed the 
effects of diet on lipid accumulation. C.elegans treated with cholesterol shawed a dose 
dependent increase in lipid content when tested with Nile red staining of fixed 













































the opposite effect, reducing lipid levels in a dose dependent manner (Figure 14). Any 





Figure 13Effect of cholesterol on C.elegans lipid levels.  C.elegans were grown on OP50 agar plates  with 
different concentrations of cholesterol from L4 stage for 24hrs and lipid level was measured using Nile red 













































Figure 14Effect of Monosodium Glutamate on C.elegans lipid levels. C.elegans were grown on OP50 agar 
plates  with different concentrations of monosodium glutamate from L4 stage for 24hrs and lipid level was 





3.2.4 Interaction between exercise and diet 
 
Since we demonstrated that exercise affects lipid content in worms, we then examined 
another important factor, which is the interaction between energy input and expenditure. 
More specifically, we focused on the interaction between diet and exercise. C.elegans 
were treated with cholesterol or food additive, monosodium glutamate and tested for 
lipid accumulation on exercise(Figure 15).  Both exercise and monosodium glutamate 
decreased lipid accumulation significantly.  Decrease of lipid accumulation due to 










































Figure 15 Exercise and monosodium glutamate reduce lipid accumulation. C.elegans were grown from L4 
stage to one day adult stage on control, cholesterol(24μM), sodium valproate(VPA, 15mM) or monosodium 
glutamate(MSG, 24mM) plates with either 17g/l agar or 33g/l agar. Agar strength is changed to mimic 




3.2.5 Effects of Valproate on lipid metabolism 
 
After testing the effects of diet and exercise on lipid accumulation, we then tested the 
effect of the C.elegans lifespan extending drug, sodium valproate on lipid metabolism. 
Change in total lipid levels in response to valproate exposure is shown in Figure 16. We 
discovered a significant increase in lipid content between 1mM, 3mM and 9mM 
valproate and these three concentrations alone could explain the correlation of lipid 
mass to sodium valproate dose.  
Having shown that valproate affects lipid metabolism, we also tested another lipid 













































valproate (Tokuoka et al., 2008). Egg laying had a perfect negative correlation with 
valproate dose (Figure  17).  
 
Figure 16Dose response of lipid mass. Figure shows dose response of lipid mass to valproate. Lipid mass 
measured by Nile Red staining of formalin fixed wild type C.elegans after exposure to drug for 24hrs at late L4 







































Figure  17. Correlation analysis of egg laying. Egg laying shows a perfect linear correlation with valproate 
dose. Egg laying assay was performed on one day adult worms on agar plates containing sodium valproate.  
Error bars ± SEM. 
 
 
3.2.6 Effects of insulin pathway on valproate induced lipid accumulation 
 
Having demonstrated that valproate increases lipid levels, we then tested the possible 
molecular mechanism of valproate induced lipid accumulation. Because the insulin 
signalling pathway is known to modulate fat metabolism, I tested the effect of 
perturbation of this pathways on valproate induced lipid accumulation. Specifically I 
tested the effect of down regulation of the genes coding for insulin receptor, daf-2 and 
the FOXO transcription factor, daf-16 on valproate induced lipid accumulation. 
Phenotypic analysis of thedaf-16 null mutant showed a significant increase of lipid mass 
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of valproate. Butdaf-2 the substitution mutant shows a decrease in lipid mass compared 
to control on exposure to valproate (Figure 18).    
 
Figure 18Comparison of valproate effect on lipid mass of insulin and TGFβ pathway mutants. daf-2 is the 
insulin receptor mutant and daf-16 codes for the sole FOXO transcription factor, which acts down stream of 
daf-2 and is negatively regulated by daf-2.daf-1 codes for the part of receptor of TGF-β dauer pathway and 
sma-6 codes for the part of the receptor of TGF-β sma/mad pathway.C. elegans exposed to 15mM sodium 
valproate at L4 stage for 24hrs. sma-6 mutants show paralysis causing death on exposure to sodium valproate. 




3.2.7 Comparison of insulin and TGFβ pathway mutants show a similar inhibitory 
effect of DAF-16 and DAF-1 on valproate induced lipid accumulation 
 
After assessing the effect of insulin pathway on valproate induced lipid accumulation, 
we also tested the effects of the TGF-β pathway, which is also known to be involved in 
lipid metabolism, on the lipid accumulation induced by valproate. Specifically, we 
tested the effect of substitution mutation on daf-1, the type I receptor of the TGF-β 
dauer pathway and sma-6, the type I receptor of the TGF-β Sma/mad pathway. DAF-1, 
















































of valproate induced lipid accumulation, which is similar to the effect of DAF-16 
(Figure3 A).  Mutation of the type I receptor of Sma/Mab pathway (Figure3 C) causes a 
decrease in lipid when treated with valproate. sma-6 mutants like daf-2 insulin receptor 
mutants have high lipid mass compared to the wild type worms and valproate had an 
inhibitory effect on the lipid accumulation of these mutants. Unlike other mutants 




C.elegans has been used extensively in lipid studies but this is the first time it has been 
used to study the link between the effects of exercise and obesity caused by valproate. 
The findings suggest C.elegans is a good model system to study obesity in a much 
simpler model, with different diets, variable exercise programs and ease of genetic 
manipulation.  The availability of mutant lines for most genes also helps to dissect the 
underlying genetic mechanisms in obesity and exercise in C.elegans.  
 
3.3.1C.elegans is a good obesity model 
 
Obesity can be induced in C.elegans by genetic mechanisms, by varying diet or 
modifying exercising. For example in the present study it is found that mutants of fat 
metabolism such as daf-2 and nhr-80  accumulate fat. daf-2encodes the sole C.elegans’ 
insulin receptor like protein. NHR-80 regulates expression of ∆9 desaturases fat-5,6 and 
7 genes, which regulates fatty acid metabolism and accumulates more saturated 
fats(Brock and Watts, 2006).Cholesterol is a well-known dietary component that cause 
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obesity. The current study found that supplementation of cholesterol causes fat 
accumulation in wild type C.elegans. C.elegans are auxotrophs for sterol biosynthesis 
as they lack enzymes required for denovo biosynthesis of sterols (Matyash et al., 2001). 
Therefore, their sole source of cholesterol is from the diet and can be used to study the 
effects of differing concentrations of dietary cholesterol, without interference from 
denovo synthesized cholesterol. High fat diets are known to cause obesity in human and 
mice. 
1.125% dietary monosodium glutamate (MSG) is known to cause weight gain, adiposity 
and reduce insulin sensitivity in feline models and it is known to cause obesity in human 
(Collison et al., 2009). Therefore, it is interesting to investigate how MSG may affect 
lipid levels and its underlying molecular mechanisms, as it is a food additive 
increasingly used in the fast food industry.  A decrease in lipid levels was observed on 
exposure to MSG at the concentration range tested and may indicate a dose dependent 
difference in effects. These findings again suggest C.elegans is a good model system to 
study obesity.  
 
3.3.2 Developing an effective methodology for lipid quantification in C.elegans 
 
Several methods have been developed to study lipid content in nematodes. Sudan Black 
dye is found to be error prone in C. elegans due to washing steps with ethanol. Nile red 
staining of live C.elegans was a popular method as it provides a way to study lipid 
accumulation in the live nematode. However, the suitability of this method was 
questioned recently as it was found that Nile red is identified by the C.elegans as a 
foreign body and is directed to lysosoms for degradation.  It is also suggested that this 
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has led to the misconception that C.elegans store fat in lysosomal bodies in the gut. 
Therefore lipid staining of formalin fixed C.elegans has been suggested. This method 
involves fixation of C.elegans with formalin followed by quick freeze thawing to crack 
the cuticle for Nile red staining. The stained C.elegans are mounted on agarose pads and 
Nile red fluorescence intensity is measured. This method has several drawbacks. Nile 
red gives fluorescence in hydrophobic environment and its fluorescence is quenched by 
water(Greenspan et al., 1985). When mounted on agarose pads, agarose gives high 
background fluorescence. Also mounting on agarose pads is time consuming and only a 
few samples can be done as Nile red loses its fluorescence with time. Therefore, the 
original method was modified to make it simple, quick and to reduce background 
staining. This is achieved by replacing the step of mounting on agarose pads with 
adding fixed stained C.elegans directly on to 96 well plates with 10μl water where they 
get attached to the plate bottom due to hydrophobic interactions. Nile red gives 
fluorescence in hydrophobic environments. Use of an aqueous environment for 
mounting reduces background fluorescence. Nile red tends to lose fluorescence intensity 
over time. This modified step reduces time taken and thus reduces the effect of loss of 
Nile red intensity during measurement between samples. This modified method shows 
daf-2 mutants and cholesterol supplemented wild type C.elegans to have high fat levels 
in a dose dependent manner. Due to the high fat content of egg yolk, eggs are expected 
to have higher lipid levels than the rest of the body. Limitations of this novel method 
include the possible disruption of lipid stores on fixation with formalin and possible 
quenching of the signal by water in addition to background. It also does not provide any 
details of the types of lipids in the sample. Extraction of lipids into organic solvents 
followed by quantification using spectroscopy would be another possibility. However, 
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that will require the time consuming picking of individual worms and extraction may 
not be 100% efficient. Another option would be to quantify lipids using several of these 
methods and get the mode of the values. That will be time consuming and difficult to 
perform. Label free stimulated Raman scattering microscopy proposed as a better option 
but that requires special instrumentation(Wang et al., 2011).   This modified Nile red 
staining of fixed worms provides an easy assay system to quantify lipid accumulation 
but requires fluorescence imaging facilities. Lipid quantification of C.elegans requires 
further improvements to make a reliable, simple assay system to quantify different types 
of lipids. 
 
3.3.3 Exercising decreaseslipidmass in C.elegans 
 
In this study, we have tested the effects of exercising on nematodes. The possibility of 
forcing C.elegans to do physical exercise is tested by growing them on agar plates with 
different agar concentrations ranging from 5g/l to 35g/l. Crawling on different 
concentrations of agar requires different amounts of energy (KIM et al., 1999) and it is 
therefore comparable to different amounts of physical exercise. C.elegans grown on 
35g/l agar had the lowest amount of lipid. The total lipid level increased when agar 
concentration is decreased up to 20g/l. C.elegans makes a grove when crawling on agar 
surface and it needs more energy to crawl on high gel strength medium than soft agar as 
it may need to spend more energy to make a grove on high gel strength medium than in 
soft agar medium. This needs more caloric expenditure, which explains the observed 
results. Agar concentrations below 17g/l were soft and C.elegans showed burrowing 
and at 5g/l they changed to a swimming mode of movement. Burrowing may give more 
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exercise than swimming resulting in a lower level of lipid mass from 10g/l to 15g/l agar 
concentrations. Exercising C.elegans in liquid medium with varying densities may have 
been better because it will eliminate the possibility of changing mode of movement. But 
solid agar was preferred due to the difficulty of identifying contamination in liquid 
medium and difficulty of comparing data with other experiments. 
Exercise also significantly reduced lipid level in C.elegans with accumulated fat due to  
sodium valproate (Figure 15, page 47). Exercising also reduced fat in wild type 
C.elegansand C.elegans treated with MSG but it failed to decrease lipid accumulated 
due to cholesterol. This may indicate an important medical phenomenon where lipid 
accumulation due to cholesterol may be resistant to exercise while lipid accumulation 
due to other factors may decrease by exercise. High density lipoprotein cholesterol is 
found to increase with increasing aerobic exercise training in men(Leon and Sanchez, 
2001).Exercise reduce total serum cholesterol and triglycerides in women(Lokey and 
Tran, 1989).The observed differences in the Nile red intensity of Figure 13(page 45) and 
Figure 15(page 47)could possibly be due to a saturation effect. Other factors such as 
humidity, slight variations in temperature also affect growth of C.elegans and can cause 
variations in lipid level. With short life span, C.elegans also provides a good model 
system to study the effect of exercise on life span. This data suggest C.elegans to be a 
good model system to study the effects of exercise on lipid levels. The ideal method 
would be to monitor the energy expenditure on exercising and relate that with lipid 
level. This may be performed by measuring the amount of oxygen consumed or the 





3.3.4 Increase of lipid mass by valproate is dependent on daf-2 but independent of 
daf-16 
 
Mutant analysis shows that valproate induced lipid accumulation requires both daf-2 
and sma-6 activity but is independent of daf-1 and daf-16. Activation of daf-2 prevents 
nuclear localization of daf-16 and its effects on transcription of downstream targets  ( 
(Tatar et al., 2003). Mutation of daf-2 relieves this inhibitory effect on DAF-16, which 
may act probably via its downstream target genes to inhibit increase of lipid mass by 
sodium valproate. Valproate cause more lipid accumulation in daf-1 and daf-16 mutants 
than in wild type worms suggesting an inhibitory effect of DAF-16 and DAF-1 on 
valproate induced lipid accumulation. It has been suggested that DAF-16 may be acting 
as a repressor of metabolic genes that inhibit energy storage (Ogg et al., 1997) and the 
present study supports that.  
To understand the molecular mechanisms of how insulin signalling pathway affect 
valproate induced lipid accumulation expression profiling was done on C.elegans 














In the previous chapter I describe a high fat phenotype observed in C.elegans following 
exposure to Sodium Valproate.  I found that this lipid accumulation of valproate 
exposure is affected by the insulin signalling and TGF-β pathways. I also observed 
paralysis of the TGF-β Sma/Mad pathway type I receptor mutant in response to 
valproate indicating a novel neuronal phenotype. But what could be the possible 
molecular changes associated with these observed phenotypes?  
In order to understand the underlying molecular changes associated with valproate 
exposure, I performed expression profiling on C.elegans exposed to different 
concentrations of Sodium Valproate. I saw a marked down regulation of nuclear 
components on exposure to valproate (Figure 19).  By analysing these expression 
profiles, a possible hypothesis is generated to explain the increase of lipid accumulation 
in valproate exposure. In the last chapter I discuss the molecular changes of valproate 
exposure associated with neuronal function.  
 
Figure 19 Diagram depicting the observations found during the present study on C.elegans exposed to 
valproate. The molecular changes associated with these observations are further tested by expression profiling 




4.2.1 Correlation analysis 
 
After showing that valproate has both metabolic and neuronal functions phenotypically, 
I assessed the molecular features associated with these phenotypes by microarray 
expression profiling. To do this, I first identified genes who‘s expression significantly 
varied on exposure to valproate, before investigating the correlation between valproate 
and lipid accumulation. Significantly changed gene expressions identified by correlation 
analysis with 1% BH corrected p value on valproate exposure identified an overall 
positively correlated gene expressions with a marked down-regulation in genes coding 
for components located in the nucleus. A positive correlation of cellular functions such 
as dephosphorylation, cellular detoxification, structural components and lipid 
metabolism (Table 3, page 61) are accompanied by a negative correlation of cell 
division, reproductive development process and neuron differentiation (Table 5, page 
70).  Lists of genes in each cluster are given in  
Table 4 (page 63) and Table 6 (page 72). After identifying the significantly changed 
microarray expression profile associated with Valproate, I then put the positively 
correlated and negatively correlated expression profiles with valproate into functional 
groups using DAVID to identify any GO functional terms that were significantly 
enriched in each cluster.  
 
4.2.1.1DAVID fucntional clustering of the positively correlated expression profile 
 
The positively correlated expression profile of valproate exposure was enriched in the 
functional terms such as structural constituent of cuticle, phosphate metabolic process, 
lipid metabolism, carbohydrate binding, iron ion binding, limonene and pinene 
degradation and glutathione transferase.  
A number of collagen genes are identified under the functional term ‗structural 
constituent of cuticle‘. Several uncharacterised phosphatases, serine/threonine kinases, 
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are among the genes under the functional term phosphate metabolic process. It also 
contains several hydroxysteroid dehydrogenases, which are involved in steroid 
synthesis(Stelzer et al., 2008), glycerol-3-phosphate dehydrogenase which links 
carbohydrate metabolism with lipid metabolism(Turyn et al., 2003) by converting 
dihydroxyacetone phosphate to glycerol-3-phosphate. This enzyme is involved in lipid 
biosynthesis by providing glycerol-3-phosphate for the formation of glycerol by 
dephosphorylation. Glycogen synthase kinase is also among that group. Glycogen 
synthase kinase phosphorylates its subject and inhibit glycogen synthesis(Jarvill-Taylor 
et al., 2001). Guanylate cyclase is also positively correlated with valproate under this 
category. Guanylate cyclase is involved in the synthesis of cGMP which signal for 
insulin secretion(Lucas et al., 2000). In addition to the above mentioned genes, several 
ABC transporters and multidrug resistance genes are also found under the functional 
term ‗ATP binding‘. Choline kinase B which catalyses the committed step of the 
formation of phosphocholine for phosphatidyl choline synthesis(Warden and Friedkin, 
1985), the main phospholipid found in eukaryotic membranes is also positively 
correlated under this category. Glutamine synthase, which catalyses the formation of 
glutamine from glutamate terminating neurotransmission (Safran et al., 2010) is also 
found under this functional group. MAP kinase, which affects several biological 
functions is also among these positively correlated ATP binding category. Several 
UDP-glucuronosyl transferases and lectins are found under the functional terms ‗lipid 
glycosylation‘ and ‗carbohydrate binding‘. Several cytochrome 450 genes were 
identified under the functional term ‗iron ion binding. Tryptophan-2,3-dioxigenase, the 
enzyme that catalyzes the rate limiting step in tryptophan degradation via kynurenine 
pathway(Moroni, 1999) and phytanoyl-CoA dioxygenase which is involved in alpha-
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oxidation of fatty acids (Wanders et al., 2003) are also included in this cluster with 
abnormal dauer formation genes daf-9 and daf-36. emb-8 found in this cluster is known 
to code for NADPH cytochrome p450 reductase (Rappleye et al., 2003) that is predicted 
to function in fatty acid modification by reduction of P450 monooxygenase enzymes.  
In addition to cytochrome p450 genes, enoyl-CoA hydrates which catalyse the second 
step in β-oxidation of fatty acids (Mittendorf et al., 1998) are identified under the 
functional term limonene and pinene degradation.  
Acyl-CoA dhydrogenase and 3-hydroxyacyl-CoA dehydrogenase which catalyse the 
first and third steps in β-oxidation of fatty acids (Kantor et al., 2000) are found in the 
cluster ‗oxidation reduction‘. It also contains glucose-6-phosphate dehydrogenase which 
catalyses the rate limiting step in pentose phosphate pathway and makes NADPH 
required for lipid synthesis (Pandolfi et al., 1995). 
In addition to these lipid metabolising genes, a number of major sperm proteins are also 
identified. These proteins are the most abundant proteins found in C.elegans sperm and 
they help the sperm to propel and once released they act as hormones that contracts 
oviduct and oocyte maturation. In addition to major sperm protein, spe-41 is a gene 
required for proper sperm oocyte interaction. 
Several glutathione transferases involved in cellular detoxification are also enriched in 




Table 3 DAVID functional clustering of expression profiles positively correlated with valproate exposure. A 
threshold of 1% BH corrected p value is used to identify the significant expressions. 
Cluster Enrichment 
score 
Term Count Benjamini 
1 20.604504 SMART:PTPc 48 2.01E-25 
  GOMF:phosphatase activity 79 5.66E-23 
  SP_PIR:hydrolase 81 4.71E-04 
2 15.848884 INTERPRO:Nematode cuticle collagen, N-terminal 56 6.12E-19 
  INTERPRO:Collagen triple helix repeat 61 7.15E-18 
  GOMF:structural molecule activity 99 3.80E-12 
3 9.3937479 GOBP:phosphate metabolic process 151 3.70E-36 
  GOBP:phosphorylation 96 1.11E-15 
  SMART:SH2 26 6.30E-10 
  GOMF:ATP binding 127 0.003548 
  GOMF:adenyl nucleotide binding 134 0.003644 
  GOMF:purine nucleotide binding 144 0.06807 
4 9.3438724 INTERPRO:Metallophosphoesterase 28 1.28E-10 
5 5.380872 SP_PIR:collagen 34 1.46E-09 
  SP_PIR:cuticle 13 7.91E-04 
6 5.2624126 INTERPRO:Glutathione S-transferase, N-terminal 20 1.83E-06 
  INTERPRO:Thioredoxin fold 24 0.01276 




  GOMF:carbohydrate binding 31 0.041588 
8 3.8045691 GOMF:iron ion binding 49 5.27E-04 
  Cytochrome P450, conserved site 20 6.66E-04 
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  KEGG:Limonene and pinene degradation 8 0.006625 
  GOMF:electron carrier activity 37 0.009878 
  SP_PIR:Monooxygenase 19 0.013434 
9 3.4384841 INTERPRO:Major sperm protein 27 5.39E-08 
  INTERPRO:PapD-like 25 1.55E-07 
  SP_PIR:cytoskeleton 21 0.109352 
10 2.9954186 SMART:BRCT 11 0.00155 
  INTERPRO:Ankyrin 17 0.100955 
11 2.2248019 INTERPRO:Protein of unknown function DUF856, 
Caenorhabditis species 
5 0.03768 
12 2.0831552 SMART:CHK 8 0.054519 
13 1.750404 PIR_SUPERFAMILY:glutathione transferase 8 0.15639 
  KEGG:Metabolism of xenobiotics by cytochrome 
P450 
6 0.090779 
14 1.6786155 SMART:CLECT 32 0.121572 
15 1.6736906 INTERPRO:NADH:flavin oxidoreductase/NADH 
oxidase, N-terminal 
5 0.063405 
16 1.4671233 PIR_SUPERFAMILY:gliadin 5 0.12707 
17 1.431552 SMART:NRF 6 0.142466 
18 1.3562886 INTERPRO:Protein of unknown function DUF38, 
Caenorhabditis species 
35 0.038335 
23 1.1386328 INTERPRO:2Fe-2S ferredoxin, iron-sulphur binding 
site 
6 0.098803 
26 0.9791065 INTERPRO:Heat shock protein Hsp20 6 0.166244 
28 0.9443988 SMART:ZnMc 10 0.129871 
29 0.8904833 KEGG:Fatty acid metabolism 8 0.164282 
43 0.3840152 INTERPRO:ABC transporter-like 13 0.048339 




Table 4 Lists of genes in each DAVID functional cluster of positively correlated with valproate expression 
profile identified by regression analysis with a BH corrected p value of 1% are shown in the table.  Functional 










R06B10.1, R06B10.2, ZK484.7, W03F11.4, PHOPHATASE, F23B12.1, T22C1.8, F52H3.6, F47B3.1, 
W01B6.6, Y57G11C.6, Y54G2A.24, Y62F5A.10, ZK783.5, F36H1.3, T20B6.1, F52E1.8, F42C5.5, 
Y113G7C.1, F55H12.5, C02B10.6, W03D8.2, C55B7.3, F20H11.4, C34D4.2, C17H12.5, Y105C5B.3, 
Y105C5B.15, C27A2.4, M05B5.1, C15H7.3, T16G12.7, Y22D7AR.12, C48B6.4, Y39B6A.18, 
Y22D7AR.7, M04G7.2, R09E10.9, GSP-3, C33H5.16, GSP-4, CDC-25.4, Y69E1A.4, T28F4.3, C46A5.1, 
Y41D4A.5, F22D6.9, F35C11.2, VHP-1, Y54F10BM.3, F13D11.1, C43E11.5, F40G12.10, B0207.1, 
C23G10.1, Y71H2AM.16, TYROSINE-PHOSPHATASE, F58G1.3, ZK354.8, ZK354.9, T13B5.3, 
F54F12.1, Y48G1C.5, ZK616.7, C24D10.1, R155.2, ZK938.1, H06I04.5, R155.3, C33F10.8, F47B3.6, 






DPY-8, COL-58, DPY-4, DPY-20, COL-3, DPY-13, COL-156, COL-155, COL-94, COL-117, COL-152, 
COL-98, COL-113, COL-111, COL-112, COL-91, COL-90, COL-48, COL-13, COL-49, BLI-2, COL-150, 
BLI-1, SQT-2, SQT-1, LON-3, COL-85, COL-141, COL-88, COL-89, COL-107, COL-41, COL-103, 
COL-149, COL-182, COL-176, COL-71, COL-175, COL-137, COL-174, COL-173, COL-138, COL-79, 
COL-130, COL-77, COL-133, COL-73, COL-170, COL-126, COL-162, COL-127, COL-60, COL-167, 






R06B10.1, K06H7.8, R06B10.2, C18H7.4, ZK666.8, F26A1.3, TAG-191, R10D12.10, ZK484.7, 
F48G7.10, F01D4.3, W09C3.1, C03C10.2, C14A4.13, W06F12.3, C27D8.1, F54H5.2, T22C1.8, F26E4.5, 
W03A5.1, F47B3.1, ZC449.3, ZC581.7, F42C5.5, F57B9.8, F55H12.5, C02B10.6, R13H9.5, M7.7, 
C55B7.3, F20H11.4, F26A1.4, T19D12.5, B0207.7, C56C10.6, ZC373.3, Y47G6A.13, R09E10.9, 
C33H5.16, CDC-25.4, DLK-1, H05L14.1, C46A5.1, F35C11.2, VHP-1, Y54F10BM.3, C43E11.5, 
F21F3.2, B0207.1, KIN-5, TYROSINE-PHOSPHATASE, T06C10.3, GCY-2, Y48G1C.5, ZK616.7, 
R155.2, ZK593.9, R155.3, C33F10.8, T25B9.4, C50F4.10, SPE-6, T05A7.6, PPH-2, D2024.1, C35E7.10, 
C05C12.1, Y69F12A.1, R03D7.5, T05C12.1, Y73B6A.1, W03F11.4, C25A8.5, W02B12.12, Y50E8A.6, 
B0218.5, TAG-344, Y116A8C.38, B0222.9, GPDH-1, Y57G11C.6, W01B6.6, FRK-1, F38E1.3, GSKA-3, 
Y62F5A.10, ZK783.5, F35C11.3, F36H1.3, Y39G8C.2, T20B6.1, W01B6.5, F25F2.1, ZK507.1, 
Y113G7C.1, M05D6.1, ZK945.6, B0252.1, VHA-19, C34F11.5, GCY-12, F59A3.8, F53C3.1, C17H12.5, 
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ZK507.3, Y116A8C.24, Y43C5B.2, F59A6.4, C15H7.3, M05B5.1, KIN-26, Y22D7AR.12, C48B6.4, 
Y22D7AR.7, Y39B6A.18, M04G7.2, C28A5.6, T14E8.1, C08F8.6, D2045.5, F23C8.7, T28F4.3, 
Y41D4A.5, T15B12.2, C55C3.4, F41G3.5, F40G12.10, F36H12.8, K09C6.1, KIN-31, F36H12.9, MPK-2, 
Y18H1A.10, ZK354.6, C39H7.1, T11F8.4, ZK354.8, Y71F9AL.2, C49C8.1, F54F12.1, F09A5.2, 





K06H7.8, B0286.3, W02H5.8, C18H7.4, ZK666.8, F26A1.3, TAG-191, R10D12.10, F48G7.10, F01D4.3, 
HUM-8, W09C3.1, MRP-2, C03C10.2, C14A4.13, MRP-3, W06F12.3, HUM-5, C27D8.1, ABT-5, ABT-4, 
F54H5.2, ABT-2, ABT-1, F26E4.5, W03A5.1, ZC449.3, F57B9.3, ZC581.7, F57B9.8, R13H9.5, M7.7, 
M04C3.1, F26A1.4, T19D12.5, GARS\/AIRS\/GART, B0207.7, C56C10.6, ZC373.3, Y47G6A.13, DLK-1, 
H05L14.1, F21F3.2, KIN-5, T06C10.3, GCY-2, ZK593.9, WHT-4, WHT-5, HAF-7, T25B9.4, C50F4.10, 
WHT-8, WHT-6, SPE-6, T05A7.6, WHT-1, C35E7.10, D2024.1, C05C12.1, Y69F12A.1, R03D7.5, HSP-
3, T05C12.1, Y73B6A.1, C25A8.5, CKB-2, SPE-15, W02B12.12, B0218.5, TAG-344, Y113G7B.14, 
B0222.9, Y116A8C.38, FRK-1, F38E1.3, GSKA-3, GLN-2, F35C11.3, Y39G8C.2, W01B6.5, F25F2.1, 
ZK507.1, M05D6.1, B0252.1, 6-PHOSPHOFRUCTOKINASE, C34F11.5, GCY-12, F59A3.8, F53C3.1, 
ZK507.3, Y116A8C.24, Y43C5B.2, F59A6.4, KIN-26, C28A5.6, T14E8.1, Y11D7A.14, C08F8.6, 
F23C8.7, D2045.5, TAT-2, T15B12.2, C55C3.4, F41G3.5, C01G12.8, C29F7.3, F36H12.8, K09C6.1, KIN-
31, F36H12.9, MPK-2, ACT-5, Y18H1A.10, ZK354.6, C39H7.1, T11F8.4, Y71F9AL.2, C49C8.1, 





T16G12.7, R08C7.8, ZC477.2, GSP-3, GSP-4, Y69E1A.4, PHOPHATASE, F23B12.1, F22D6.9, F40B5.2, 
F52H3.6, Y40H4A.2, C23G10.1, F58G1.3, Y54G2A.24, ZK354.9, ZK938.1, C30A5.4, F44B9.9, 
W03D8.2, C47A4.3, H25K10.1, C34D4.2, F25B3.4, Y105C5B.3, Y105C5B.15, ZK856.5, R13A5.11  
5 collagen 
COL-58, COL-70, COL-175, COL-71, COL-3, COL-174, DPY-13, COL-155, COL-173, COL-117, COL-
115, COL-113, COL-79, COL-111, COL-112, COL-110, COL-91, COL-90, COL-73, COL-48, COL-13, 
COL-49, COL-170, BLI-1, SQT-1, LON-3, COL-104, COL-167, COL-88, COL-141, COL-107, COL-103, 






GST-15, Y45G12C.3, F56A4.4, GST-42, GST-14, GST-29, GST-16, GST-39, GST-38, GST-33, GST-24, 





UGT-16, UGT-28, UGT-39, UGT-33, UGT-41, UGT-20, UGT-44, UGT-13, UGT-1, UGT-54, UGT-25, 





UGT-29, UGT-16, UGT-39, UGT-19, UGT-28, UGT-33, UGT-22, UGT-32, UGT-41, UGT-44, UGT-20, 
UGT-13, UGT-54, UGT-1, UGT-25, UGT-36, UGT-47, UGT-5, UDP-GLUCOSYLTRANSFERASE, 










T10E10.4, LEC-7, UGT-28, CLEC-85, UGT-41, CLEC-67, UGT-44, UGT-20, UGT-25, UGT-47, CLEC-
168, CLEC-44, CLEC-167, UGT-40, CLEC-68, CLEC-169, LEC-11, LEC-10, UGT-16, W04B5.3, CLEC-





CYP-13A2, CYP-13A6, CYP-13A7, CYP-13A4, CYP-13A5, CYP-13A8, MLT-7, PHOPHATASE, 
F23B12.1, GLB-32, CYP-43A1, F52H3.6, CYP-33C8, CYP-14A3, B0222.9, Y54G2A.24, VEM-1, 
W03D8.2, C28H8.11, Y105C5B.9, C34D4.2, CYC-2.2, CYP-33D3, CYP-35C1, DAF-9, T16G12.7, GSP-
3, GSP-4, Y69E1A.4, CYP-33B1, CYP-33E2, CYP-33E3, F22D6.9, F55B11.1, DAF-36, C23G10.1, 
F58G1.3, ZK354.9, F15E6.6, CYP-34A8, EMB-8, CYP-34A6, ZK938.1, CYP-13A12, C47A4.3, CYP-





DAF-9, CYP-13A2, CYP-34A8, CYP-13A6, CYP-13A7, CYP-34A6, CYP-13A4, CYP-13A5, CYP-13A8, 
CYP-13A12, CYP-33B1, CYP-33E2, CYP-33E3, CYP-35A3, CYP-33D3, CYP-43A1, CYP-35C1, CYP-











DAF-9, W01C9.4, CYP-13A2, CYP-13A6, ACDH-4, CYP-13A7, CYP-13A4, CYP-13A5, F54C8.1, CYP-
13A8, ACDH-2, CYP-33B1, CYP-33E2, T05C12.3, ACDH-8, DHS-25, F39B2.3, F55B11.1, Y50E8A.6, 
Y9C9A.16, SOD-5, CYP-33C8, CYP-14A3, DAF-36, GPDH-1, R05D8.7, FMO-3, F36A2.3, ZC449.3, 
CYP-34A8, CYP-34A6, Y39G8B.1, C28H8.11, CYP-13A12, Y105C5B.9, CYP-35A3, CYC-2.2, CYP-






F38H4.6, MSP-31, MSP-32, Y48B6A.5, MSP-36, ZC262.1, Y38F2AR.10, MSP-113, Y59E9AR.7, 
ZK1248.4, C10H11.7, C35E7.9, SSP-11, F13A7.1, MSP-40, MSP-152, Y59E9AR.1, SSP-16, Y53F4B.19, 
R05D3.5, Y23H5A.4, MSP-142, F42A9.7, C14A4.8, MSP-56, MSP-57, ZK1307.4, MSP-59, MSP-53, 
MSP-19, MSP-55, T13F2.12, DCT-9, F58A6.9, MSP-10, F36H12.3, MSP-64, MSP-63, MSP-65, SSP-9, 
K06A5.3, F52F12.8, C35D10.11, SSP-32, MSP-45, ZK354.7, F58E6.5, C35A5.4, MSP-81, C36H8.1, 







F38H4.6, MSP-31, Y48B6A.5, MSP-32, MSP-36, Y38F2AR.10, MSP-113, Y73B6A.1, HUM-8, 
Y59E9AR.7, HUM-5, SPE-15, TBA-8, ZK1248.4, TBA-7, C10H11.7, C35E7.9, TBB-6, F13A7.1, MSP-
40, MSP-152, Y59E9AR.1, W02A2.5, Y53F4B.19, Y113G7C.1, Y19D2B.1, DLC-6, Y23H5A.4, MSP-
142, F42A9.7, F55D12.6, MSP-56, MSP-57, ZC155.2, MSP-59, MSP-53, MSP-19, MSP-55, Y11D7A.14, 
F58A6.9, MSP-10, F36H12.3, MSP-64, MSP-63, MSP-65, HIS-70, K06A5.3, F52F12.8, ACT-5, ZK354.7, 
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MSP-45, F58E6.5, Y48G1C.5, C35A5.4, T06E4.5, MSP-81, H06I04.5, C36H8.1, MSP-49, C25D7.1, 




F26D2.10, C49G7.1, Y47D3A.22, F36D3.5, C01G10.1, H32C10.3, C18H2.3, C18H2.5, T08G3.7, 


















GST-42, GST-38, GST-7, GST-8, GST-5, GST-22, GST-6, GST-30 
 
 
4.2.1.2 DAVID fucntional analysis of the negatively correlated expression cluster 
 
Genes showing negative correlated expression profiles following valproate exposure 
were enriched in functional terms such as cell division, DNA replication, regulation of 
transcription, mediator complex and RNAII transcription factor activity. The genes 
negatively correlated under the functional term cell division includemes-1 involved in 
the positioning of early mitotic spindle and associated P granules(Berkowitz and 
Strome, 2000),  ptc-1 required for the isolation of meiotic nuclei from one 
another(Bürglin and Kuwabara, 2006),  pig-1 gene product required for normal polarity 
in asymmetric cell division yielding apoptotic cells vs neurones(Chien et al., 2013), cdk-
5 that affects pronuclear migration (Park et al., 2012, Goodwin et al., 2012), sqv-5 
which encodes a chondroitin synthase that is required for cytokinesis; gonad migration 
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and vulval morphogenesis (Herman et al., 1999, Yamada et al., 1999, Toyoda et al., 
2000), let-99 required for mitotic spindle orientation(Tsou et al., 2002),evl-20 required 
for micron cytokinesis (Antoshechkin and Han, 2002, Radcliffe et al., 2000, 
Bhamidipati et al., 2000), cks-1, which encodes the cyclin dependent protein kinase 
regulatory subunit that inactivates M-phase promoting factor (Polinko and Strome, 
2000), mei-1 and mei-2 required for oocyte meiotic spindle formation(Mains et al., 
1990, Clark-Maguire and Mains, 1994), mau-2 required for mitotic chromosome 
segregation; egg laying and axonal migration (Hekimi et al., 1995, Takagi et al., 1997, 
Bénard et al., 2004, Seitan et al., 2006), knl-1 and knl-3; the components of kinetochore 
required for spindle elongation and chromosome separation (Gönczy et al., 2000, Desai 
et al., 2003, Cheeseman et al., 2004), ligase, puf-3 required for spindle positioning 
(Piano et al., 2000, Wickens et al., 2002), cpg-1 which codes for chondroitin 
proteoglycan required for chromosomal segregation during meiosis (Lee and Schedl, 
2001, Kamath et al., 2003) andcdc-26, which codes for anaphase promoting complex 
(Li et al., 2004, Dong et al., 2007). 
DNA polymerase, DNA helicase, cel-1; an mRNA capping enzyme, ligase, rnr-2 ; a 
ribonucleotide reductase, which synthesises deoxyribonucleotides from ribonucleotides, 
rfc-2 and rfc-3 ; DNA replication factors, pcn-1,which codes for proliferating cell 
nuclear antigen ; an essential component of DNA replication and repair machinery are 
enriched in the functional term ‗DNA replication‘.  
nhr-66 a transcription factor whose expression is known to up-regulate on exposure to 
cholesterol(Novillo et al., 2005, Miyabayashi et al., 1999), histone deacetylase 6 which 
repress transcription, isw-1 which codes for  a chromatin remodelling protein(Andersen 
et al., 2006), lin-40 which forms part of the nucleosome remodelling  and histone 
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deacetylation (NURD) complex(Solari and Ahringer, 2000, Chen and Han, 2001), 
transcription initiation factor IIA small chain homolog,  met-2 a histone 
methyltransferase, spr-2, which codes for a member of the SET protein complex that 
functions in chromatin remodelling; DNA repair and transcriptional regulation (Wen et 
al., 2000, Fan et al., 2003),atf-2 which activates transcription factor 2(Wang et al., 
2006),lsd-1 a lysine specific histone demethylase that repress transcription comes under 
the functional term regulation of transcription. 
 In addition to these chromatin remodelling and general transcription factors several 
transcription factors involved in neurone growth and differentiation are also found in 
this cluster. They include  ceh-30 which is involved in neuronal cell fate; 
determination(Peden et al., 2007),  ast-1 which codes an ETS-box transcription factor 
that is required for proper initiation and maintenance of dopamine neuron fate which 
itself is regulated by LIN 11(Hutter et al., 2005, Schmid et al., 2006, Flames and 
Hobert, 2009),egl-43 which is egg laying defective and affects HSN cell migration and 
the development of the phasmid neurones(Desai et al., 1988),unc-120 required for 
locomotion and muscle development,ceh-36 which codes for a transcription factor 
required for specification of the AWC olfactory neuron and for establishing left-right 
asymmetry of the ASEL and ASER gustatory neurons(Lanjuin et al., 2003),  pcaf-1 
which codes C.elegans’ sole histone acetyl transferase, lim-4 which is required for 
differentiation of AWB chemosensory neurones; some RID motor neurone 
differentiation; expression of ser-2 and SAA neutrite outgrowth(Sagasti et al., 1999, 
Tsalik et al., 2003);   lin-32 required for the development of neurones(Mitani et al., 
1993), cfi-1 which acts downstream of LIN-32 and affects differentiation of URA 
sensory neurone; AVD and PVC inter-neurones(Shaham and Bargmann, 2002), unc-130 
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that affects the generation of AWA and ASG chemosensory neurones and is required 
for the expression of unc-129 TGFβ guidance factor(Sarafi-Reinach and Sengupta, 
2000), unc-42 which are egg laying defective and is required to specify the fate of ASH 
sensory neurones, AVA; AVD and AVE interneurones and some motor 
neurones(Wightman et al., 1997, Baran et al., 1999, Brockie et al., 2001). 
Several other genes coding for transcription factors including egl-18 which is egg laying 
defective, nhr-40 a nuclear hormone receptor where the mutants are slow moving and 
uncoordinated with reversing direction and going in circles and several components of 
the  transcription mediator complex rgr-1; mdt-8; mdt-11 and  mdt-15 are enriched in 
the functional term ‗regulation of transcription‘.   It is observed that C.elegans goes in 
circles and change direction more frequently on exposure to valproate. Several 
components of the mediator complex and the RNAII transcription factor activity are 
also negatively correlated with valproate. 
A striking feature of this negatively correlated expression profile of valproate exposure 
is that most of them code for nuclear components. The above analysis identified the 
molecular pathways linked to this down regulation of nuclear components. Ninety-two 
of them made a single network indicating a common mechanism for gene expression, 
which is affected by valproate. Most of them are interconnected with rfc-3 having the 
highest connectivity score (Figure 20, page74). rfc-3is connected to 27 components out 
of the 92 interconnected components (Table 7, page 75). The top ten genes found in this 
search are mapped in WormNet to identify their connectivity among themselves and is 
given in Table 8. Thereforerfc-3 could be a key gene through which down-regulation of 
nuclear components occur following valproate exposure. To identify the regulators of 
these pathways, I looked at the transcription factors connected to these components. 
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vab-3 is the transcription regulator that had the highest connectivity score. It was 
connected to 7 components implying it to be a key regulator of the negative correlation 
of nuclear components with valproate dose. Since vab-3 is also down-regulated on 
exposure to valproate, it may be having an inhibitory effect on a key component that 
cause down regulation of genes coding for nuclear components. TheWnt signalling 
pathway, which has been described previously to be involved in valproate 
exposure(Gurvich and Klein, 2002) regulates vab-3 expression (Johnson and 
Chamberlin, 2008). I also mapped the transcription factors identified in this analysis on 
WormNet to find the transcription factor with highest connectivity to other transcription 
factors which are negatively correlated and that was also found to be vab-3 (Figure 21, 
page80). vab-3 is also positively regulated by RNA polymerase II promoter supporting 
the hypothesis that valproate may be acting on this promoter to bring its effects. sma-6, 
daf-2 and daf-16 which are found to be involved in valproate induced lipid 
accumulation in the phenotypic analysis are connected to this cluster of transcription 
factors via unc-3, an immunoglobulin domain containing transcription factor.  
 
Table 5 DAVID functional clustering of gene expression profiles negatively correlated with valproate. A 
threshold of 1% BH corrected p value is used to identify the significant expressions. 
Cluster Enrichment score Term Count Benjamini 
1 5.418025 GOBP:tissue morphogenesis 50 8.70E-05 
  GOBP:morphogenesis of an epithelium 48 1.06E-04 
  GOBP:reproductive developmental process 86 0.003037 
  GOBP:hermaphrodite genitalia development 74 0.003626 
  GOBP:sex differentiation 80 0.003775 
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2 4.5862188 SP_PIR:cell cycle 18 6.34E-05 
  GOBP:cell division 29 0.004132 
3 2.7895358 GOBP:DNA replication 14 0.006634 
  GOBP:DNA metabolic process 21 0.086511 
  KEGG:Mismatch repair 6 0.099903 
  KEGG:Base excision repair 5 0.198048 
4 2.333731 INTERPRO:Immunoglobulin-like fold 13 0.067869 
5 2.1367808 SP_PIR:nucleus 80 3.93E-04 
  SP_PIR:Homeobox 18 4.73E-04 
  GOMF:DNA binding 79 0.087607 
  SMART:HOX 18 0.14043 
  SP_PIR:dna-binding 47 0.075483 
6 2.0183949 GOCC:nucleoplasm 11 0.019123 
  GOCC:nuclear lumen 12 0.064516 
  GOCC:Srb-mediator complex 5 0.123916 
  GOCC:intracellular organelle lumen 14 0.157436 
8 1.9788232 GOCC:chromatin 12 0.003851 
9 1.9677001 SP_PIR:sh3 domain 8 0.072719 
10 1.9072694 GOBP:cellular component morphogenesis 20 0.036085 
  GOBP:neuron differentiation 13 0.062106 
  GOBP:cell projection organization 14 0.079005 
  GOBP:cell motion 15 0.145949 
11 1.8748935 GOBP:chromosome organization 24 0.003969 
  GOBP:kinetochore assembly 4 0.088987 
  GOBP:centromere complex assembly 4 0.088987 
13 1.7863499 SP_PIR:tpr repeat 7 0.079355 
16 1.7044824 GOBP:cell cycle 42 0.004196 
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17 1.6861614 SP_PIR:wnt signaling pathway 6 0.076356 
19 1.5877662 GOBP:glycosaminoglycan metabolic process 4 0.052188 
25 1.345056 SP_PIR:glycoprotein 39 0.037395 
  SP_PIR:signal 34 0.150913 
27 1.2345633 GOBP:protein-DNA complex assembly 9 0.088448 
41 0.9299484 SP_PIR:mitosis 7 0.177892 
63 0.5220007 SP_PIR:myristate 6 0.103074 
 
 
Table 6 Lists of genes in each DAVID functional cluster of down-regulated valproate correlated expression 
profile identified by regression analysis with a BH corrected p value of 1% are shown in the table.  Functional 
















LIN-17, C31H1.8, EGL-43, SDZ-30, EVL-14, MIG-14, GFI-2, SQV-5, SOX-2, DPY-17, Y65B4A.6, HCP-3, 
SEM-5, MOM-1, M01B12.5, ARL-5, CEH-30, HTZ-1, CE7X_3.2, CYK-1, TAG-246, KNL-1, UNC-61, 
KNL-3, F39B2.1, Y65B4BR.8, MCM-7, F33H2.5, CLEC-1, CPG-1, KBP-4, CSN-1, EGL-18, Y110A7A.8, 
NPP-4, F42G2.6, ABI-1, R08C7.4, VAB-1, CHTL-1, SCC-1, MET-2, KBP-1, TCL-2, UFD-2, ANI-1, UBA-
2, ISW-1, LIN-40, WEE-1.3, DSH-2, F25B5.2, CPAR-1, RFC-3, EIF-3.E, C06A5.3, EVL-20, ZK858.1, 
RSP-6, RSP-5, TEN-1, ZK616.4, C07A9.2, GEI-17, ZK686.1, UNC-6, C15C6.4, UNC-5, T20B12.1, 
F48C1.4, COGC-3, RNP-6, SYS-1, SAN-1, F09F9.4, DPY-22, NCBP-1, F25H5.5, Y71G12B.11, UTX-1, 





LIN-17, EGL-43, SDZ-30, EVL-14, MIG-14, GFI-2, SOX-2, DPY-17, Y65B4A.6, HCP-3, MOM-1, SEM-5, 
M01B12.5, CE7X_3.2, HTZ-1, CYK-1, TAG-246, KNL-1, UNC-61, KNL-3, F39B2.1, Y65B4BR.8, MCM-
7, F33H2.5, CLEC-1, KBP-4, CSN-1, EGL-18, Y110A7A.8, NPP-4, F42G2.6, ABI-1, R08C7.4, CHTL-1, 
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SCC-1, MET-2, KBP-1, TCL-2, ANI-1, UBA-2, ISW-1, LIN-40, F25B5.2, DSH-2, RFC-3, CPAR-1, EIF-
3.E, C06A5.3, EVL-20, ZK858.1, RSP-6, RSP-5, ZK616.4, C07A9.2, GEI-17, ZK686.1, C15C6.4, 
T20B12.1, F48C1.4, COGC-3, RNP-6, SYS-1, SAN-1, F09F9.4, DPY-22, NCBP-1, F25H5.5, Y71G12B.11, 






LIN-17, EGL-43, SDZ-30, EVL-14, MIG-14, GFI-2, SQV-5, SOX-2, DPY-17, Y65B4A.6, HCP-3, SEM-5, 
MOM-1, M01B12.5, ARL-5, CEH-30, HTZ-1, CE7X_3.2, CYK-1, TAG-246, KNL-1, UNC-61, KNL-3, 
F39B2.1, Y65B4BR.8, MCM-7, F33H2.5, CLEC-1, KBP-4, CSN-1, EGL-18, Y110A7A.8, NPP-4, F42G2.6, 
ABI-1, R08C7.4, CHTL-1, SCC-1, MET-2, KBP-1, TCL-2, ANI-1, UBA-2, ISW-1, LIN-40, F25B5.2, DSH-
2, CPAR-1, RFC-3, EIF-3.E, C06A5.3, EVL-20, ZK858.1, RSP-6, RSP-5, TEN-1, ZK616.4, C07A9.2, GEI-
17, ZK686.1, UNC-6, C15C6.4, UNC-5, T20B12.1, F48C1.4, COGC-3, RNP-6, SYS-1, SAN-1, F09F9.4, 




F22B3.4, MES-1, PTC-1, CDK-5, PIG-1, CDC-25.2, MCM-5, F23C8.9, ANI-1, SQV-5, LET-99, C28C12.2, 
CYK-1, EVL-20, CKS-1, MEI-1, MEI-2, MAU-2, KNL-1, KNL-3, ZK353.1, LIG-1, MCM-7, PUF-3, CPG-





DNA-2, Y57A10A.15, DIV-1, CEL-1, MCM-5, LIG-1, F23C8.9, MTSS-1, MCM-7, F33H2.5, RNR-2, PCN-






DNA-2, Y57A10A.15, DIV-1, CEL-1, GEI-17, LIG-1, MCM-5, F23C8.9, MTSS-1, Y75B8A.6, NUC-1, 











C48E7.2, Y38A10A.6, AST-1, CEH-27, MCM-5, SOX-2, SOX-3, T09A5.8, TBX-33, RAD-54, HCP-3, 
C07E3.6, MLS-2, Y62E10A.17, CEH-30, HTZ-1, CEH-32, HLH-1, CEH-34, NHR-66, UNC-120, 
Y75B8A.6, CEH-36, F44E2.7, MCM-7, CEY-1, F33H2.5, CEY-2, CEY-3, HMG-1.1, PMS-2, ZTF-1, LIM-
4, EGL-18, HIL-5, PCN-1, HIL-7, LIN-32, F42G2.6, DNA-2, CEH-45, VAB-3, NHR-58, GAK-1, 
Y57A10A.15, CFI-1, C05D10.1, DIV-1, CEC-1, MET-2, ATF-2, NHR-15, FKH-5, UNC-130, UNC-42, 
ISW-1, LIN-40, RFC-2, Y116A8C.13, CPAR-1, RFC-3, CEH-2, CEH-5, CEH-13, LIG-1, CEH-16, MTSS-1, 







SET-1, AST-1, EGL-43, CEH-27, MCM-5, LSD-1, TBX-33, F41H10.6, C07E3.6, MLS-2, Y62E10A.17, 
CEH-30, CEH-32, HLH-1, CEH-34, CEH-36, UNC-120, NHR-66, CEY-1, CEY-2, PCAF-1, CEY-3, LIM-4, 
EGL-18, LIN-32, F42G2.6, CEH-45, VAB-3, NHR-58, CFI-1, MET-2, ATF-2, NHR-15, UNC-130, FKH-5, 
SPR-2, UNC-42, ISW-1, LIN-40, CEH-2, B0336.13, CEH-5, CEH-13, CEH-16, UNC-3, NHR-40, RGR-1, 
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CEH-45, VAB-3, AST-1, NHR-58, MET-2, CEH-27, NHR-15, ATF-2, FKH-5, UNC-130, TBX-33, UNC-
42, C07E3.6, LIN-40, MLS-2, Y62E10A.17, CEH-30, CEH-2, CEH-32, CEH-5, CEH-13, HLH-1, CEH-34, 
CEH-16, UNC-3, NHR-66, CEH-36, UNC-120, NHR-40, RGR-1, CEY-1, MDT-8, CEY-2, CEY-3, PCAF-1, 


















Figure 20Network of interconnected nuclear component genes in the down-regulated expression profile of 
sodium valproate exposure. Connections between the nuclear components of the down-regulated expression 
profile of valproate exposure identified in regression analysis at BH corrected p valur of 1% are mapped in 








Table 7 WormNet analysis of the genes ranked by highest connectivity. Nuclear component genes down-
regulated on valproate exposure identified in regression analysis with a BH corrected p value of 1%  are 
ranked according to the highest connectivity. 92 Seed genes were mapped with a p value of 9.8461e
-70
. 
Rank Locus_ID Symbol Score #_linked_seed / 
#_valid_seed 
GO_P 
1 C39E9.13 rfc-3 4.76 27/92 DNA replication; DNA repair; 
gametogenesis; locomotory behavior; 
embryonic development (sensu Metazoa); 
positive regulation of growth rate; 
hermaphrodite genitalia development; 
2 W03D2.4 pcn-1 4.72 35/92 reproduction; cytokinesis; regulation of DNA 
replication; embryonic development (sensu 
Metazoa); embryonic cleavage; 
3 F32D1.10 mcm-7 4.67 24/92 reproduction; cytokinesis; DNA replication 
initiation; embryonic development (sensu 
Metazoa); embryonic cleavage; 
hermaphrodite genitalia development; 
4 F58F6.4 rfc-2 4.19 7/92 DNA replication; gametogenesis; locomotory 
behavior; embryonic development (sensu 
Metazoa); 
5 R10E4.4 mcm-5 4.15 20/92 cytokinesis; DNA replication initiation; 
embryonic development (sensu Metazoa); 
embryonic cleavage; 
6 F57B10.12 mei-2 4.10 19/92 meiotic spindle organization and biogenesis; 
microtubule depolymerization; meiosis; 
embryonic development; embryonic 
development (sensu Metazoa); 
7 F14F3.1 vab-3 4.03 7/92 regulation of transcription, DNA-dependent; 
multicellular organismal development; 
anterior/posterior pattern formation; 
regulation of cell adhesion; tail tip 
morphogenesis (sensu Nematoda); cell fate 
commitment; regulation of transcription; 
positive regulation of transcription from RNA 
polymerase II promoter; 
8 R08C7.3 htz-1 4.02 25/92 larval development (sensu Nematoda); 
nucleosome assembly; chromosome 
organization and biogenesis (sensu 
Eukaryota); locomotory behavior; embryonic 
development (sensu Metazoa); positive 
regulation of growth rate; post-embryonic 
body morphogenesis; 
9 Y45F10A.2 puf-3 3.99 19/92 cytokinesis; embryonic development (sensu 
Metazoa); cellular osmoregulation; 
pronuclear migration; embryonic cleavage; 
10 C28C12.2 na 3.94 16/92 cytokinesis; larval development (sensu 
Nematoda); chromosome segregation; 
locomotory behavior; embryonic 
development (sensu Metazoa); growth; 






Table 8 WormNet analysis of the genes ranked by highest connectivity. Nuclear component genes down-
regulated on valproate exposure identified in regression analysis with a BH corrected p value of 1%  are 
ranked according to the highest connectivity. The top ten genes are mapped in WormNet for their connectivity 
among each other with a p value of 6.8318e
-28




















































































































































































































































































































































































































































































































Figure 21 WormNet analysis of transcription factors negatively correlated with valproate exposure and their 
interaction with the insulin and TGF-β Sma/Mad pathway. Transcription factors significantly negatively 
correlated with  valproate exposure with a BH corrected p value of 1% are mapped in WormNet to identify 
possible interactions. daf-2 , daf-16 and sma-6 are added to identify their link to these transcription factors. 
Vab-3 had the highest connectivity score of 3.95. Insulin signalling pathway is connected to these transcription 
factors via unc-3. 
 
 
4.2.2Comparison of correlation analysis with SAM analysis 
 
Simple correlation analysis identifies only linear relationships. But Significant Analysis 
of Microarray (SAM) is designed to identify any genes differentially regulated in a 
number of sample groups. Therefore by applying this approach to the different dose 
groups we can identify nonlinear relationships as well. Therefore significantly altered 
gene expression profiles identified by regression analysis at 1% BH corrected p value 
are compared with significant expression profile identified by SAM analysis at 1% 
FDR. SAM identified 571 genes not identified by regression analysis (Figure 22, 
page81). These expression profiles identified only by SAM were enriched in functional 
terms such as structural constituents of cuticle (Table 9, page81) and muscle 




Figure 22 Comparison of significant gene expression profiles identified by regression analysis and SAM 
analysis. A threshold of 1% BH corrected p value was used in regression analysis and a 1%FDR in SAM 
analysis.  Positively correlated expression profile with valproate identified by regression analysis is given as 




Table 9 DAVID functional clustering of significant expression profiles with a bell shaped curve with dose 
identified only by SAM but not by regression analysis. A threshold of 1% BH corrected p value is used in the 









1 3.6658165 INTERPRO:Nematode cuticle collagen, N-
terminal 
8 5.67E-04 
  GOMF:structural constituent of cuticle 8 4.29E-04 
  INTERPRO:Collagen triple helix repeat 8 0.001144 
  GOMF:structural molecule activity 9 0.041234 







Table 10 DAVID functional clustering of significant expression profiles with an inverted bell shaped curve 
with dose  identified only by SAM but not by regression analysis. A threshold of 1% BH corrected p value is 







1 3.5403603 GOTERM_BP_FAT GO:0051146~striated muscle cell 
differentiation 
4 
  GOTERM_BP_FAT GO:0055002~striated muscle cell 
development 
4 
  GOTERM_BP_FAT GO:0055001~muscle cell development 4 
  GOTERM_BP_FAT GO:0042692~muscle cell differentiation 4 
  GOTERM_BP_FAT GO:0007517~muscle organ development 4 
2 2.127062 SP_PIR_KEYWOR
DS 
alternative splicing 8 
3 2.0742409 GOTERM_MF_FA
T 



















4.2.3Genes correlated with lipid accumulation, egg laying and valproate dose 
 
After getting the significant expression profile, I looked at the overlap between 
differentially regulated genes in egg laying, lipid mass and valproate exposure on three 
replicates at a threshold of p value <1% FDR with BH correction for multiple testing 
(Figure 23, page83). Since lipid mass and valproate dose are highly correlated, most of 
the genes picked by correlation analysis of lipid mass are identified by correlation 
analysis of valproate dose except 135 genes. But lipid mass plateaued after 15mM 




Figure 23 Overlap in expression profiles of egg laying, lipid mass and valproate exposure. Genes correlated to 
valproate dose captures 92%  of the expression profile correlated with lipid mass and egg laying. Expression 
profile correlated only with lipid mass could explain the nonlinear dose response of lipid mass. 
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A shift from membrane components to amino acid biosynthesis is a land mark of 
decrease of lipid at high valproate doses (Figure 24, page86). Down regulation of 
neuronal function genes is followed by an up-regulation of lipid catabolism genes and 
G-protein coupled receptors. This also involves down-regulation of histone 
phosphorylating enzyme kin-1.ser-4, serotonin receptor is negatively correlated with 
lipid level and down regulation of serotonin pathway is known to increase lipid level. 
acs-1 codes for acyl CoA synthetase which is involved in fatty acid synthesis in the 
cytosol(Zhang et al., 2011).hyl-2 codes for ceramide 
 
 synthase which catalyses  the transfer of acyl units to sphingosine to make ceramide 
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Figure 24 Figure shows the expression profiles of 135 genes positively (panel A) and negatively correlated with 
valproate (panel B) unique to lipid metabolism identified in Venn diagram in figure 5.Numbers across top of 
each heatmap indicate valproate concentration. The degree of expression is indicated with a red to green scale 




Enrichment of functional terms such as structural molecule activity, detoxification, 
electron carrier activity and cell signalling characterize the negatively correlated 
expression profile of valproate exposure with egg laying (Table 11). None of the 
functional terms were significantly enriched in the expression profile positively 
correlated with egg laying.  
 
Table 11 Functional terms enriched in negatively correlated expression profile with egg laying on valproate 









1 16.139254 INTERPRO: Nematode cuticle collagen, N-terminal 35 9.34E-19 
  INTERPRO: Collagen triple helix repeat 37 8.04E-18 
  GOMF:structural molecule activity 41 5.33E-08 
2 5.4068484 INTERPRO:Glutathione S-transferase/chloride channel, 
C-terminal 
11 1.43E-04 
  INTERPRO:Thioredoxin fold 16 1.90E-04 
3 4.2267186 INTERPRO:Protein of unknown function DUF38 23 7.21E-05 
  SMART:FBOX 25 0.001636 
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4 3.127229 SP_PIR:cuticle 7 0.022424 




7 1.7383587 KEGG: Metabolism of xenobiotics by cytochrome P450 4 0.131267 
  KEGG: Glutathione metabolism 4 0.148172 
8 1.6178212 GOMF: electron carrier activity 15 0.139609 
9 1.4996211 UP_SEQ: signal peptide 20 0.102358 
  GO_MF: peptidase activity 23 0.156726 
 
Enrichment of functional terms such as structural molecule activity, detoxification, 
energy balance, lipid metabolism and tryptophan metabolism characterize the 
expression profile positively correlated with lipid mass on valproate exposure (Table 
12). There was no significant enrichment of any functional terms negatively correlated 
with lipid mass on valproate exposure identified by regression analysis. But SAM 
analysis identified expression profiles negatively correlated with lipid mass on valproate 
exposure enriched with functional terms, such as cell adhesion, muscle development 
and differentiation, lectin, neuronal transmission, EGF-like, cell signalling and calcium 
binding (Table 13, page 90).  
 
Table 12 Functional terms enriched in positively correlated expression profile with lipid mass on valproate 













  INTERPRO: Collagen triple helix repeat 54 8.81E-
19 
  GOMF:structural molecule activity 73 4.03E-
09 
2 11.800575 SMART:PTPc 31 1.17E-
13 
  GOMF:phosphatase activity 53 4.57E-
13 
  SP_PIR:hydrolase 58 0.00709
2 
3 5.367098 INTERPRO:UDP-glucuronosyl/UDP-glucosyltransferase 21 1.13E-
05 
  GOBP:lipid glycosylation 14 1.67E-
05 
  GOMF:carbohydrate binding 25 0.04265
9 
4 5.0846709 INTERPRO:Metallophosphoesterase 20 1.17E-
06 
  SMART: PP2Ac 16 1.49E-
06 
5 4.4116928 GOBP:phosphorus metabolic process 94 3.57E-
17 
  GOBP:phosphorylation 58 3.00E-
06 
  SMART: SH2 17 1.78E-
05 




7 3.2404504 INTERPRO: Glutathione S-transferase, C-terminal 16 1.77E-
05 
  INTERPRO:Thioredoxin fold 20 0.01082
9 
  KEGG:Metabolism of xenobiotics by cytochrome P450 6 0.02801
2 
8 2.5528737 INTERPRO: CHK kinase-like 8 0.02351
5 
9 2.4919646 KEGG:Limonene and pinene degradation 7 0.00626
6 
  INTERPRO: Cytochrome P450 15 0.01097
7 
  GOMF: iron ion binding 32 0.07844 
  SP_PIR:Monooxygenase 13 0.15443
9 
10 1.6688352 SMART: CLECT 25 0.10239
3 
11 1.4612299 INTERPRO: Major sperm protein 15 0.01097
7 




  GOMF: FMN binding 6 0.09615
2 
17 1.1341216 INTERPRO: Protein of unknown function DUF38 26 0.13293
2 




19 1.0861378 INTERPRO: Peptidase, metallopeptidases 9 0.15576
6 
21 1.0164771 KEGG:Tryptophan metabolism 6 0.06714
1 






Table 13 DAVID functional clustering of expression profile negatively correlated with lipid mass on valproate 









1 3.1470645 INTERPRO:EGF-like, type 3 6 0.032117 
  GOBP:biological adhesion 5 0.037047 
  GOBP:cell adhesion 5 0.037047 
2 2.9611154 GOBP:striated muscle cell development 5 0.001132 
  GOBP:striated muscle cell differentiation 5 0.001132 
  GOBP:muscle cell development 5 7.14E-04 
  GOBP:muscle cell differentiation 5 0.001066 
  GOBP:actin filament-based process 4 0.102589 
  GOBP:actomyosin structure organization 3 0.136371 
  GOBP:myofibril assembly 3 0.136371 
  GOBP:cellular component assembly involved in 
morphogenesis 
3 0.136371 
3 2.7803265 INTERPRO:type lectin, conserved site 5 0.027124 
91 
 
  INTERPRO:type lectin-like 8 0.042207 
  SP_PIR:Lectin 6 0.102251 
  INTERPRO:C-type lectin 8 0.058599 
  SMART:CLECT 8 0.19063 
4 2.5607565 INTERPRO:Immunoglobulin subtype 5 0.047875 
  INTERPRO:Immunoglobulin-like 6 0.024368 
  SMART:IG 5 0.041076 
  INTERPRO:Immunoglobulin-like fold 5 0.058698 
  INTERPRO:Immunoglobulin 4 0.058254 
  INTERPRO:Immunoglobulin I-set 4 0.060697 
  INTERPRO:Immunoglobulin V-set 3 0.070281 
5 2.2104446 GOBP:cell-cell signaling 6 0.007249 
  GOBP:synaptic transmission 4 0.170817 
  GOBP:transmission of nerve impulse 4 0.170817 
6 2.1595663 INTERPRO:EGF-like, type 3 6 0.032117 
  GOMF:calcium ion binding 8 0.071871 
  INTERPRO:EGF-like region, conserved site 7 0.055396 
  INTERPRO:Laminin G, subdomain 2 3 0.074657 
  INTERPRO:Laminin G 3 0.074657 
  INTERPRO:EGF 4 0.086806 
  INTERPRO:EGF-like 5 0.100631 
7 1.612791 UP_SEQ:signal peptide 10 0.166592 
  SP_PIR:signal 10 0.088608 





Functional terms such as detoxification, energy balance, structural molecule activity, 
major sperm protein, cytoskeleton, heat shock protein, fatty acid metabolism and ABC-
transporter like were enriched in the expression profile positively correlated with 




Table 14 Functional terms enriched in positively correlated expression profile with valproate identified by 









1 20.604504 SMART:PTPc 48 2.01E-
25 
  GOMF:phosphatase activity 79 5.66E-
23 
  SP_PIR:hydrolase 81 4.71E-
04 
2 15.848884 INTERPRO:Nematode cuticle collagen, N-terminal 56 6.12E-
19 
  INTERPRO:Collagen triple helix repeat 61 7.15E-
18 
  GOMF:structural molecule activity 99 3.80E-
12 




  GOBP:phosphorylation 96 1.11E-
15 
  SMART:SH2 26 6.30E-
10 
  GOMF:ATP binding 127 0.00354
8 
  GOMF:adenyl nucleotide binding 134 0.00364
4 
  GOMF:purine nucleotide binding 144 0.06807 
4 9.3438724 INTERPRO:Metallophosphoesterase 28 1.28E-
10 
5 5.380872 SP_PIR:collagen 34 1.46E-
09 
  SP_PIR:cuticle 13 7.91E-
04 
6 5.2624126 INTERPRO:Glutathione S-transferase, N-terminal 20 1.83E-
06 
  INTERPRO:Thioredoxin fold 24 0.01276 
7 5.0544358 GOBP:lipid glycosylation 16 3.09E-
05 
  INTERPRO:UDP-glucuronosyl/UDP-glucosyltransferase 23 5.97E-
05 
  GOMF:carbohydrate binding 31 0.04158
8 
8 3.8045691 GOMF:iron ion binding 49 5.27E-
04 




  KEGG:Limonene and pinene degradation 8 0.00662
5 
  GOMF:electron carrier activity 37 0.00987
8 
  SP_PIR:Monooxygenase 19 0.01343
4 
9 3.4384841 INTERPRO:Major sperm protein 27 5.39E-
08 
  INTERPRO:PapD-like 25 1.55E-
07 
  SP_PIR:cytoskeleton 21 0.10935
2 
10 2.9954186 SMART:BRCT 11 0.00155 
  INTERPRO:Ankyrin 17 0.10095
5 
11 2.2248019 INTERPRO:Protein of unknown function DUF856  5 0.03768 
12 2.0831552 SMART:CHK 8 0.05451
9 
13 1.750404 PIR_SUPERFAMILY:glutathione transferase 8 0.15639 
  KEGG:Metabolism of xenobiotics by cytochrome P450 6 0.09077
9 
14 1.6786155 SMART:CLECT 32 0.12157
2 




16 1.4671233 PIR_SUPERFAMILY:gliadin 5 0.12707 




18 1.3562886 INTERPRO:Protein of unknown function DUF38 35 0.03833
5 
23 1.1386328 INTERPRO:2Fe-2S ferredoxin, iron-sulphur binding site 6 0.09880
3 
26 0.9791065 INTERPRO:Heat shock protein Hsp20 6 0.16624
4 
28 0.9443988 SMART:ZnMc 10 0.12987
1 
29 0.8904833 KEGG:Fatty acid metabolism 8 0.16428
2 
43 0.3840152 INTERPRO:ABC transporter-like 13 0.04833
9 
  COG:Defense mechanisms 8 0.07714
9 
 
Functional terms such as reproductive development process, cell division, neuron 
differentiation, cell cycle, Wnt signalling, glycoprotein and protein-DNA complex 
assembly were enriched in the expression profile negatively correlated with valproate in 
regression analysis (Table 15).  
Table 15 Functional terms enriched in negatively correlated expression profile with valproate identified by 
regression analysis at a threshold of 10% FDR. 
Cluster Enrichment score Term Count Benjamini 
1 5.418025 GOBP:tissue morphogenesis 50 8.70E-05 
  GOBP:morphogenesis of an epithelium 48 1.06E-04 
  GOBP:reproductive developmental process 86 0.003037 
  GOBP:hermaphrodite genitalia development 74 0.003626 
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  GOBP:sex differentiation 80 0.003775 
2 4.5862188 SP_PIR:cell cycle 18 6.34E-05 
  GOBP:cell division 29 0.004132 
3 2.7895358 GOBP:DNA replication 14 0.006634 
  GOBP:DNA metabolic process 21 0.086511 
  KEGG:Mismatch repair 6 0.099903 
  KEGG:Base excision repair 5 0.198048 
4 2.333731 INTERPRO:Immunoglobulin-like fold 13 0.067869 
5 2.1367808 SP_PIR:nucleus 80 3.93E-04 
  SP_PIR:Homeobox 18 4.73E-04 
  GOMF:DNA binding 79 0.087607 
  SMART:HOX 18 0.14043 
  SP_PIR:dna-binding 47 0.075483 
6 2.0183949 GOCC:nucleoplasm 11 0.019123 
  GOCC:nuclear lumen 12 0.064516 
  GOCC:Srb-mediator complex 5 0.123916 
  GOCC:intracellular organelle lumen 14 0.157436 
8 1.9788232 GOCC:chromatin 12 0.003851 
9 1.9677001 SP_PIR:sh3 domain 8 0.072719 
10 1.9072694 GOBP:cellular component morphogenesis 20 0.036085 
  GOBP:neuron differentiation 13 0.062106 
  GOBP:cell projection organization 14 0.079005 
  GOBP:cell motion 15 0.145949 
11 1.8748935 GOBP:chromosome organization 24 0.003969 
  GOBP:kinetochore assembly 4 0.088987 
  GOBP:centromere complex assembly 4 0.088987 
13 1.7863499 SP_PIR:tpr repeat 7 0.079355 
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16 1.7044824 GOBP:cell cycle 42 0.004196 
17 1.6861614 SP_PIR:wnt signaling pathway 6 0.076356 
19 1.5877662 GOBP:glycosaminoglycan metabolic process 4 0.052188 
25 1.345056 SP_PIR:glycoprotein 39 0.037395 
  SP_PIR:signal 34 0.150913 
27 1.2345633 GOBP:protein-DNA complex assembly 9 0.088448 
41 0.9299484 SP_PIR:mitosis 7 0.177892 
63 0.5220007 SP_PIR:myristate 6 0.103074 
 
 
Overall, the expression profile correlated with valproate exposure is enriched with all 
the functional terms that could explain expression profiles correlated with egg laying 
and lipid mass (Table 16). It identified nuclear components such as DNA repair, cell 
cycle, DNA replication, cell division, transcription and nucleotide binding which are not 
identified by the expression profiles correlated with lipid or egg laying. Therefore it was 
decided to concentrate only on expression profile correlated with valproate exposure. 
 
Table 16 Summary of DAVID functional clustering of expression profiles correlated with egg laying, lipid 
mass and valproate concentration identified by regression analysis. 













Structural molecule activity/Collagen/cuticle/ 
cytoskeleton 
48 84  133  
Cellular detoxification  24 56  75  
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Amino acid and protein metabolism/ 
Peptidase 
 23 14  35  
Lipid metabolism   26  32  
Tissue morphogenesis      50 
Reproductive development   15   86 
Cell cycle/DNA replication/DNA 
repair/Cell division 
    19 96 
Neuron differentiation      31 
Chromosome organization      36 
Phosphorus metabolism/Phosphatase   175  258  
Carbohydrate binding   50  63  
 ion binding   32  55  
Transporter     30  
Cell signalling   20    40 
Redox reactions  15 38  42  
Carbohydrate metabolism      43 
Transcription       84 
Nucleotide binding      144  
Nucleus      143 
 
Regression analysis identified one sixth of the probe IDs in the array to be correlated 
significantly with valproate dose at a threshold of < 1% BH corrected p value (Table 17, 
page 99). qPCR verification was not performed as use of low throughput methods to 
verify highthroughput results is questionable.  
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 SAM analysis identified 1744 significant expression profiles at a threshold of 1% FDR 






Figure 25 Dendogram of SOTA cluster analysis of significant expression profile identified by SAM at a 
threshold of 1% FDR. Degree of gene expression is shawn by a scale of red to green with red indicating higher 
expression. Three replicates were done for each drug concentration. 
 
 
Table 17 Significant expression profiles identified by regression analysis at different threshold values. 
Expression profiles correlated with average of three replicates or with replicates are shown for each 
phenotype. For egg laying, only average of the three replicates were considered as the samples were unpaired 
with microarray samples. 
FDR 1% 5% 10% 15% 
Egg laying (Average) 10794 17202 


































0       3       6      9     12    15    18    24mM VPA concentration 
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Lipid (Replicates) 2313 5659 8823 
Valproate (Average) 6089 18574 21686 
Valproate (Replicate) 7002 13503 17321 20004 
 
 
There were 1742 probe IDs with significant expression profiles at 1% FDR SAM with 1 
fold change(S3: Supplementary Material). Out of these only 363 could be converted to 
Wormbase gene IDs using DAVID gene ID conversion tool. Out of these 363 genes, 97 
had a negative correlation with the valproate concentration.  
Regression analysis identified down regulation of most of the nuclear components as a 
remarkable feature of valproate exposure, which was not detected by SAM analysis. In 
biological systems, a slight change in the concentration of one key gene product could 
result in the amplification of a downstream cascade of events. Use of a high threshold 
would eliminate these key genes leaving only the downstream targets.  
To concentrate on a highly significant smaller number of expression profiles, it was 
decided to focus on significant expression profile identified by SAM at 1% FDR. 
Clustering revealed that this significant expression profile could be summarised in four 




After deciding on the significant expression profile to work on, I clustered themin to 
groups with similar expression patterns because genes showing similar expression 
patterns normally have common regulatory mechanisms(Sturn et al., 2002). CAST 
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(Clustering Affinity Search Technique) clustering of this significant expression profile 
with a threshold affinity value of 0.4 identified four clusters with two main clusters 
composed of 1249 positive and 485 negatively correlated expression profiles with 
valproate dose (Figure 26). It also identified two other clusters with a few gene 
expression profiles with a bell shape curve and an inverted bell shape curve on valproate 
exposure. In CAST, the user defines an affinity threshold between 0-1 and each 
expression profile allocated to a specific cluster if its affinity to that cluster exceeds the 
threshold value. Thresholds near one make many clusters with less variability and 
threshold values near zero make few clusters with high variability. The advantage is that 




Figure 26Centroid graphs showing CAST clustering of significant expression profile identified by SAM 




4.2.4.1 Expression profile positively correlated with valproate concentration 
 
Out of the 1249 gene expressions positively correlated with valproate concentration, 
only 263 had known functions. HCL clustering identifies most of these genes in a single 
cluster indicating positive correlation with dose of these genes to have a common 
regulatory mechanism (Figure 27). These were enriched with cellular detoxification, 
transporters, F-box proteins and G-protein coupled receptors. Several nuclear hormone 
receptors, neuropeptides and genes regulated by DAF-16 are also positively correlated 

















Figure 27 Heat map showing HCL clustering of expression profile positively correlated with valproate dose. 
Expression profile identified by CAST as positively correlated with valproate dose is shown as a heat map. 
HCL clustering of these genes identified two clusters with one cluster containing only one gene (cluster 1) and 
the other cluster containing therest of the genes (cluster 2). This second cluster contains two sub-clusters. 
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C-type Lectin (2) 
Sperm activation Without Mating (2) 
UDP-GlucuronosylTransferase (2) 
Acyl CoA DeHydrogenase 
Adenine phosphoribosyltransferase 






Cellular detoxification (42) 
Lectins (20) 
Lipid metabolism (16) 
F-box proteins (16) 
Nuclear hormone receptors (10) 
Transporters (9) 
Genes regulated by DAF-16 (6) 
G-protein coupled receptors (6) 
Life span (5) 






Cluster 2.1 contained only 11 genes and cluster 2.2 contained the rest of the genes. This shows that valproate 
exposure cause an up-regulation of genes as a single cluster which indicates a common mechanism for the 
regulation of expression of these genes.  Number of genes of each type are given in parentheses.Degree of gene 
expression is given in a scale of red to green where red indicates higher expression. Valproate concentration is 
given above the heatmap. 
 
 
Table 18 David functional clustering of expression profile positively correlated with valproate dose identified 








1  41.35963  IPR008160:Collagen triple 
helix repeat  
57  8.86E-55  1.71E-52  
2  10.52595  GO:0030246~carbohydrate 
binding  
24  5.70E-11  3.06E-09  
  GO:0030259~lipid 
glycosylation  
12  1.14E-10  2.85E-08  
3  4.969211  IPR001128:Cytochrome 
P450  
14  8.89E-10  2.86E-08  
4  4.747159  IPR004046:Glutathione S-
transferase, C-terminal  
11  1.48E-08  3.57E-07  
5  4.427775  IPR001304:C-type lectin  15  1.66E-04  0.00267324  
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6  3.838634  GO:0040002~collagen and 
cuticulin-based cuticle 
development  
9  1.31E-04  0.008099457  
7  2.452669  IPR001810:Cyclin-like F-
box  
15  0.016232595  0.160943813  
8  1.634829  GO:0008340~determination 
of adult life span  
10  0.023183073  0.565849655  
10  1.128651  SM00276:GLECT  3  0.035408898  0.10712004  
9  1.301845  IPR016040:NAD(P)-
binding domain  
7  0.027971981  0.239498173  
11  1.109851  IPR017871:ABC 
transporter, conserved site  
7  3.81E-04  0.005636084  
 
 
4.2.4.1.1 CAST clustering of expression profile positively correlated with valproate 
dose 
 
SOTA clustering of expression profile positively correlated with valproate dose 
identified by CAST is shown as centroids graphs in Figure 28 (page106). It identifies 
four clusters enriched in different GO functional terms and there is a gradual transfer 
from one cluster to the next starting from cluster 4 on increasing drug dose. Dendogram 
of the four clusters shows this gradual up-regulation of the genes of the four clusters 
(Figure 29, page106). At lower valproate doses, an up-regulation of genes involved in 
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cellular detoxification, lectins and ABC transporters is seen (Figure 30, page107). 
Further increase of valproate dose caused an up-regulation of genes coding for FBOX 
proteins, lipid glycosylation and determination of life span. Much higher valproate dose 
is required for the up-regulation of genes involved in growth regulation, collagen 




Figure 28 SOTA Four cluster analysis of expression profile positively correlated with valproate dose. SOTA 
clustering of expression profile positively correlated with valproate dose identified by CAST is shown as 
centroids graphs.Expression profiles with ≤ 1% FDR in SAM are taken as significant. 
 
 
Figure 29 Dendogram of four cluster analysis of expression profile positively correlated with valproate dose. 
SOTA clustering of expression profile positively correlated with valproate dose identified by CAST is shown in 
the dendogram. Expression profiles with ≤ 1% FDR in SAM are taken as significant. Numbers across top of  
heatmap indicate valproate concentration. The degree of expression is  indicated with a red to green scale 
where the higher expression is given by red. 
 





Figure 30 Four cluster analysis of expression profile positively correlated with valproate exposure. DAVID 
functional clustering of expression profiles of each cluster is shown next to the heat map of the respective 
cluster.Numbers across top of  heatmaps indicate valproate concentration. The degree of expression is  





Cluster Enrichment Score Term Count PValue Benjamini 
1 20.6575 IPR008160:Collagen triple helix repeat 28 1.27E-38 7.38E-37 
2 2.259283 GO:0040002~collagen and cuticulin-based  
cuticle development 
5 2.97E-04 0.013131 
3 2.162389 cuticle 4 9.55E-05 0.002812 
  signal peptide 6 0.019037687 0.369543 
4 1.760744 GO:0010171~body morphogenesis 13 4.03E-07 3.59E-05 
6 1.000599 GO:0006508~proteolysis 7 0.010605571 0.211193 
7 0.900505 GO:0040008~regulation of growth 13 0.039822552 0.514872 
 
Cluster Enrichment Score Term Count PValue Benjamini 
1 16.5654 IPR008160:Collagen triple helix repeat 26 7.32E-29 2.56E-27 
2 8.889744 collagen 16 4.91E-20 2.60E-18 
3 3.641014 IPR001810:Cyclin-like F-box 9 0.001897612 0.032693 
4 2.224764 IPR004045:Glutathione S-transferase, N-terminal 4 0.002912604 0.040013 
5 1.990804 GO:0030259~lipid glycosylation 4 0.001310132 0.158905 
7 0.875629 iron 4 0.048988219 0.412821 
 
Cluster Enrichment Score Term Count PValue Benjamini 
1 7.803873 IPR002213:UDP-glucuronosyl/UDP-glucosyltransferase 10 2.12E-10 1.63E-08 
  GO:0030259~lipid glycosylation 7 5.31E-08 6.21E-06 
2 3.83731 IPR004046:Glutathione S-transferase, C-terminal 6 4.40E-06 1.69E-04 
3 3.078754 GO:0030246~carbohydrate binding 12 1.52E-08 1.45E-06 
4 1.535437 GO:0008340~determination of adult life span 5 0.029145 0.684484 
5 1.402542 IPR017973:Cytochrome P450, C-terminal region 4 0.005735 0.084759 
6 1.104109 SM00256:FBOX 5 0.033329 0.111871 
9 0.586723 IPR003439:ABC transporter-like 3 0.028896 0.221873 
 
Cluster Enrichment Score Term Count PValue Benjamini 
1 6.034186 IPR016186:C-type lectin-like 9 9.65E-07 1.40E-05 
2 5.175213 GO:0055114~oxidation reduction 11 1.14E-07 6.04E-06 
  IPR001128:Cytochrome P450 7 3.07E-07 5.94E-06 
3 4.713796 GO:0030246~carbohydrate binding 7 1.34E-04 0.001636 
4 2.349013 IPR002213:UDP-glucuronosyl/UDP-glucosyltransferase 4 0.003166127 0.030189 
7 0.519549 IPR003439:ABC transporter-like 3 0.016079331 0.11088 
 
-2.44  0.13  2.19 




























4.2.4. 1.2 Network analysis of the four clusters positively correlated with valproate 
exposure 
 
After identifying the separate clusters which could be having common regulatory 
elements, I did Network Analysis of those clusters to identify those possible common 
regulatory elements. I used WormNet to identify the underlying gene interactions. 
Because daf-2, daf-16 and sma-6 were found to be involved in valproate induced lipid 
accumulation in the phenotypic analysis I did, I also generated networks of the genes in 
these clusters including these three genes to find their role at the molecular level. 
Network analysis of the four clusters with WormNet shows the first cluster to be mainly 
involved in collagen synthesis (Figure 31, page110). 
The main network of interconnected genes of the second cluster contained dao-4, which 
is connected to dao-6 (Figure 32, page116). Both of these genes are regulated by DAF-
16.  
The third cluster contains genes known to be regulated by DAF-16, such as dod-19, 
dod-20 and dod-24 (Figure 33, page122). dod-19 is a hub gene and dod-24 connects 
several hub genes. Unlike the first two clusters, the network generated with genes of 
this cluster contains mainly genes involved in cellular detoxification with some genes 
involved in collagen synthesis and lipid metabolism.  
Connected genes in the fourth cluster (Figure 34, page125) made a network of genes 
with two sub-clusters connected to each other via daf-36. daf-36is involved in a 
hormone biosynthetic pathway that produces the ligand for daf-12, which regulates the 
entering of C.elegans into high fat dauer stage(Rottiers et al., 2006).  
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Because sma-6, daf-2 and daf-16are found to affect valproate induced lipid 
accumulation, I also did the network analysis including those three genes to find their 
position in the interaction networks. All clusters, except the first cluster, were connected 
to daf-2, daf-16 and sma-6 indicating an involvement of insulin signalling and TGF-β 
Sma/Mad pathways on valproate exposure.  Also this analysis identifies B0286.3 as a 
key gene which may act upstream of sma-6. This is an uncharacterized gene in 
C.elegans and RNAi studies have shown it to cause larval arrest and larval lethality 
when mutated (WormBase).  The human ortholog of this gene is 
phosphoribosylaminoimidazole carboxylase, a bifunctional enzyme, the activities of 
which are required for steps 6 and 7, respectively, of purine biosynthesis.  
Cluster one is connnected to cluster 2 via dao-4, which is connected to daf-2 and sma-6 
(Figure 35, page131). This indicates an overalll involvement of insulin signalling and 
sma-6 on positively correlate expression profile on valproate exposure. This could be 
tested by analysing the overlap between the positively corelated expression profile on 
valproate exposure of the wild type C.elegans with the negatively correlated 
expresssion profile of sma-6 mutants.  
When all four clusters positively correlated with valproate are considered, the 
transcrition factors in or associated with all the four clusters show that most of them are 






Figure 31Network graph of seed genes of SOTA cluster 1 of positively correlated genes with valproate 
identified by CAST. (A) Out of 51 genes, 42 genes were mapped in WormNet v. 2. Out of the 42 genes, 29 





not found in WormNet. grd-1 is predicted to be involved in cholesterol dependent hedge-hog like signalling 
and is shown to be involved in growth, cuticle adhesion and mail tail development. This cluster is mainly 
composed of genes involved in collagen synthesis.  (B) Same cluster with daf-2, daf-16 and sma-6 added. These 
three genes made a separate cluster from the main cluster. This shows that this expression profile is not 
directly connected to any of these three genes. 
Table 19Evidence codes for 21 types of data sets incorporated in WormNet 
Evidence code Data set description 
CE-CC Co-citation of worm gene 
CE-CX Co-expression among worm genes 
CE-GN Gene neighbourhoods of bacterial and archaeal orthologs of worm genes 
CE-GT Worm genetic interactions 
CE-LC Literature curated worm protein physical interactions 
CE-PG Co-inheritance of bacterial and archaeal orthologs of worm genes 
CE-YH High -throughput yeast two hybrid assays among worm genes 
DM-PI Fly protein physical interactions 
HS-CC Co-citation of human genes 
HS-CX Co-expression among human genes 
HS-DC Co-occurance of domains among human proteins 
HS-LC Literature curated human protein physical interactions 
HS-MS Human protein complexes from affinity purification/mass Spectrometry 
HS-YH High -throughput yeast two hybrid assays among human genes 
SC-CC Co-citation of yeast genes 
SC-CX Co-expression among yeast genes 
SC-DC Co-occurance of domains among yeast proteins 
SC-GT Yeast genetic interactions 
SC-LC Literature curated yeast protein physical interactions 
SC-MS Yeast protein complexes from affinity purification/mass Spectrometry 
SC-TS Yeast protein interactions inferred from tertiary structures of complexes 
 
Table 20Transcription factors in or associated with SOTA cluster 1 of positively correlated genes with 

























































































Table 21 Seed genes of SOTA cluster 1 of genes positively correlated with valproate dose identified by CAST 
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Figure 32 Network graph of seed genes of SOTA cluster 2 of genes positively correlated with valproate 
identified by CAST. (A)Out of 84 genes, 66 genes were mapped in WormNet v. 2. Out of the 66 genes, 34 which 
were connected to each other are shown in the figure. Transcription factors nhr-25 and nhr-234were not 
connected to other genes in the cluster. Transcription factors nhr-245 and nhr-202 are not found in the 





regulated in daf-2 mutants in a DAF-16 dependent manner. sma- 6 mutants show high expression of spp-9. 
The largest network generated contains genes involved in collagen synthesis and a separate smaller network 
contains genes involved in cellular detoxification. (B) Same cluster with daf-2, daf-16 and sma-6 added. These 
three genes were connected to the main cluster. daf-2 and daf-16 seems to be downstream of sma-6 and this sub 
cluster connects clusters involved in cellular detoxification with cell morphogenesis, mainly collagen synthesis. 
 
 
Table 22 Transcription factors in or associated with SOTA cluster 2 of genes positively correlated with 
valproate identified by CAST. These transcription factors either  disconnected or are not found in WormNet. 
Locus_ID Symbol GO_P GO_C GO_F 
C27C7.8 nhr-259 regulation of transcription, 
DNA-dependent; 
nucleus; transcription factor 
activity; steroid hormone 
receptor activity; 
Y38E10A.18 nhr-234 regulation of transcription, 
DNA-dependent; 
nucleus; transcription factor 
activity; steroid hormone 
receptor activity; zinc ion 
binding; sequence-specific 
DNA binding; 
ZK1025.10 nhr-245 regulation of transcription, 
DNA-dependent; 
nucleus; transcription factor 
activity; steroid hormone 
receptor activity; zinc ion 
binding; sequence-specific 
DNA binding; 
M02H5.4 nhr-202 regulation of transcription, 
DNA-dependent; 
nucleus; transcription factor 
activity; steroid hormone 





ZK180.5 na col-149 sqt-1 sqt-2 col-90 
col-175 col-138 col-91 col-
13 col-60 col-111 dpy-13 
col-38 col-156 col-77 pqn-54 







Table 23 Seed genes of SOTA cluster 2 of genes positively correlated with valproate identified by CAST 
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Figure 33 Network graph of seed genes of SOTA cluster 3 of genes positively correlated with valproate 
identified by CAST. (A)Out of 73 genes, 53 genes were mapped in WormNet v. 2. Out of the 53 genes, 29, 
which were connected to each other, are shown in the figure.The majority of the genes in this network are 
involved in cellular detoxification. It also contains some genes involved in collagen synthesis and lipid 
metabolism.  dod-20 and dod-19 mutants are known to have reduced fat content and is regulated by DAF-16. 
far-3 codes for a fatty acid binding protein and expression of far-3 is down regulated in sir-2; lin-35 double 
mutant. dod-24 connects hub genes of several sub clusters and it is also known to be regulated by DAF-16. (B) 
Same cluster with daf-2, daf-16 and sma-6 added. These three genes were connected to the main cluster. daf-2 







Table 24 Transcription factors in or associated with SOTA cluster 3 of genes positively correlated with 


























































Table 25Seed genes of SOTA cluster 3 of genes positively correlated with valproate identified by CAST ranked 





































































































































































































Figure 34Network graph of seed genes of SOTA cluster 4 of genes positively correlated with valproate 
identified by CAST. (A) Out of 51 genes, 32 genes were mapped in WormNet v. 2. Out of the 32 genes, 20 
which were connected to each other are shown in the figure. These genes were clustered into two network 
modules connected via daf-36, which functions in a hormone biosynthetic pathway and produce the ligand for 





lipid metabolism as well as lifespan. DAF-36 is a cholesterol 7- desaturase and is a key enzyme in 
steroidogenesis. (B) Same cluster with daf-2, daf-16 and sma-6 added. These three genes were connected to the 
main cluster. daf-2 and daf-16 seems to be downstream of sma-6 , which is connected to a second smaller 
cluster via daf-36. 
 
 
Table 26Transcription factors/ regulators of transcription factors in or associated with SOTA cluster 4 of 



















































































































































































































































































































































































Table 27 Seed genes of SOTA cluster 4 of genes positively correlated with valproate identified by CAST 



















































































































































































Figure 35 Network graph of seed genes of SOTA cluster 1 and 2 together of genes positively correlated with 
valproate identified by CAST with daf-2, daf-16 and sma-6 added. (A) Out of 138 genes, 111 genes were 
mapped in WormNet v. 2. Out of the 111 genes, 79 which were connected to each other are shown in the 




Table 28 Analysis of transcription factors in or associated with all the four clusters of genes positively 



















































na    
ZK180.
5 





Activator Lipid storage,  
reproduction 
Fat content reduced, 
reduced brood size 
F44E7.8 nhr-
142 













   
Y55D5
A.5 
daf-2 repressor Dauer entry and exit,  
dauer larval development, 
 determination of adult lifespan, 
 insulin receptor signalling pathway, 
Fat content increased 
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 lipid storage, 
 locomotion,  
nematode larval development,  
organ senescence,  
positive regulation of multicellular 
organism growth,  
protein aotophosphorylation,  
regulation of response to reactive oxigen 
species,  
reproduction, response to heat,  
transmembrane receptor protein tyrosine 
kinase signalling pathway.  
F02E9.4 pqn-
28 
   
Y49A3
A.1 
na  Lipid storage, phospholipid biosynthesis 
process 
Fat content reduced 
 
 
4.2.4.2 Expression profile negatively correlated with valproate concentration 
 
After showing that the positive correlation with valproate exposure is via insulin and 
TGF-β Sma/Mad pathways probably through steroid hormone signalling, I then looked 
at the expression profile negatively correlated with valproate exposure. CAST clustering 
identified 485 expression profiles negatively correlated with valproate exposure. Only 
90 of these had a known function on gene ID conversion and functional annotation done 
by DAVID gene ID conversion tool and functional annotation tool. HCL clustering of 
these known genes separated them into several different clusters shown in Figure 36. 
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Unlike the positively correlated expression profile, which had several similar genes, this 
negatively correlated expression profile had dissimilar genes (Table 29, page 135). 
Cluster 1.1 contains rab family member, a family of proteins known to associate with 
lipid droplets in mammals. Cluster 2.1 contains BBS (Bardet-Biedl Syndrome) protein, 
a syndrome associated with obesity(Forsythe and Beales, 2012).  
 
 
Figure 36 Heat map showing HCL clustering of expression profile negatively correlated with valproate dose. 
Expression profile identified by CAST as negatively correlated with valproate dose is shown as a heat map. 
HCL clustering of these genes identified several clusters and the genes in these clusters are shown in Table 
29.Numbers across top of heatmap indicate valproate concentration. The degree of expression is  indicated 








Table 29This table shows the genes in each cluster in Figure 36.  Number of genes of each type are given in 
parentheses. 
Cluster 1.1 Cluster 1.2 Cluster 2.1 Cluster 2.2 
C-type lectin (5) C-type lectin (5) C-type lectin (4) Uncoordinated (2) 
ARF-Like (2) Collagen (3) Groundhog (2) Coronin 
Cutclin (2) THaumatiN family (2) Helix Loop Helix (2) Slowpoke potassium 
channel family 
Acetylcholinesterase Acetylcholinesterase Glutamate Receptor 
family (AMPA) 
Myosin Light Chain 
neuronal ceroid 
lipofuscinosis related 
Blistered cuticle Resistance to Inhibitors of Cholinesterase 
Enhancer of unc-40 
Ventral Axon guidance 
defects 





Carnitine Palmitoyl Transferase Dystrobrevin homolog  
Homeobox Cuticlin GalactoFuranose synthesis (UGM, UDP-
galactopyranose mutase) 
FriZzled homolog Fatty acid desaturase Collagen  
Dumpy F-box B protein Hexosaminidase  
Dynein Light chain FerroPortiN Lipase related  
Gamma Butyrobetaine 
Hydroxylase 
Intermediate Filament, C Insulin related  
Intermediate Filament, 
A 
Invertebrate LYSozyme L1 CAM Adhesion 
molecule homolog 
 
Insulin related INneXin Suppressor/Enhancer of 
Lin-12 
 
Jun N-terminal Kinase Nematode AStacin protease (only Slit (Drosophila)  
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BMP-1/Tolloid homolog in C. 
elegans) 
homolog 
RAB family abnormal NUClease Syntrophin  
Rho GTPase Activating 
protein 
PHAryngeal gland Toxin-related Uncoordinated  
TransThyretin-Related 
family domain 
PLeXin D-amino-acid oxidase 2  
Uncoordinated SCP-Like extracellular protein Probable galactose-1-phosphate 
uridylyltransferase 
Others (4) TropoNin T Amino acid Transporter Glycoprotein subunit 
 2 (Zwei) IG-domain protein BBS (Bardet-Biedl 
Syndrome) protein 
 




DAVID functional clustering identified this negatively correlated expression profile to 








Table 30 David functional clustering of expression profile negatively correlated with valproate dose identified 




Term Count PValue Benjamini 

























































11 1.349825 GO:0007267~cell-cell signaling 6 0.00272 0.160903 
  










acting on L-amino acid peptides 
12 0.0272 0.67043 









Transcription factors unc-86 and unc-120are negatively correlated with valproate 
exposure (Table 31, page 139). Down regulation of unc-86cause fat accumulation due to 
low serotonin levels which cause nuclear localization of DAF-16. (Liang et al., 2006). 
unc-120  is a member of MADS-box family and is required for expression of actin and 
myosin.   
Several genes involved in neurotransmission are negatively correlated with valproate 
exposure. These include genes coding for acetyl choline esterase, ric-3; which is 
required for maturation and function of four different nicotinic acetylcholine receptors, 
genes involved in axon navigation/guidance, synapse formation, K
+
 channel and 
glutamate receptor(Halevi et al., 2002, Ben-Ami et al., 2005, Shteingauz et al., 2009).   
The expression profiles of several genes involved in lipid metabolism including 
dehydrogenases, fatty acid desaturases, lipases and insulin were also negatively 
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correlated with valproate exposure.  GTPases, genes involved in WNT signalling, CDK 
andjun kinases are also among the expression profiles negatively correlated with 
valproate.  A number of genes coding for C-type lectins, intermediate filaments and 
collagen are also negatively correlated with valproate dose.  
Table 31 Known genes with expression profiles negatively correlated with valproate dose identified by CAST. 
 Gene name Description 
Insulin related ins-23, ins-8 INSulin related 
Transporters  aqp-2 AQuaPorin or aquaglyceroporin 
related 
atgp-2 Amino acid Transporter 
GlycoProtein subunit 
 C41D11.9 TM2 domain-containing protein 
C41D11.9 
 cbn-1 Calcium BiNding protein 
homolog 
Kinases cdk-5 Cyclin-Dependent Kinase family 
jnk-1 Jun N-terminal Kinase 
Neuronal unc-41 UNCoordinated 
ACE-1, ace-3 abnormal ACEtylcholinesterase 
ric-3 Resistance to Inhibitors of 
Cholinesterase 
Y69A2AR.5 D-amino-acid oxidase 2 
arl-3, arl-6 ARF-Like 
cln-3.2 human CLN (neuronal ceroid 
lipofuscinosis) related 
zig-8 2 (Zwei) IG-domain protein 
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cdh-6 CaDHerin family 
lad-2 L1 CAM ADhesion molecule 
homolog 
slt-1 SLiT (Drosophila) homolog 
plx-2 PLeXin 
eva-1 Enhancer of unc-40 Ventral Axon 
guidance defects 
syg-2 SYnaptoGenesis abnormal 
slo-1 SLOwpoke potassium channel 
family 
glr-1 GLutamate Receptor family 
(AMPA) 
bbs-5 BBS (Bardet-Biedl Syndrome) 
protein 
unc-86 UNCoordinated 
 cfz-2 Caenorhabditis FriZzled homolog 
 ceh-13 Homeobox 
 grd-16 GRounDhog (hedgehog-like 
family) 
 grl-11 GRound-Like (grd related) 
 sel-7 Suppressor/Enhancer of Lin-12 
Collagen col-135, col-165, col-184, col-74 COLlagen 
dpy-17 DumPY : shorter than wild-type 
Cytoskeleton/mus
cle related 
unc-120, unc-52 UNCoordinated 
cut-3, cut-5 CUTiclin 
cutl-13 CUTiclin-Like 




dyb-1 DYstroBrevin homolog 
stn-1 SynTrophiN 
dylt-2 DYnein Light chain (Tctex type] 
ifa-3 Intermediate Filament, A 
ifc-1 Intermediate Filament, C 
mlc-1 Myosin Light Chain 
tnt-4 TropoNin T 
Lectins clec-140, clec-160, clec-24, clec-26, clec-31, 
clec-33, clec-35, clec-43, clec-48, clec-49, 
clec-51, clec-52, clec-54, clec-60 
C-type LECtin 
Lipid metabolism cpt-3 Carnitine Palmitoyl Transferase 
dhs-21 DeHydrogenases, Short chain 
fat-6 FATty acid desaturase 
gbh-2 Gamma Butyrobetaine 
Hydroxylase 
lips-4 LIPaSe related 
 fbxb-114 F-box B protein 
 fpn-1.2 FerroPortiN 
 glf-1 GaLactoFuranose synthesis 
(UGM, UDP-galactopyranose 
mutase) 
 hex-5 HEXosaminidase 
 rab-28 RAB family 
 rga-2 Rho GTPase Activating protein 
 hlh-13, hlh-32 Helix Loop Helix 
 ifta-2 IntraFlagellar Transport 
Associated 
 ilys-3 Invertebrate LYSozyme 
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 inx-8 INneXin 
 nas-39 Nematode AStacin protease (only 
BMP-1/Tolloid homolog in C. 
elegans) 
 nspc-9 Nematode Specific Peptide 
family, group C 
 nuc-1 abnormal NUClease 
 phat-5 PHAryngeal gland Toxin-related 
 scl-3 SCP-Like extracellular protein 
 thn-1, thn-2 THaumatiN family 
 ttr-1 TransThyretin-Related family 
domain 
 ZK1058.3 Probable galactose-1-phosphate 
uridylyltransferase 
 
SOTA clustering showed the negatively correlated expression profile to be a single 
cluster. This also suggests a common down regulatory mechanism of genes on valproate 
exposure.  
 
4.2.4.2.1 Network analysis ofexpression profilesdown-regulated with valproate 
dose 
 
After showing that the negatively correlated expression profile of valproate exposure is 
involved in lipid accumulation and acts as a single cluster, I then set to identify any 
regulatory mechanisms. For that I did Network analysis using WormNet. Only 68 genes 
out of 90 known genes mapped in WormNet (Figure 37, page149).  Thirty seven of these 
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genes were connected to each other making three networks with 7 genes and another 
larger network with the rest of the connected genes. It comprised of two sub-clusters 
connected to each other via tnt-4.  Smaller sub cluster contains several genes involved 
in G-protein coupled receptor activity.  Larger sub cluster contains several genes 
involved in cuticle development including some collagen synthesis genes.  fat-6, which 
has stearoyl-CoA 9-desaturase activity, is a key gene in fat metabolism found in this 
cluster. hlh-13 and dyb-1 are transcription factors found connected to each other in a 
smaller network.  
To find the role played by insulin signalling and TGF-β pathways on negatively 
correlated expression profile on Valproate exposure, I reconstructed the networks 
adding daf-2, daf-16 and sma-6.  When the networks were reconstructed after adding 
daf-2, daf-16 and sma-6, it showed sma-6 to act as a key gene which connects 
acetylcholine esterase genes with the insulin signalling and it also connected them with 
the two clusters of the largest network via tnt-4 (Figure 38, page150).  
Transcription factor analysis identified several transcription regulators involved in 
reproduction to be negatively correlated with valproate exposure. These include egl-5, a 
gene, which causes egg laying defective in mutant and unc-86(Table 32, page 144). unc-
86 codes for a transcription factor required for correct fate determination and 
differentiation of neuronal lineages including egg laying neurons(Horvitz and Sulston, 
1980).It is also required for tph-1 and cat-1 expression in serotonergic neurons and for 
neutrite outgrowth(Sze et al., 2002).   
Genes with the highest connectivity included several cuticle components, GTP-binding, 
Calcium and Zinc ion binding and acetylcholine esterase (Table 33, page 147).  
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Analysis of transcription factors in or associated with expression profile negatively 
correlatedwith valproate identified most of them to be regulated by RNA polymerase II 
promoter (Table 34, page 150). This indicates RNA polymerase II promoter to be a 
target of valproate exposure, which results in selective down regulation of expressions. 
 
Table 32 Transcription factors/ regulators of transcription factors in or associated with down-regulated genes 
identified by CAST 
Locus_ID Symbol GO_P GO_C GO_F 
W10D5.1 mef-2 regulation of transcription, DNA-
dependent; 




Y48C3A.17 efl-2 regulation of progression through cell 







C25A1.11 aha-1 regulation of transcription, DNA-
dependent; signal transduction; 
locomotory behavior; response to 
xenobiotic stimulus; intracellular 
receptor-mediated signaling pathway; 
positive regulation of growth rate; 
positive regulation of locomotion; 
positive regulation of body size; 
















Y75B8A.1 php-3 regulation of transcription, DNA-
dependent; regulation of transcription; 





F16H11.4 ceh-1 regulation of transcription, DNA-
dependent; regulation of transcription; 





F33D11.4 ceh-12 regulation of transcription, DNA-
dependent; regulation of transcription; 





C08C3.1 egl-5 negative regulation of transcription 
from RNA polymerase II promoter; 
regulation of transcription, DNA-
dependent; anterior/posterior pattern 
formation; oviposition; regulation of 
cell adhesion; tail tip morphogenesis 
(sensu Nematoda); regulation of 
transcription; 





B0304.1 hlh-1 larval development (sensu Nematoda); 
regulation of transcription from RNA 
polymerase II promoter; muscle 
development; locomotory behavior; 
embryonic development (sensu 







Metazoa); positive regulation of growth 
rate; post-embryonic body 






F01D4.6 mec-3 regulation of transcription, DNA-
dependent; mechanosensory behavior; 
response to mechanical stimulus; 
regulation of transcription; neuron 
development; 
nucleus; DNA binding; 
transcription factor 




F48D6.3 hlh-13 larval development (sensu Nematoda); 
locomotory behavior; embryonic 
development (sensu Metazoa); growth; 





regulation of transcription, DNA-
dependent; gametogenesis; locomotory 
behavior; embryonic development 
(sensu Metazoa); positive regulation of 
growth rate; locomotion; 




R13A5.5 ceh-13 larval development (sensu Nematoda); 
regulation of transcription, DNA-
dependent; locomotory behavior; 
embryonic development; cell-cell 
adhesion; growth; positive regulation of 
body size; post-embryonic body 











C30A5.7 unc-86 regulation of transcription, DNA-
dependent; locomotory behavior; 
mechanosensory behavior; response to 
mechanical stimulus; oviposition; 
positive regulation of locomotion; 
regulation of transcription; neuron 
development; 









Table 33 Seed genes of down-regulated genes identified by CAST ranked by total connectivity. First ten genes 
are shown in the table 
Rank Symbol Score #_linked_seed 
/ #_valid_seed 
GO_P GO_C GO_F 
1 col-165 4.25 7/76 phosphate 
transport; 
cytoplasm; structural constituent 
of cuticle; 
2 col-74 4.18 6/76 phosphate 
transport; 
cytoplasm; na 
3 cut-3 3.58 9/76 positive regulation 
of body size; 
na na 














5 phat-5 3.08 5/76 na na na 
6 dyb-1 2.92 2/76 na na calcium ion binding; 
zinc ion binding; 







intracellular; GTP binding; 
8 thn-2 2.77 6/76 na na na 
9 clec-60 2.73 5/76 na na sugar binding; 
10 ace-3 2.50 1/76 acetylcholine 
catabolic process 





















Figure 37  Network graph of seed genes that show negative correlation with increasing valproate dose 
identified by CAST.(A) Out of 90 genes, 68 genes were mapped in WormNet v. 2. Out of the 68 genes, 37 of 







Figure 38 Network graph of seed genes showing negative correlation with valproate, identified by CAST with 
daf-2, daf-16 and sma-6 added. (A) Out of 93 genes, 71 genes were mapped in WormNet v. 2. This shows an 
involvement of sma-6 in connecting ace-1 and 3, which are acetylcholine esterases with the cellular metabolism 
via daf-2 and daf-16. Also it connects this neuronal and metabolic signals via tnt-4 to the other two subclusters 
identified in the expression profile negatively correlated with valproate exposure. 
 
 




Biological process RNAi phenotypes 
W10D5.
1 
mef-2 Regulation of acetylcholine 
secretion, neurotransmission, 
negative and positive regulator of 
transcription from RNA polymerase 
II promoter 
 






aha-1 Positive regulation of transcritption  
from RNA polymerase II promoter, 
 body morphogenesis,  
intracellular  receptor signalling 
pathway, locomotion,  
nematode larval development,  









php-3 Regulation of transcription Posterior body morphology variant 
F16H11.
4 
ceh-1 Regulation of transcription  
F33D11.
4 
ceh-12 Regulation of transcription  
C08C3.1 egl-5 Negative regulation of transcritption 
from RNA polymerase II promoter, 
anterior posterior pattern 
specification, oviposition, protein 
catabolic process, regulation of cell 
adhesion, tail tip morphogenesis 
Coiler, ectopic neuron, egg laying 
defective, HSN migration variant, male 
mating defective, serotonin deficient  
B0304.1 hlh-1 Positive regulation of transcritption 
from RNA polymerase II promoter, 
body morphogenesis, locomotion, 
muscle organ development, 
nematode larval development, 
protein oligomerization, reproduction 
dumpy, embroyonic arrest, embroyonic 
lethal, locomotion variant, lumpy, 
reduced brood size, slow growth, sterile 
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F01D4.6 mec-3 Positive regulation of transcritption 
from RNA polymerase II promoter, 
mechanosensory behavior, neuron 
differentiation, neurone 
development,  
dendrite development variant, neuron 
development variant, neuronal outgrowth 
variant, sluggish, touch resistant 
F48D6.3 hlh-13 Locomotion, nematode larval 
development, embroyo development 
ending in birth  
Embroyonic lethal, larval arrest, 




Body morphogenesis, locomotion, 
reproduction, protein catabolic 
process, nematode larval 
development 
Dumpy, egg laying defective, 
embroyonic lethal, locomotion reduced, 
paralysed, reduced brood size, slow 
growth, sluggish, sterile, thin 
R13A5.5 ceh-13 Axon guidance, axonal fasciculation, 
body morphogenesis, cell-cell 
adhesion, dendrite development, 
embroyo development, locomotion, 
nematode larval development, 
regulation of transcription 
Axon fasciculation variant, backward 
locomotion variant, axon midline 
crossing variant, body elongation 
defective, dumpy, embroyonic 
development variant, locomotion variant, 
small 
C30A5.7 unc-86 Positive regulation of transcritption 
from RNA polymerase II promoter, 
Axon extension, dendrite 
development, locomotion, neuron 
development, meiotic chromosome 
segregation, oviposition, response to 
mechanical stimulus 
Egg laying defective, axon outgrowth 
variant, bag of worms, cell 
differentiation variant, locomotion 
variant, neurone degradation, reduced 






4.2.4.3Network analysis of transcription factors in or associated with valproate 
expression profile 
 
After showing that probably up-regulation of genes on valproate exposure is via steroid 
hormone signalling and the down-regulated expression profile of valproate exposure is 
through RNA polymerase II promoter and both of these expression profiles are known 
to be regulated by insulin and TGF-β Sma/Mad signalling pathways, I then set to 
analyse the link between these two expression profiles. For that, I developed a network 
of the transcription factors in (or associated with) these two expression profiles to find 
the key regulators. Network analysis of expression profiles positively and negatively 
correlated with valproate of transcription factors in or associated with valproate 
exposure identified by WormNet shows most of these transcription regulators to be 
associated with the insulin signalling pathway (Figure 39, page154). daf-2 connects the 
two main sub-clusters of transcription factors positively and negatively correlated with  
valproate exposure.   
pqn-28 codes for  a histone acetylase.  hlh-30 codes for a transcription factor and is 
known to result in reduced fat storage when silenced by RNAi.  Y49A3A.1 codes for a 
homolog of choline/ethanolaminephosphotransferase. egl-5 mutant has a egg laying 
defective, coiler, serotonin deficient phenotype, phenotypes also observed on valproate 
exposure. As explained earlier, unc-86 is required for the expression of cat-1 and tph-1 







Figure 39 Network analysis of transcription factors in, or associated with, positively(red box) and 
negatively(green box) correlated expression profiles of valproate exposure identified by WormNet analysis. 
Networkwas generated by adding sma-6 and daf-16 to the transcription factors in or associated with valproate 
exposure expression profile. 
 
 
4.2.4.4 Expression profiles showing a bell shape and an inverted bell 
shapendistributions 
 
There were 7 genes showing an expression profile of bell curve and 4 genes showing an 
inverted bell curve. ins-7, which codes for one of the insulin like peptides in C.elegans 
shows a bell shaped expression profile with valproate exposure. INS-7is known to act as 
an agonist for DAF-2receptor and makes a positive feedback loop to amplify DAF-2 
activity.daf-2 mutants are known to have high lipid mass and therefore this could not 
explain the increase of lipid mass on valproate exposure(Pierce et al., 2001, Murphy et 
al., 2003, Husson et al., 2007). 
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mup-2, which encodes muscle contractile protein, troponin-c, shows an inverted bell 
shaped expression profile. This gene product affects muscle contraction, epidermal 
morphogenesis and is required for growth and fertility (Myers et al., 1996, McArdle et 






4.3.1 Correlation analysis 
 
Expression profiles that correlate with valproate dose show an increase in the expression 
of several genes involved in lipid biosynthesis and catabolism. Steroid synthesis is 
expected to increase on exposure to valproate with an increase in the expression of 
hydroxysteroid dehydrogenases. The gene coding for glycerol-3-phosphate 
dehydrogenase(gpdh-1) which links carbohydrate metabolism with lipid metabolism by 
converting dyhydroxyacetone phosphate to glycerol-3-phosphate is also positively 
correlated with valproate. This enzyme is involved in lipid biosynthesis by providing 
glycerol-3-phosphate for the formation of glycerol by dephosphorylation. Guanylate 
cyclase is involved in the synthesis of cGMP, which signals for insulin secretion. 
Insulin helps in lipid synthesis by increasing the uptake of glucose into adipocytes and 
increasing fatty acid synthesis in the liver and reducing breakdown of fat in adipose 
tissue. Choline kinase B, which catalyzes the committed step of the formation of 
phosphocholine for phosphatidyl choline synthesis, the main phospholipid found in 
eukaryotic membranes is also positively correlated with valproate under this category. 
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Therefore, an increase in phospholipids is also expected on valproate exposure. UDP-
glucuronosyl transferases, which are involved in lipid glycosylation are also positively 
correlated with valproate. It also contains glucose-6-phosphate dehydrogenase, which 
catalyses the rate limiting step in pentose phosphate pathway and makes NADPH 
required for lipid synthesis. Cellular detoxification also depends on NADPH and is one 
of the functional terms enriched in the expression profile positively correlated with 
valproate dose.Since cell division is found to show a negative correlation with valproate 
dose, the purpose of activation of pentose phosphate pathway would be to provide 
NADPH required for cellular biosynthesis and for detoxification rather than the 
production of pentoses. 
As a result synthesis of lipids, especially steroids, phospholipids and 
glycophospholipids are expected to increase on valproate exposure.  
Gene coding for phytanoyl-CoA dioxygenase, which is involved in alpha-oxidation of 
fatty acids is positively correlated with valproate. The enzymes that catalyse the first 
three steps of β-oxidation Acyl-CoA dhydrogenase, enoyl-CoA hydratase and 3-
hydroxyacyl-CoA dehydrogenase are all positively correlated with valproate. Therefore 
an increase in the fatty acid degradation is expected due to an increase in both alpha and 
beta oxidation of fatty acids.  
As a result some lipid synthesis and degradation of fatty acid pathways are expected to 
increase with valproate. 
Glycogen synthase kinase inhibits glycogen synthesis by phosphorylating glycogen 
synthase enzyme. Glycogen synthase kinase shows a positive correlation with valproate 
dose and as a result,a depletion of glycogen stores on exposure to valproate is expected. 
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Since oxidation of fatty acids and a reduction in glycogen synthesis expected on 
exposure to valproate, an overall reduction in energy storage may occur. 
Down regulation of nuclear components is a key feature of valproate exposure.  A DNA 
replication factor, rfc-3 could be a key gene of this down regulation of nuclear 
components and is the gene with the highest connectivity to other nuclear components 
down-regulated on valproate exposure. The second gene with the highest connectivity 
which is also directly connected to rfc-3is pcn-1. pcn-1 codes for the C.elegans ortholog 
of proliferating cell nuclear antigen (PCNA)(Piano et al., 2000). It is an essential 
component of DNA repair and replication machinery and serves as a processivity factor 
for DNA polymerase delta (Boulton et al., 2002) . It directly interacts with CKI-2, a 
cyclin dependent kinase inhibitor homolog that may be required for cell cycle 
progression and play a role in DNA damage check point pathway. Valproate could be 
acting via RNA polymerase II promoter to bring this down regulation of genes and a 
key regulator of that could be vab-3, a transcription factor (Figure 40, page157).  
 
Figure 40 Summary of the findings of the correlation analysis. Cellular functions expected to upregulate due to 




Correlation analysis helps to identify linear relationships in gene expression but it 
cannot identify genes coregulated. It also fails to identify gene interactions. Spearman 
rank correlation was used in this study as it can identify nonmonotonous relationships. 
SAM analysis can identify nonlinear relationships. To understand the key genes 
involved in regulation of genes, which interact with each other, I also performed 
clustering and network analysis. 
 
4.3.2 Clustering and network analysis 
 
In the four cluster analysis of the positively correlated expression profile on valproate 
exposure, there is a gradual increase in the concentration of valproate where a rapid 
increase in the up-regulation of gene sets is observed in each cluster. This clearly shows 
that based on valproate dosage different gene sets could be positively correlated with 
valproate, which could bring different clinical outcomes. The first cluster is connected 
to grd-1 gene. grd-1 gene is predicted to be involved in cholesterol dependent hedge-
hog like signalling and is known to be involved in growth, cuticle adhesion and mail tail 
development. It is mainly composed of collagen genes indicating valproate to play a 
role in morphogenesis.  
 The other three clusters give some indication that insulin signalling pathway could play 
an important role in the up-regulation of genes on valproate exposure. For examplethe 
second, third and fourth clusters are directly connected to daf-2 or connected to daf-2 
via sma-6. In the phenotypic characterization of lipid accumulation on valproate 
exposure, it is shown that accumulation of lipid on valproate exposure requires sma-6 
and daf-2.  DAVID functional clustering identifies second and third clusters to be 
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enriched in lipid glycosylation. In cluster one, which is not directly linked to daf-2, daf-
16 or sma-6, the expression profile shows a rapid up-regulation at 18mM of valproate. 
At this valproate dose, both lipid level and lifespan starts to decrease on increasing 
valproate concentration. This cluster is mainly composed of collagen genes. Therefore 
lack of direct involvement of insulin signaling pathway and sma-6 could be a possible 
reason for the decrease of lipid level and lifespan on valproate concentrations above 
18mM. This disconnection from insulin signaling pathway could be the reason for the 
shift from membrane components to amino acid biosynthesis at valproate doses above 
18mM, where amino acids synthesized would be utilized to make collagen. Different 
valproate concentrations up-regulate different sets of gene networks indicating the 
presence of some valproate dose sensitive molecular switches that regulate the gene 
expression on valproate exposure. The fourthcluster, which is associated with daf-2 has 
two subnetworks, which are connected with each other via daf-36. daf-36 is involved in 
the production of ligand for daf-12, which regulates the entering  of  C.elegans into high 
fat dauer stage. Therefore lipid accumulation on exposure to valproate could be via daf-
36 under the control of daf-2.  
Network analysis of the four clusters identified by SOTA clustering of the expresssion 
profile positively correlated with valproate exposure indicates all clsuters except cluster 
1 to be directly connneted to insulin signalling via daf-16 (Figure 41, page160). Cluster 1 
is indirectly connected to the rest of the clusters via dao-4, which is known to be 
regulated by daf-16. It also identified B0286.3 as a key gene, uncharacterized gene in 
C.elegans, which is known to cause larval arrrest and larval lethality on mutation. The 




Figure 41 Figure showing the summary of the analysis of the expression profile positively correlated with 
valproate exposure identified by CAST clustering and separated into four clusters by SOTA.  Genes known to 
be involved in insulin signalling in each cluster are shown with their connection to daf-16. Green shows low 





Several genes involved in lipid metabolism are negatively correlated with valproate.fat-
6, a key gene in lipid metabolism is down-regulated. Down regulation of fat-6 cannot 
explain the increase of lipid level by valproate as this is known to decrease the lipid 
level by increasing β- oxidation. unc-86 is required for the fate determination and 
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mechanosensory neurons and chemosensory neurons. unc-86  is also required for the 
expression of tph-1 and cat-1 in serotonergic neurons and for neutriteoutgrowth. tph-
1encodes tryptophan hydroxylase ,the key enzyme in serotonin biosynthesis. Down 
regulation of it cause C.elegans to have low serotonin levels.  Serotonin up-regulate a 
subset of peroxisomal and mitochondrial β- oxidation genes (Mullaney and Ashrafi, 
2009b). Reduced serotonin levels cause fat accumulation, dauer formation and reduced 
egg laying in C.elegans. It also cause down regulation of insulin and TGF-β pathways 
(Sze et al., 2000). Down regulation of unc-86 may contribute to the changes in lipid 
content, neuronal and egg laying on valproate exposure.   
Therefore both lipid synthesis and degradation pathways are affected on valproate 
exposure and fat accumulation observed on valproate exposure could be the net result of 
both pathways.  
Transcription factor analysis show steroid hormone signalling to be a main target of 
valproate, which results in up-regulation of genes and down regulation of genes by 
valproate to be  via the RNA polymerase II promoter.  
The main objective of studying model organisms is to understand the human biology in 
an ethically accepted way. Studying worm networks gives a lot of information related to 
worm biology but how much of that information is valid for mammalian system could 
be understand only by relating it to mammalian systems at ortholog level.To understand 
the overlap of C.elegans expression data with mammalian systems, I performed 
Ingenuity Network Analysis, which maps C.elegans data to mammalian gene networks 




5.0 INGENUITY NETWORK ANALYSIS OF TRANSCRIPTIONAL RESPONSE 




Pathway analysis, in the context of this project can be defined as the bioinformatics 
analysis used to identify, biological networks linking genes that share a given property 
(eg. correlated to increasing doses of a drug treatment)(Viswanathan et al., 2008). The 
approaches used to reconstruct these pathways can be either data or knowledge driven.  
In the data driven approach, gene to gene relationships are generated from observational 
data, such as microarray experiments, where as in a knowledge driven approach genes 
are linked because of pre-existing knowledge and the bioinformatics approach aims at 
identifying the connections that are consistent with some criteria (e.g. protein protein 
interaction or transcriptional link).  
Here we describe the network analysis of the gene expression signatures identified in 
the previous chapters performed using the knowledge management system Ingenuity 
Pathway Analysis (IPA).  IPA map the gene identifiers provided to the gene objects in 
the Ingenuity Pathway Knowledge Base. Then it generates networks by overlaying 
these focus genes on to a global network in the Knowledge Base. The specificity of 
connectivity of these focus genes were calculated by the percentage of connectivity to 
other focus genes. Then the networks are generated starting with the focus gene with the 
highest specific connectivity. Each network is limited to 35 focus genes for easier 
visualization and analysis. 
IPA analysis revealed a negative correlation of NFkB signalling and MYC with 
valproate dose (Figure 42, page 163). In lipid metabolism, a positive correlation withβ-
163 
 
oxidation of fatty acids, steroid and phospholipid synthesis, as well as cholesterol and 
phospholipid transport are found with valproate dose.  
 
Figure 42 Diagram showing the cellular functions correlated with valproate dose identified by Ingenuity 
Pathway Analysis. Cellular functions with positive correlation are shown in red and the negative correlation 




After identifying the significant expression profile and the functional terms associated 
with valproate exposure, I then set to assess the possible homology in mammalian 
system to this expression profile identified in C.elegans. For that I mapped the 
C.elegans gene signatures associated with valproate exposure on IPA knowledgebase. 
First the genes which do not show a monotonic relationship were identified by SAM 
analysis (significance <1% FDR) and were pooled together with the genes from the 
correlation analysis with a threshold of BH corrected  p value < 1% and mapped to 
Ingenuity knowledgebase. Ingenuity pathway analysis generated 11 significant 
networks with a score >30 (Figure 43, page164). Except network 3, all the other 









Figure 43 Interactions between networks identified by Ingenuity analysis. Gene identifiers associated with 
valproate exposure with a significance level of 1% BH corrected p value in correlation analysis were pooled 
with the gene identifiers with a significance level of 1% FDR in SAM analysis. Networks were generated by 
mapping these gene identifiers to gene objects in a global network in Ingenuity Pathway Knowledge Base 
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easier visualization. Networks generated with a score of  > 30 are shown in the diagram with their connectivity 
to other networks generated. 
 
 
Table 35 gives a summary of the ingenuity analysis. The significance score of each 
network isdetermined by Fisher's exact test using the whole database as a reference set. 
The most significant network was involved in development disorder, Genetic disorder 
and neurological disease with a score of 50 and 32 focus molecules. 
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Table 35Summary of the functions of the networks identified by Ingenuity Pathway analysis. Threshold used was p value < 1% with BH correction for multiple testing pooled 





Similar to the DAVID analysis originally applied to the genes identified by the 
correlation analysis, this pathway analysis also shows an obvious down regulation of 
genes coding for nuclear components (Figure 44, page167).
 
Figure 44Combination of all the genes mapped by Ingenuity shows a clear down regulation of nuclear 
components. Genes which do not show a monotonic relationship were identified by SAM analysis (significance 
<1% FDR) and were pooled together with the genes from the correlation analysis with a threshold of BH 
corrected p value < 1%. Genes in all the significant networks generated are pooled together to identify cellular 
localization of protein products of expression profile associated with valproate exposure. Focus molecules 
corresponding to gene expression profiles negatively (green) and positively (red) correlated with valproate 
dose are shown with the focus molecules identified by the IPA which are connected to the network but not 
found in the data set (white). 
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Figure 45 (page177) to Figure 55 (page187) show the most significant networks generated 
by Ingenuity on the pooled expression profiles identified by Correlation analysis and 
SAM with a threshold of corrected 1% FDR with BH correction for multiple testing. 
After generating those significant networks I identified different functions associated 
with it to generate hypothesis to explain the affects of valproate.  
 
5.2.1 NFkB signalling may be downregulated on valproate exposure 
 
IPA identified an NFkB signature associated to valproate exposure. This is found to be 
negatively correlated with valproate due to a negative correlation found with TXNRO1, 
thioredoxindisulfide reductase, a cytoplasmic component, which activates NFkB and 
NKAP.NFkB requires thioredoxine reduction for DNA binding(Arnér and Holmgren, 
2000).As expected SLIT2, whose expression is increased by NFkB and SLC11A2 and 
SLC3A1 transporters, which require NFkB for expression show negative correlation 
with valproate dose. SARM1, a negative regulator of NFkB, shows a positive 
correlation with valproate, which further supports the hypothesis that NFkB pathway is 
down-regulated on valproate exposure. Network 1 generated by Ingenuity Pathway 
Analysis (Figure 45, page 177)   identified NFkB to be the most connected gene.   
 
5.2.2 Downregulation of c-myc is expected on valproate exposure 
 
Both PUF60 and FUBP1, a helicase, show a negative correlation with valproate dose. 
PUF60 is known to repress the activation of c-myc by FUBP1. c-myc regulates the 
expression of 15% of genes by recruiting histone acetyl transferase.  NME2 , which is 
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required for the activation of MYC also shows a negative correlation with valproate 
dose. Therefore, a down regulation of c-myc is expected on valproate exposure.  
 
5.2.3 Β-oxidation is expected to increase on valproate exposure 
 
Several genes involved in β-oxidation including HSD17B4, HSD17B8, HSD17B14, 3-
hydroxyacyl-CoA dehydrogenase and HADH are positively correlated with valproate 
dose. In network 5, ACOT8, involved in oxidation of fatty acids is positively  correlated 
with valproate. In network 3 Phospholipase B (PLB1), which hydrolyse phospholipids 
and ECHS1, involved in β-oxidation are also positively correlated with valproate. In 
network 5 carboxy esterase, lipase involved in cholesterol ester hydrolysis, 
phospholipase and ALDH3A2 involved in oxidation of long chain aliphatic aldehydes 
to fatty acids are positively correlated with valproate. In network 10 DECRT; which is 
involved in β-oxidation show positive correlation with valproate. In contrast HSD17B12 
which is involved in fatty acid elongation also show positive correlation with valproate. 
In network 9 Rxr, a co-repressor that induce histone acetylation and chromatin 
condensation and activate fatty acid oxidation genes is identified by the pathway 
analysis, a gene not present in the dataset. These data suggest a hypothesis where 






5.2.4 Phospholipid level is expected to increase on valproate exposure 
 
In network 11 expression of cytoplasmic phosphate cytidyltransferase choline 
(PCYT1A); the rate limiting enzyme in phosphatidylcholine biosynthesis is positively 
correlated with valproate dose.  This is the most abundant phospholipid in animals and 
plants.Therefore an increase in phospholipids is expected on exposure to valproate.  
 
5.2.5 Steroid synthesis is expected to increase with an increase in lipid mobilization 
on exposure to valproate 
 
In network 5(Figure 49, page 181), palmitoyl-CoA hydrolase, CYP3A7, involved in the 
formation of estriol shows a positive correlation with valproatedose.In network 9, T 
POR involved in steroidogenes is also shows a positive correlation with valproate. In 
network 3STARD3 involved in lipid trafficking has a negative correlation with 
valproate. Two cell membrane transporters ABCG4, which is involved in cholesterol 
transport and ABCG1, which is involved in both cholesterol and phospholipid transport 
are positively correlated with valproate. 
Expression of insulin degrading enzyme (IDE), which terminates insulin activity is  also 
positively correlated with valproate. Network 9 (Figure 53, page 185) identified several 
cytoplasmic proteins involved in lipid metabolism. They include POR involved in 
steroidogenesis, FABP4 a transporter involved in fatty acid metabolism, CYP2J2, which 
cause epoxidation of arachidonic acid are all positively correlated with valproate dose, 
while phospholipase D and prostaglandin reductase expression is negatively correlated 
with valproate. These observations supports the hypothesis that both steroid synthesis 
and lipid mobilization are increased by valproate. 
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5.2.6 Chromatin remodelling is expected to be downregulated on valproate 
exposure 
 
In network 6 (Figure 50, page182) several nuclear components involved in RNA 
processing and chromatin remodelling are negatively correlated with valproate. These 
include the key mediator of Notch signalling, RBPJ, transcription stimulator, CEBPZ, 
poly(A) binding protein PABPN1, RNA binding TIAL1, co-repressor complex SPOP 
and chromatin remodelling components ACTL6B and SWI-SNF. Network 8 (Figure 52, 
page 184) reveals the expression of a number of nuclear components involved in 
chromatin remodelling by histone deacetylation and cell cycle control to be negatively 
correlated with valproate. These include PBRM1 and SMARCE1, components of 
chromatin remodelling complex SWI/SNF,  KDM1A and CHD4, RBBP4 , MTA3 
components of histone deacetylase complex and Mi2, a component of nucleosome 
deacetylase complex. These data supports a hypothesis where chromatin remodelling is 
decreased on exposure to valproate.  
 
5.2.7 DNA replication, progression through cell cycle and DNA damage repair are 
decreased on valproate exposure 
 
In network 7 (Figure 51, page183) several nuclear components involved in cell cycle 
control and transcription are negatively correlated with valproate. Helicase and 
ribonucleotide reductase are also among the negatively correlated nuclear components. 
In network 8 other nuclear components negatively correlated with valproate include cell 
cycle control proteins such as the metaphase promoting factor (CDK-1), mitosis spindle 
assembly checkpoint protein (MAD2L1), anaphase promoting complex (ANAPC10), 
cell cycle regulated kinase involved in microtubule formation at spindle pole in 
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chromosome segregation (AURKA) and CDC14A which dephosphorylate p53 and 
regulate DNA replication. These are connected to APC in the wnt signalling pathway. 
In network 9 cell membrane components WNT5B and SFRP2 in wnt signalling are 
negatively correlated with valproate dose.  In network 9, expression of DUSP8, which 
inactivate SAPK is positively correlated with valproate. SAPK , a nuclear component is 
stress activated protein kinase, which recruit general transcription factors.Network 
11(Figure 55, page 187) reveals a remarkable negative correlation of nuclear proteins 
with valproate dose involved in DNA damage repair, DNA replication factor C and 
DNA replication initiation. DNA damage repair genes include CLSPN; the upstream 
regulator of CHECK1 that trigger checkpoint arrest in response to DNA damage which 
is required for efficient DNA replication in normal S phase, PMS2 that do DNA 
mismatch repair by binding to MLH1, POLH; the polymerase specialized in replicating 
UV-damaged DNA, ligase (LIG1) and CHECK2; which inhibit CDC25C phosphatase 
and prevent entry into mitosis when DNA damaged or replication is blocked.HELQ; 
helicase, CRC2; the origin recognition complex, MCM2 and  MCM5, MCM7 and 
MCM10;  components of pre-replication complex, SMARCB1; a SWI/SNF related 
actin dependent regulator of chromatin transcription, CDC45; which load DNA 
polymerase α into chromatin and DNA polymerase are among the components of DNA 
replication initiation which are negatively correlated with valproate. This supports a 
hypothesis that DNA replication, progression through cell cycle and DNA damage 





5.2.8 Transcription is expected to be downregulated by valproate 
 
Network 10 (Figure 54, page186) reveals a remarkable negative correlation of the 
expression of nuclear genes involved in transcription, mainly the mediator complex 
with valproate dose. Mediator, MED8; mediator complex essential for the activation of 
CDK8 and CDK8; the component of RNA polymerase II holoenzyme complex, which 
links mediator and general transcription machinery are negatively correlated with 
valproate. Expression of RNA polymerase II, RNA polymerase III, TAF3;which helps 
to recognize the promoter, general transcription factor GTF2F2, GTF2E1;which recruit 
TFIIH to initiation complex,  CDK7;an essential component of TF11H transcription 
factor, HCFC1;  a transcription regulator,  are all negatively correlated with valproate. 
Network 3 (Figure 47, page179) shows the negative correlation of components of RNA 
polymerase II complex and AIP, which is also a nuclear component involved in the 
regulation of many xenobiotic metabolizing enzymes. These findings suggest a 
hypothesis that transcription is decreased mainly via the mediator complex when 
exposed to valproate.  
 
5.2.9 Translation is also expected to be downregulated by valproate 
 
The second network generated (Figure 46, page178) shows a remarkable negative 
correlation of components of the spliceosome. This network is connected to network 5 
where the components of the translation initiation factor, post splicing complex are 




5.2.10 Valproate may affect neuronal function 
 
The second(Figure 46, page 178) network shows negative correlation of several cell 
membrane components involved in neurotransmission with valproate dose. These 
include AGRN, a protein involved in the aggregation of post synaptic proteins(Misgeld 
et al., 2005), NTN1, which is involved in axon guidance and cell migration, ATP1A3, a 
Na+/K+ pump and ACLY , required for acetylcholine biosynthesis.  In network four 
(Figure 48, page180), several cytoplasmic components involved in neurotransmission are 
also negatively correlated with valproate. These include DBH, which converts 
dopamine to norepinephrine, ITSN1, which is involved in synaptic vesicle recycling and 
GABARAP, which helps to cluster GABA receptors. Glutamate carboxy peptidase 
expression is increased. Plasmamembrane components glutamate receptor, which is 
involved in excitatory neurotransmission is positively correlated with valproate. In 
network 7(Figure 51, page 183) several plasma membrane components involved in 
nervous system development and notch signalling are negatively correlated with 
valproate. These include PLXDC2 , a signalling molecule in proliferation and 
differentiation of the nervous system, NRCAM, involved in neuronal cell adhesion and 
EFNB2 , involved in nervous system development. In network 8(Figure 52, page184) 
there is also negative correlation of the expression of growth factor induced 
transcription regulator MIER1 and PAX6, which regulate transcription in developing 
nervous system with valproate. In network 8 expression of a cell membrane component 




 channel is also negatively correlated with 
valproate dose. Expression of ANXA7, a voltage sensitive Ca
2+
 channel is positively 
correlated with valproate.  PTS, a cytoplasmic component involved in the biosynthesis 
of tetrahydrobiopterin, the irreversible step in the formation of the cofactor for serotonin 
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biosynthesis and NO synthase activity is positively correlated with valproate dose. 
Therefore valproate is predicted to affect neural functioning.  
 
5.2.11 mRNA processing may  bedecreased by valproate 
 
In network 4 (Figure 48, page 180), several RNA processing components are negatively 
correlated with valproate including CELF1, which is involved in mRNA splicing, and 
EXOSC7, involved in mRNA degradation. GIT2, a protein required for receptor 
internalization TOE1 which inhibit cell growth and cell cycle are also nuclear 
components that are negatively correlated with valproate exposure.  
 
5.2.12 Cellular detoxification is predicted to increase on valproate exposure 
 
Several cytoplasmic components involved in detoxification are positively correlated 
with valproate. These include glutathione transferase, HPGDS, SOD2, GSTP1, Sod, 
GSTZ1 and membrane component Abcb1b. UGCG, which is involved in glycosphingo 
lipid biosynthesis. In network 5 (Figure 49, page181) several membrane bound ABC 
transporters involved in xenobiotic transport are positively correlated with valproate. In 
network 11(Figure 55, page187), expression of cytoplasmic cystathionase; which 
converts cystathione to cysteine that is required for glutathione synthesis is also 
positively correlated with valproate supporting a hypothesis that cellular detoxification 




5.2.13 Jun signalling may decrease on valproate exposure 
 
In network 8(Figure 52, page 184) cytoplasmic component mitogen activated protein 
kinase (Mapk) in Jun signalling is also negatively correlated with valproate. In network 
9(Figure 53,185) several components including jnk, MAPK10 and SAPK  in the Jnk 
pathway are negatively correlated with valproate dose. 
 
5.2.14 G protein coupled signal transduction is also expected to decrease with 
valproate 
 
In network 9(Figure 53, page 185) in addition, expression of several cytoplasmic 
components of G protein signal transduction including GNB5, which regulate GNA 
signal transduction, RGS7, which inhibit signal transduction by increasing GTPase 
activity of GNA and GNAI1 which inhibit cyclase controlled cAMP level  are 
negatively correlated with valproate.  
 
5.2.15 Tryptophan metabolism may increase with valproate 
 
In network 10 expression of cytoplasmic acyl CoA dehydrogenase (ACAD8);an 
enzyme that is involved in catabolism of branched chain amino acids is positively 
correlated with valproate.  The expression of Tryptophan 2,3-dioxygenase (TDO2) 
which catalyzes the rate limiting step in the kynurenine pathway, the major pathway of 
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to gene expression profiles negatively (green) and positively (red) correlated with valproate dose are shown 
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Ingenuity Pathway Analysis also identified expression of genes related to nuclear 
functions to be down-regulated. These include chromatin remodelling, DNA replication, 
progression through cell cycle, DNA damage repair, transcription and mRNA 
processing. These functions mainly related to functions required for the progression 
through cell cycle and valproate expected to decrease cell division. Since these mapped 
on ortholog level to mammalian system, in mammalian system also these nuclear 
functions are expected to be down-regulated, which could be tested by studying the cell 
division in human cell lines exposed to valproate. 
Network 1 generated by Ingenuity Pathway Analysis (Figure 45, page 177)   identified 
NFkB to be the most connected gene. Even though NFkB homolog not found in 
C.elegans(Kurz and Ewbank, 2003), this finding suggests valproate to act via NFkB in 
mammalian system. Further supporting this hypothesis, valproate decreases NFkB 
binding to DNA in rat(Rao et al., 2007).  NKAP, which activates NFkB is also 
negatively correlated with valproate in network 5 further supporting the hypothesis that 
valproate decreases NFkB signalling. 
In the second network generated NME2, which is required for the activation of MYC is 
negatively correlated with valproate supporting the hypothesis that MYC is down-
regulated by valproate. Valproate is known to down-regulate myc in neuroblastoma cell 
line BE[2]-C too(Cinatl et al., 2002). MYC is a promising target for anticancer drugs 
and this finding suggest a possible anticancer effect of valproate through down-
regulation of myc. 
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Ingenuity Pathway Analysis also predicts β-oxidation to be increased on valproate 
exposure. HSD17B4 expression is increased on valproate exposure. It is a bifunctional 
enzyme involved in β-oxidation of fatty acids with enoyl-CoA hydratase, D-3- 
hydroxyacyl –CoA dehydrogenase and 3-ketoacyl-CoA thiolase activities. HSD17B8, 
3-hydroxyacyl-CoA dehydrogenase and HADH are also positively correlated with 
valproate. HADH has 3-hydroxyacyl-CoA dehydrogenase activity.  Expression of 
cytoplasmic acyl CoA dehydrogenase (ACAD8), an enzyme that is involved in 
catabolism of branched chain amino acids and fatty acid β-oxidation is positively 
correlated with valproate.  Expression of ECHS1which catalyse the second step of fatty 
acid β-oxidation by hydrating 2-trans-enoyl-coenzyme A (CoA) intermediates to L-3-
hydroxyacyl-CoAs is also positively correlated with valproate. Expression of ACOT8 
and palmitoyl-CoA hydrolase which are thioesterases, which catalyse the last step of 
fatty acid β-oxidation, is positively correlated with valproate. Phopholipase B (PLB1), 
which hydrolyze phospholipids and release fatty acids is also positively correlated with 
valproate. Valproate treated patients show higher concentrations of serum triglycerides 
implying catabolism of lipids and release of fatty acids(Pylvänen et al., 2006). 
Therefore, an increase in β-oxidation is expected on valproate exposure. Thishypothesis 
could be tested by a similar test to what is done by Franz Knoop in 1904 where he 
showed that fatty acids are degraded by sequential removal of two carbon units. Can 
feed C.elegans with straight chain fatty acids labelled at ω- carbon atom and test for the 
rate of production of acetic acid in the presence and absence of sodium valproate. 
STARD3 involved in lipid trafficking is negatively correlated with valproate.   FABP4 a 
transporter involved in fatty acid metabolism is positively correlated with valproate. 
Two cell membrane transporters ABCG4, which is involved in cholesterol transport and 
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ABCG1, which is involved in both cholesterol and phospholipid transport are positively 
correlated with valproate. Therefore an increase in cholesterol and phospholipid 
transport is expected on exposure to valproate. 
 Ingenuity Pathway Analysis also show activation of several genes involved in steroid 
synthesis due to the up-regulation of CYP3A7, involved in the synthesis of estriol; 
cholesterol; steroids and other lipids. POR involved in steroidogenesis and membrane 
component Abcb1b UGCG, which is involved in glycosphingo lipid biosynthesis is 
positively correlated with valproate. HSD17B12, which is involved in fatty acid 
elongation is also positively correlated with valproate. Expression of cytoplasmic 
phosphate cytidyltransferase choline (PCYT1A); the rate limiting enzyme in 
phosphatidylcholine biosynthesis is positively correlated with valproate.This is the most 
abundant phospholipid in animals and plants. As a result, an increase in steroid 
synthesis, especially cholesterol, glycosphingo lipids and phosphatidylcholine are 
expected on exposure to valproate. Further supporting this hypothesis, valproate 
increases androgen levels in human(Rättyä et al., 2001).  
Expression of carboxy esterase, lipase involved in cholesterol ester hydrolysis, 
phospholipase and ALDH3A2 involved in oxidation of long chain aliphatic aldehydes 
to fatty acids are also positively correlated with valproate. Expression of Phospholipase 
D, which hydrolyse phosphatidylecholine to phosphatidic acid and prostaglandin 
reductase involved in arachidonic acid metabolism is down-regulated.Further 
supporting this finding, valproate treatment reduces arachidonate cascade in platelets of 
human (Kis et al., 1999).  Rxr, a co-repressor that induce histone acetylation and 
chromatin condensation and activate fatty acid oxidation genes is identified by the 
pathway analysis, a gene not present in the dataset. These results suggest valproate to 
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modulate lipid level and the net result would be an increase in total lipids as seen in 
phenotypic analysis. 
Expression of insulin degrading enzyme (IDE), which terminates insulin activity is 
positively correlated with valproate, which may explain the activation of DAF-16. 
Valproate causes hyperinsulinemia in human, which contradict with this finding 
(Pylvänen et al., 2002). But our correlation analysis identified insulin secretion to 
increase on exposure to valproate. 
Therefore valproate may decrease lipid accumulation by increasing β-oxidation of fatty 
acids.  But it may increase cholesterol and other steroid synthesis, glycosphingolipid 
and phosphatidylcholine biosynthesis resulting in an overall accumulation of lipids. 
Phenotypic changes predicted to occur on exposure to valproate are summarised in 
Figure 56.  
 
Figure 56 Phenotypic changes predicted to occur on exposure to valproate. Phenotypic changes expected to 










As discussed in the previous chapters valproate causes lifespan extension and dauer 
formation probably via the insulin signalling pathway. Therefore we thought this 
pathway may also play a role in the lipid accumulation on valproate exposure. To assess 
this I compared the expression profile associated with valproate exposure and the 
expression profiles of insulin signalling pathway mutants.  Specifically I compared the 
expression profile of wild type C.elegans exposed to valproate with the daf-2 insulin 
receptor mutant and with daf-2;daf-16 double mutant where both insulin receptor and 
the gene coding for FOXO transcription factor daf-16 are mutated. This analysis 
revealed most of the gene expression changes associated with valproate exposure to be 




One major limitation of Ingenuity Pathway analysis is the smaller percentage (<15%) of 
genes mapped to Ingenuity pathways. Therefore genes of interesting pathways were 
checked for their expression patterns in heatmaps in TMev. TMev is a set of microarray 
data analysis tools including tools to cluster, visualize, classify, statistically analyse data 
and helps to discover biological themes. This is performed to identify any trends in 
expression patterns of pathways by visualization because general patterns in an 
expression profile associated with a specific pathway is not expected in random noise 
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and would reveal a biological theme. Expression profiles with <1% FDR in SAM 
analysis were considered significant. Significantly altered Gene expressions from 
insulin receptor daf-2 up to daf-16 is shown in Figure 57 (page 194). As expected, when 
the inhibitory effect of receptor is relieved, most of the genes downstream of daf-
16were positively correlated with valproate exposure (Figure 58, page194).  This could 
explain the plateau effect of lipid level obtained at higher valproate doses. Valproate 
increases expression of daf-16 down- stream genes and they exert an inhibitory effect 
on the increase of lipid by valproate bringing the plateau effect. If this is true, then 
valproate should be increasing lipid levels by some other means other than via the 
insulin signalling pathway. None of the genes in the TGF-β dauer pathway show 
significant changes in the expression profile and only two genes, unc-129 and sma-3, in 
the sma-mab pathway were significantly changed on valproate exposure (Figure 59, 
page 195). unc-129 encodes a growth factor signalling molecule that functions as a 
dorsalward axonal guidance cue(Colavita and Culotti, 1998) and sma-3 encodes a smad 
protein, which interacts with lin-31 transcription factor. Genes in the SIRT1 pathway 
are negatively correlated with valproate (Figure 60, page195). Down regulation of hcf-1 
relieves its inhibitory action on daf-16. This shows that when the inhibitory action on 
daf-16 is relieved, its mRNA level increases. There was no significant change in the 
gene expressions in the GABA pathway. AMPK phosphorylate daf-16 directly(Greer et 
al., 2007). Some genes coding for the 20 different possible C.elegans AMPK subunits 
were positively correlated with valproate(Figure 61, page196). This could partly explain 
the lifespan extension of C.elegans on valproate exposure but cannot explain the 
changes in lipid content. daf-15/let-363, the C.elegans TOR pathway components, did 
not show any significant changes in expression profile. daf-15 and let-363 mutants are 
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known to have high lipid content (Jia et al., 2004). This complex is known to interact 
with insulin signalling as daf-16 negatively regulates daf-15 expression. 
 
Figure 57Heatmap of significant expression profiles of genes from daf-2 insulin receptor upto daf-16 on 
exposure to valproate. This shows a down regulation of this part of the insulin signalling pathway.Expression 
profiles with <1% FDR in SAM analysis were considered significant.Numbers across top of heatmap indicates 
valproate concentration. The degree of expression  indicated with a red to green scale where the higher 




Figure 58Heatmap of expression profile of genes down stream of daf-16 and daf-16. This shows an 
upregulation of most of the daf-16 downstream genes.Expression profiles with <1% FDR in SAM analysis 
were considered significant.Numbers across top of heatmap indicates valproate concentration. The degree of 






Figure 59Heatmap of significant expression profile of genes in TGF-β sma/mad pathway. Expression profiles 
with <1% FDR in SAM analysis were considered significant.Numbers across top of heatmap indicates 
valproate concentration. The degree of expression  indicated with a red to green scale where the higher 




Figure 60Heatmap of significant expression profile of genes from sir-2 to daf-16.  This shows a down regulation 
of sir-2 pathway. Expression profiles with <1% FDR in SAM analysis were considered significant.Numbers 
across top of heatmap indicates valproate concentration. The degree of expression  indicated with a red to 






Figure 61Heatmap of significant expression profile of amp kinase genes. Expression profiles with <1% FDR in 
SAM analysis were considered significant.Numbers across top of heatmap indicates valproate concentration. 
The degree of expression  indicated with a red to green scale where the higher expression is given by red. 
 
 
Then I assessed the GO functional terms linked to the expression profile dependent on 
insulin on valproate exposure by DAVID analysis.  
Three genes downstream of daf-16, a steroid dehydrogenase, lysozyme and a UDP-
glucuronosyl transferase are associated with the functional term ‗determination of adult 
life span‘ and are positively correlated with valproate. These were identified as the 
DAF-16 dependent expression profile positively correlated with valproate(Figure 62, 
page197). 
DAF-16 dependent negatively correlated expression profile of valproate exposure had 
bbs-5, which is required for regulation of insulin secretion. Mutants of this gene are 
known to have increased levels of insulin, biogenic amines and neuropeptides (Figure 






Figure 62 Nuclear DAF-16 dependent expression profile positively correlated with valproate exposure. 
Numbers across top of heatmap indicates valproate concentration. The degree of expression  indicated with a 





Figure 63 Nuclear DAF-16 dependent expression profile down-regulated on valproate exposure. Numbers 
across top of heatmap indicates valproate concentration. The degree of expression  indicated with a red to 
green scale where the higher expression is given by red. 
 
 
DAF-2 dependent expression profile positively correlated with valproate had several 
collagen genes and glutathione transferase genes associated with functional terms 
Cluster Enrichment 
Score 
Term Count PValue Benjamini 
1 2.045856 GO:0008340~determination 
of adult life span 




Term Count PValue Benjamini 
1 4.358941 GO:0008340~determination 
of  
adult life span 
















































‗structural constituent of cuticle‘ and ‗glutathione transferase activity‘.  DAF-2 




Figure 64  DAF-2 dependent expression profile positively correlated with valproate exposure. Numbers across 
top of heatmap indicates valproate concentration. The degree of expression  indicated with a red to green scale 






















Term Count PValue Benjamini 
1 6.221541 GO:0042302~structural constituent of 
cuticle 
14 1.28E-10 1.30E-08 






Figure 65  DAF-2 dependent expression profile downregulated on valproate exposure. Numbers across top of 
heatmap indicates valproate concentration. The degree of expression  indicated with a red to green scale where 
the higher expression is given by red. 
 
Analysis of the insulin dependent expression profile of valproate exposure revealed only 
a few functional terms to be associated with the insulin dependent part of the expression 
profile. It shows that determination of adult life span to be associated with DAF-16 and 
cellular detoxification, collagen and lectins to be associated with the receptor DAF-2.  
Therefore most of the response to valproate exposure is insulin independent.  
Ingenuity pathway analysis revealed lipid metabolism and amino acid metabolism to be 
dependent on nuclear DAF-16 (Figure 66,). HSD17B12 involved in fatty acid 
elongation, haematopoetic prostaglandin D synthase (HPDGS), fatty acid binding 
proteins (FABP) which is involved in fatty acid uptake, transport and metabolism and 
ABHD4 involved in the biosynthesis of N-acyl ethanol amine are all positively 
correlated with valproate which are dependent on DAF-16.  
 
Cluster Enrichment Score Term Count PValue Benjamini 
1 2.019904 IPR016186:C-type lectin-
like 




















Figure 66 Ingenuity system pathway analysis of nuclear DAF-16 dependent expression profile of valproate 
exposure. Focus molecules corresponding to gene expression profiles .positively (red) correlated with valproate 
dose are shown with the focus molecules identified by the IPA which are connected to the network but not 
found in the data set (white). 
 
 
The expression of DAF-16 dependent valproate exposure genes are compared with a 
dataset of daf-16;daf-2 double mutant with daf-2. This reveals an inhibitory effect of 
DAF-16 on valproate induced lipid accumulation genes (Table 36, page 201).  This 
would explain the increase of lipid mass on valproate treated daf-16 mutants compared 






Table 36 Lipid metabolism related DAF-16 dependent expression profile of valproate exposure. Expression of 
DAF-16 dependent valproate gene expressions are identified in daf-16(mu86);daf-2(e1370) vs daf-2(e1370 
(PUMA database Shaw et al. 2007) 
Gene 
symbol 
Gene Agilent ID Mean 
expression 
lbp-8 Lipid Binding Protein A_12_P119973 -0.35926 
stdh-2 STeroid DeHydrogenase family A_12_P119903 0.103837 
oac-6 O-ACyltransferase homolog A_12_P101511 -0.07638 




DAF-2 dependent expression profile of valproate exposure was analysed by Ingenuity 
Systems Pathway Analysis (Figure 67). This shows lipid metabolism, amino acid 
metabolism, cellular detoxification and transport to be dependent on DAF-2. Gene 
coding for prostaglandin-D synthase (HPGDS) which is involved in prostaglandin 
synthesis and detoxification is positively correlated with valproate and AGPAT-6 which 
transferes acyl groups to lysophosphatidic acid and convert it into phoaphatidic acid is 
negatively correlated with valproate.  Phosphatidic acid is the common metabolite 




Figure 67 Ingenuity system pathway analysis of  DAF-16 independent DAF-2 dependent expression profile of 
valproate exposure. Focus molecules corresponding to gene expression profiles negatively (green) and 
positively (red) correlated with valproate dose are shown with the focus molecules identified by the IPA which 









6.2.1 Identification of a few functions to be dependent on daf-16 is not due to 
inefficient inactivation of daf-16 by RNAi 
 
Only a few functional terms were associated with DAF-16 dependent expression profile 
of valproate exposure. The possibility of this to be due to inefficient inactivation of 
genes by RNAi is tested by analysing another data set of daf-2; daf-16 double mutant vs 
daf-2 (Available in PUMAdb by Show et al. 2007 Exp. ID 105871, 105873 and 
105845)(Shaw et al., 2007). The null mutant daf-16(mu86) was compared with the 
double mutant daf-16(mu86);daf-2(e1370).  Only a few genes negatively correlated 
with valproate were identified as significant expression profile with a 1% FDR 1fold in 
SAM analysis in this comparison (Table 37). Therefore the few functions associated 
with DAF-16 dependent component identified cannot be due to inefficient inactivation 
ofdaf-16 by RNAi.  
Table 37 DAVID gene ID conversion of the significant expression profile identified in daf-16(mu86) compared 
with daf-16(mu86); daf-2(e1370) 




A_12_P111479 taf-3 TAF (TBP-associated transcription factor) 
family 
A_12_P101622 nhr-225 Nuclear Hormone Receptor family 
A_12_P105555 vit-5 VITellogenin structural genes (yolk protein 
genes) 




A_12_P112365 Y53F4B.24 Y53F4B.24 
A_12_P113081 C10A4.2 C10A4.2 
A_12_P110918 Y17G7B.13 Y17G7B.13 
A_12_P100622 npp-16 Nuclear Pore complex Protein 





Since lifespan extension and dauer formation in C.elegans depend on insulin signalling 
pathway(Evason et al., 2008), we hypothesised that lipid accumulation on valproate 
exposure too could depend on insulin pathway. But the observation of expression 
profiles of mutants of the insulin signalling pathway reveal that most of the molecular 
changes associated with valproate to be insulin independent.DAF-16 dependent 
expression profile of valproate exposure  is expected to be involved in steroid synthesis, 
fatty acid elongation, prostaglandin D synthesis, fatty acid uptake and acylated ethanol 
amine production. It is also expected to increase insulin secretion by decreasing the 
expression of bbs-5 resulting in lipid synthesis.  Valproate treated patients show low 
estradiol levels but increased testesterone and delta-4-androstenedione levels implying 
valproate to modulate steroid levels(Murialdo et al., 1998).Therefore valproate induced 
lipid accumulation is partially affected by DAF-16 (Figure 68).  It also reveals that 
prostaglandin synthesis to be positively correlated with valproate and phosphatidate 
formation to be decreased in a DAF-2 dependent manner. Prostaglandins have 
anticonvulsant effects and anticonvulsant effects of valproate suggested to be due to 
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prostaglandins(Srivastava and Gupta, 2001). Supporting this hypothesis current study 
reveals valproate to induce prostaglandin synthesis. 
 



















In the previous chapter I showed that most part of the expression profile associated with 
valproate exposure is insulin independent. Therefore I set to assess how much of the 
lipid accumulation of valproate exposure could be explained by insulin independent 
component. To achieve this, I analysed the insulin independent component of the 
expression profile of valproate exposure. Also by comparing with TGF-β pathway 
mutants I also assessed the possible role played by that pathway on valproate induced 




The insulin independent component of expression profile associated with valproate 
exposure is tested by DAVID functional clustering to identify the functional terms 




Figure 69 Expression profile positively correlated with valproate exposure which is independent of insulin is 
shown as a heat map. DAVID functional clustering is shown in the adjacent table. Numbers across top of 
heatmap indicates valproate concentration. The degree of expression  indicated with a red to green scale where 





Category Term Count PValue Benjamini 
1  GOTERM_MF_FAT GO:0042302~structural constituent of 
cuticle 
32 1.74E-18 3.64E-16 
2 8.197562 SP_PIR_KEYWORDS collagen 22 1.24E-14 1.41E-12 
3 5.291014 GOTERM_MF_FAT GO:0030246~carbohydrate binding 21 1.09E-07 7.61E-06 
4 4.710013 SMART SM00587:CHK 8 4.28E-07 2.23E-05 
5 4.377202 KEGG_PATHWAY cel00903:Limonene and pinene degradation 8 8.52E-08 2.05E-06 
  INTERPRO IPR001128:Cytochrome P450 12 5.68E-06 2.07E-04 
  GOTERM_MF_FAT GO:0009055~electron carrier activity 18 6.99E-05 0.003662 
  GOTERM_BP_FAT GO:0055114~oxidation reduction 22 1.32E-04 0.010495 
6 2.559407 GOTERM_MF_FAT GO:0005529~sugar binding 11 5.97E-04 0.024751 
  SMART SM00034:CLECT 13 0.003338 0.056304 























Several collagen genes are identified under the functional terms ‗structural constituent 
of cuticle‘ and ‗collagen‘ (Figure 69). Lectins and UDP-glucuronosyl transferases are 
identified as ‗carbohydrate binding‘.  Several checkpoint kinases and cytochrome P450 
are also identified as independent of insulin signalling. Acyl CoA dehydrogenase which 
catalyzes the first step in β-oxidation and cytochrome P450 are identified as electron 
carrier activity.  Several glutathione transferases are identified under the functional term 
‗thioredoxine fold‘. These are all positively correlated with  valproate exposure and is 




Figure 70 Expression profile down-regulated on valproate exposure which is independent of insulin is shown 
as a heat map. DAVID functional clustering is shown in the adjacent table.Numbers across top of heatmap 
indicates valproate concentration. The degree of expression  indicated with a red to green scale where the 





Category Term Count PValue Benjamini 
1 5.131848 INTERPRO IPR016186:C-type lectin-like 15 3.23E-07 8.52E-05 
2 2.788663 GOTERM_MF_FAT GO:0005529~sugar binding 6 0.007677 0.423652 
  GOTERM_MF_FAT GO:0030246~carbohydrate binding 6 0.062878 0.787281 
3 2.60259 INTERPRO IPR011001:Saposin-like 4 6.75E-04 0.029262 
4 2.556274 UP_SEQ_FEATURE signal peptide 17 2.29E-05 0.003883 
  GOTERM_CC_FAT GO:0005576~extracellular region 8 0.066307 0.800569 
5 2.546035 GOTERM_BP_FAT GO:0055002~striated muscle cell 
development 
5 2.90E-05 0.009299 





















After assessing the functional terms associated with the insulin independent positively 
correlated expression profile with valproate, I then set to assess the functional terms 
associated with negatively correlated expression profile of insulin independent 
component of valproate exposure. Several lectins, eva-1 a gene whose function is 
required for axon migration, an acid sphingomyelinase which is required for the 
conversion of sphingomyelin to ceramide are identified under the functional terms ‗C-
type lectin like‘, ‗sugar binding‘, ‗carbohydrate binding‘, and saposine like (Figure 70, 
page 209).  Several neuronal genes are identified under ‗signal peptide‘ including acid 
sphingomyelinase, glutamate receptor, unc-52, and an abnormal acetylcholine esterase. 
These are identified as down-regulated expression profile on valproate exposure 
independent of insulin. Two insulin related genes ins-7 and ins-23 are also identified as 





channel and  unc-52 involved in myofilament assembly are identified under striated 
muscle cell development.  
 
 
7.2.1 Ingenuity Pathway Analysis of expression profile of valproate exposure 
independent of insulin signalling 
 
Out of the 1460 expression profiles of insulin independent component identified in 
comparison with the RNAi study (Murphy et al., 2003), which is uploaded into 
Ingenuity Systems Pathway Analysis, only 202 could be mapped to Ingenuity database. 
To make predictions on the possible phenotypic changes associated with the insulin 
independent expression profile, I did a transcription factor analysis. Transcription factor 
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analysis helps to predict the upstream activation or inhibition of transcription factors by 
mapping uploaded genes to Ingenuity Knowledge Base and considering the changes in 
the expression pattern of the downstream target genes of a given transcription factor 
(Figure 71, page 212).  
Ingenuity systems pathway analysis predicts lipid quantity to increase independent of 
insulin pathway due to an increase in metabolism, biosynthesis, transport and a decrease 
in efflux and hydrolysis of lipids (Figure 72, page 213). Table 38 (page 214) gives the 
details of the genes involved in fatty acid metabolism and the rationale for predicting it 
to increase. 
Table 39 gives the details of the genes involved in increase of lipid quantity and 
rationale for predicting it to increase. Figure 73 to Figure 80 (page 215 to 218) shows the 
details of the types of lipids predicted to be increased, types of lipids predicted to have 
an increase in synthesis and mobilization resulting in an overall increase in lipid 
quantity. Phospholipids and cholesterol is expected to increase (Figure 73, page 215) 
with an increase of metabolism of membrane lipids and glycosphingolipids (Figure 74, 
page 215). C.elegans does not have a cholesterol synthesis pathway. Therefore, its 
increase should be via a decrease in efflux and/or decrease in hydrolysis. Glycolipid 
synthesis is expected to rise with a decrease in ceramide synthesis (Figure 75, page 216). 
Efflux of sterols and cholesterol is predicted to decrease (Figure 76, page 216) with an 
accumulation of sphingolipids (Figure 77, page 216). Sterol transport (Figure 78, page 
217) and lipid hydrolysis (Figure 80, page 218) are expected to decrease with an increase 





Figure 71 Transcription analysis of insulin independent expression profile by Ingenuity Pathway Analysis 
software.  Transcription factors predicted to be involved are shown with their direct targets. Positively 
correlated genes with valproate are shown in red and genes negatively correlated with valproate are shown in 
green.Focus molecules corresponding to gene expression profiles negatively (green) and positively (red) 
correlated with valproate dose are shown with the focus molecules identified by the IPA which are connected 









Figure 72 Ingenuity Pathway Analysis of insulin independent component of expression profiles associated with valproate exposure. In this figure, the expression profiles 
independent of insulin are predicted to increase lipid quantity via decreasing efflux and hydrolysis. 
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Table 38 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 






Table 39 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 







Figure 73 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 




Figure 74 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 






Figure 75 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 
increasing synthesis of lipids and glycolipids. Synthesis of ceramide is predicted to decrease. 
 
Figure 76 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 
decreasing efflux of cholesterol and sterols. 
 
 
Figure 77 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 






Figure 78 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 
increasing transport of steroids. 
 
Figure 79 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 





Figure 80 Ingenuity systems pathway analysis prediction of insulin independent valproate exposure expression 
profile. This predicts valproate exposure to increase lipid quantity independent of insulin signalling by 
increasing synthesis of glycosphingolipids. 
Main limitation of this study is the use of mutants from an RNAi study which may not 
as good as a null mutant. Network analysis by Ingenuity systems pathway revealed an 
indirect link to insulin signalling in this insulin independent expression profile of 
valproate exposure (Figure 81).  The second most significant network shows cellular 






Figure 81 Ingenuity systems pathway analysis of insulin independent valproate affected gene expression 
profile. This most significant network derived shows an indirect insulin signalling.Focus molecules 
corresponding to gene expression profiles negatively (green) and positively (red) correlated with valproate 
dose are shown with the focus molecules identified by the IPA which are connected to the network but not 








Figure 82 Ingenuity systems pathway analysis of insulin independent expression profile of valproate exposure. 
This shows cellular phophorylation to be a key feature of valproate exposure. Focus molecules corresponding 
to gene expression profiles negatively (green) and positively (red) correlated with valproate dose are shown 










7.2.2 Valproate induced lipid accumulation could be partially due to TGFβ 
Sma/Mab pathway 
 
TGFβ dependent expression profile of valproate exposure was identified by comparing 
the expression profile of valproate exposure with a microarray dataset of a dbl-1 over-
expressing strain (BW1940) and a null mutant of sma-6 (sma-6(wk7)) from GEO 
database (accession number GSE15527). SMA-6 and DBL-1 are the type I receptor and 
the ligand of the Sma/Mab TGFβ related pathway (Figure 83, page 222). This 
comparison identified 43 genes that positively correlated with valproate and 10 
negatively correlated with valproate expression profiles to be dependent on Sma/Mab 
TGFβ related pathway (Figure 84, page 222). The expression profile positively 
correlated with valproate identified several genes regulated by daf-16, lectins, lysozyme 
(Table 40, page 223). It also contained O-acyltransferase, which is involved in 
glycerophospholipid synthesis. Expression profile negatively correlated with valproate 




Figure 83 TGFβ dauer and Sma/Mab pathways 
 
 
Figure 84 Comparison of the expression profile of valproate exposure with the expression profile dependent on 







Table 40Known up regulated expression profile of valproate exposure that is dependent on Sma/Mab TGFβ 
related pathway 
Agilent ID Gene Gene Name 
A_12_P117774 col-90 COLlagen 
A_12_P120298 clec-67 C-type LECtin 
A_12_P115146 F56A4.2 C-type LECtin 
A_12_P115146 clec-209 C-type LECtin 
A_12_P119327 dod-17 Downstream Of DAF-16 (regulated by DAF-16) 
A_12_P118504 dod-24 Downstream Of DAF-16 (regulated by DAF-16) 
A_12_P110068 Lys-2 LYSozyme 
A_12_P117943 oac-58 O-ACyltransferase homolog 
A_12_P103686 pes-9 Patterned Expression Site 
A_12_P108210 F26E4.12 Probable glutathione peroxidase F26E4.12 
A_12_P102462 C15C7.7 Putative GDP-fucose protein O-
fucosyltransferase 1 
A_12_P114080 spp-21 SaPosin-like Protein family 








Table 41 Known negatively correlated expression profile of valproate exposure that is dependent on Sma/Mab 
TGFβ related pathway 
Agilent ID Gene Gene Name 
A_12_P110147 bli-4 BLIstered cuticle 
A_12_P115388 clec-26 C-type LECtin 






Comparison of insulin pathway mutants with wild type C.elegans treated with valproate 
reveals that major component of the gene changes associated with valproate exposure 
are independent of insulin. Ingenuity System pathway analysis predicts valproate 
induced lipid accumulation to be partly due to this insulin independent component. This 
increase of lipid level is expected to be due to an increase in metabolism, biosynthesis, 
transport and a decrease in efflux and hydrolysis of lipids. Specifically, phospholipids 
and cholesterol is expected to increase with an increase of metabolism of membrane 
lipids and glycosphingolipids. Supporting this finding, supplementation with 
radioactively labaled phosphorus of valproate treated Saccharomyces cereviseae show 
modifications in phospholipid synthesis (Ju and Greenberg, 2003). Rats treated with 
valproate show abnormalities in muscle mitochondrial cistae and microvesicular lipid 
deposition in muscle(Melegh and Trombitás, 1997). This also suggest an abnormality in 
lipid mobilization caused by valproate and an effect of valproate on membranes. 
C.elegans does not have a cholesterol synthesis pathway. Therefore its increase should 
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be via a decrease in efflux and/or decrease in hydrolysis. In contrast to this observation, 
valproate has not affected total cholesterol levels in human(Franzoni et al., 1992). 
Glycolipid synthesis is expected to rise with a decrease in ceramide synthesis. Efflux of 
sterols and cholesterol is predicted to decrease with an accumulation of sphingolipids. 
Sterol transport and lipid hydrolysis are expected to decrease with an increase in 
synthesis of glycosphingolipids (Figure 85).  
 
Figure 85 Functions associated with lipid metabolism, which are independent of insulin signalling pathway. 
 
TGF-β pathway could be linked to glycerophospholipid synthesis on valproate exposure 
causing an increase of lipid accumulation.  
In addition to be involved in valproate induced lipid accumulation, theSma/Mab 
pathway could have a neuronal phenotype, which is shown by the paralysis of sma-6 
mutants on exposure to valproate. But daf-4 type II receptor of both dauer and  
Sma/Mab pathway was not paralysed on exposure to valproate. But daf-1mutants get 
paralysed on exposure to valproate.  Therefore this could be a phenotype of TGF-β type 
I receptors rather than a function of either pathway. In the next chapter I assess this 










Valproate is a drug known to inhibit GABA inhibitory neurotransmission. It is currently 
the most widely used antiepileptic drug (Duncan et al., 2006). It is also used to treat 
bipolar disorder and schizophrenia. Recently its therapeutic effects have been extended 
to other illnesses such as cancer, migraine, Alzheimers disease and HIV. With the 
exception of cancer and HIV, valproate is used in the treatment of diseases caused by a 
dysfunction in the nervous system (Lloyd, 2013). The  therapeutic effects of valproate 
are thought to be a result of the reduction in excitatory neurotransmission, modification 
of monoamines (Morland et al., 2012) or inhibition of sodium and potassium 
conductance (VanDongen et al., 1986). Its histone deacetylase inhibitory activity and 
interference with respiratory chain and acceleration of oxidative damage has been 
implicated in teratogenicity (Lloyd, 2013) including malformation of the nervous 
system.  
There is no record of paralysis caused by valproate in C.elegans. In this chapter I report 
for the first time a paralysis caused by valproate on C.elegans TGF-β Sma/Mad 
pathway type I receptor mutant, sma-6. The TGF-β pathway is involved in lipid 
metabolism.  After performing several paralysis assays I have developed a model to 
explain this neuronal phenotype of SMA-6 on valproate exposure where SMA-6 has a 
regulatory role on neurotransmission. This shows integration between metabolism and 






8.2.1 sma-6 mutants get paralysed by sodium valproate 
 
When we tested the TGF-β pathway mutants on valproate induced lipid accumulation, 
we saw that the TGF-β Sma/mad pathway type I receptor mutant, sma-6, gets paralysed 
by sodium valproate in a dose dependent manner (Figure 86). Similar to sma-6, unc-25 
the GABA mutant and unc-38 the acetylcholine receptor mutant also gets paralysed by 
sodium valproate in a dose dependent manner (Figure 87 and Figure 88). Because this 
indicates a novel neuronal function for sma-6, we performed several paralysis assays to 
confirm this finding.   
 
Figure 86 Paralysis of sma-6 mutant C.elegans by sodium valproate. sma-6 mutant get paralysed on exposure 































Figure 87 Paralysis of unc-38 mutant C.elegans by sodium valproate. The acetylcholine receptor mutant unc-
38 gets paralysed on exposure to valproate in a dose dependent manner.Error bars = ± SEM of four 





Figure 88Paralysis of unc-25 mutant C.elegans by sodium valproate. The GABA mutant unc-25 gets paralysed 




















































8.2.2 sma-6 has a neuronal phenotype 
 
To test whether sma-6 has a neuronal phenotype, we tested the sensitivity of a sma-6 
mutantto the acetylcholine esterase inhibitor, Aldicarb, and the acetylcholine receptor 
agonist, levamisole. Thesma-6mutantwas hypersensitive to both drugs (Figure 89 and 
Figure 90). Having shown that mutation ofsma-6can affect neuronal processes, we 
compared this hypersensitivity with mutants of both excitatory and inhibitory 
neurotransmission. Specifically, we compared sma-6 with the acetylcholine receptor 
mutant, unc-38 and the GABA defective mutant, unc-25. Our data show that sma-6 
resembles unc-25 more than unc-38. As expected unc-38, being a acetylcholine receptor 




Figure 89Sensitivity to the acetylcholine receptor agonist, Levamisole. Wild type (N2) and sma-6, unc-25, unc-





























GABA mutant unc-25 show hypersensitive to Levamisole. The acetylcholine receptor mutant, unc-38 is 





Figure 90Sensitivity to the acetylcholine esterase inhibitor, Aldicarb. Figure shows the paralysis of wild type 
(N2) and the GABA mutant unc-25, the acetylcholine receptor mutantunc-38 and TGF- β Sma/Mad pathway 
mutant sma-6on 1mM Aldicarb. Both sma-6 and unc-25 show hypersensitivity to Aldicarb but unc-38 is 
resistant to Aldicarb. Error bars = ± SEM of three independent trials. n=30 
 
 
8.2.3 sma-6 affects somatic nerve function and is post synaptic 
 
In C.elegans, the pharynx is anearly autonomous organ with its own neuronal system, 
muscles, and epithelium (Altun and Hall, 2011). After showing that valproate does 
cause paralysis on sma-6 mutant, we wanted to see whether this involves somatic or 
pharyngeal nervous system. To assess this,sma-6 mutant worms were exposed to 
valproate and observed under the microscope. Significantly paralysed worms retain 
pharyngeal pumping. The posterior region of worms showed early paralysis is which 

























striated body wall muscles may be involved in paralysis of sma-6 treated with valproate. 
Thereforesma-6 should be residing on the somatic nervous system or associated muscles 
to bring these neuronal effects. SMA-6 is expressed in dorsal and ventral hypodermis, 
pharyngeal muscle and the intestine (Altun and Hall, 2011). This shows that SMA-6 
could be acting post synaptically. The hypersensitivity shown by sma-6 mutants for the 
acetylcholine receptor agonist, levamisole, compared to the wild type further supports 
the idea that sma-6 could be post synaptic.  
 
8.2.4 Valproate cause hyperparalysis on sma-6 before causing death 
 
After showing that sma-6 has a neuronal phenotype, we wanted to clarify whether 
valproate cause paralysis of sma-6 mutants or whether it cause death without paralysis. 
Valproate treated sma-6 mutants died, which is confirmed by tissue degradation seen 
after 24hrs on staining for lipids (data not shown). Butsma-6 showed shortening of body 
length by ~50% on exposure to valproate (data not shown), which is a phenotype 
observed on hyperparalysis.  
 
8.2.5 Neuronal phenotype observed in sma-6 is a character of TGF-β type I 
receptors but not a feature of the TGF-β whole pathway or insulin signalling 
pathway 
 
After showing that valproate does cause paralysis of sma-6 mutants, I then tested 
whether this could be an attribute of the TGF-β pathway or associated insulin signalling 
pathway. To assess this, I tested the effect of valproate on TGF-β pathway mutants and 
insulin signalling pathway mutants. Specifically, I tested the effect of valproate 
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exposure on daf-1, the common type II receptor in TGF-β dauer and Sma/mad 
pathways. It did not show any paralysis (data not shown). After showing that this 
neuronal phenotype is not a feature of the TGF-β pathway, I then tested the effect of 
valproate on the daf-1, the type I receptor in TGF-β dauer pathway. Likesma-6, the 
TGF-β Sma/mad pathway type I receptor, daf-1 also showed paralysis (data not shown) 
indicating that this neuronal phenotype is a feature of type I receptors on TGF-β 
pathways. To identify whether this also involves insulin signalling pathway, I tested the 
effect of valproate exposure on insulin receptor mutant, daf-2. daf-2 did not show any 
paralysis on exposure to valproate (data not shown).   
 
 
8.2.6 Paralysis observed on sma-6 treated with valproate is via either cholinergic 
neurotransmission or GABAergic neurotransmission but not via other mechanism 
 
After confirming the hyperparalysis of sma-6mutant on valproate exposure, I then 
wanted to see whether this could be via different mechanisms other than a reduction in 
GABA inhibitory neurotransmission and activation of acetylcholine mediated excitatory 
neurotransmission. This was assessed by treating the GABA mutant, unc-25 with a 
saturating concentration of Aldicarb. This is done to bring the strongest possible 
paralysis that can be achieved by inhibiting GABA neurotransmission and activating the 
acetylcholine mediated excitatory neurotransmission simultaneously.  Valproate could 
not increase paralysis of sma-6treated with Aldicarb more than what is achieved in this 
unc-25 mutant. This shows that sma-6 could not increase the paralysis caused by the 
dual action of acetylcholine build-up and inhibition of GABAergic neurotransmission 
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confirming that sma-6 acts through one or both of these mechanisms but not some other 
mechanism(Figure 91).  
 
 
Figure 91The maximum paralysis obtained by simultaneous activation of excitatory cholinergic 
neurotransmission and inactivation of inhibitory GABAergic neurotransmission is similar to the paralysis 
obtained on activation of cholinergic neurotransmission in sma-6 treated with 15mM Sodium Valproate 
(VPA). GABA mutant unc-25 or TGF-β Sma/Mad pathway type I receptor mutant sma-6 were treated with 
the 1mM acetylcholine esterase inhibitor Aldicarb or 15mM Sodium Valproate or both. Error bars = ± SEM 




8.2.7 sma-6 mutant has inhibitory neurotransmission intact 
 
After showing that valproate cause paralysis of sma-6 either via inhibition of 
GABAergic neurotransmission or by increasing cholinergic neurotransmission, we then 
tested whether inhibitory neurotransmission is intact in sma-6. To test this I looked at 
the paralysis caused by Aldicarb on sma-6 and compared that with the paralysis caused 

























concentration of Aldicarb would bring the maximum effect of excitatory 
neurotransmission but the paralysis of sma-6 on Aldicarb was not as intense as the unc-
25 on Aldicarb supporting the hypothesis that inhibitory neurotransmission is intact in 
sma-6. Alsosma-6 shows hypersensitivity to levamisole than unc-25 and unc-25 shows 
hypersensitivity to Aldicarb than sma-6(Figure 92) further supporting the idea that sma-6 
may be acting via different mechanisms compared to unc-25. 
 
 
Figure 92sma-6 with 1mM Aldicarb show similar paralysis with unc-25 on levamisole. TGF-β Sma/Mad type I 
receptor mutant sma-6 shows highest paralysis on Levamisole when the GABA mutant unc-25 shows highest 
paralysis on Aldicarb. sma-6 on Aldicarb and unc-25 on Levamisole show similar paralysis. Error bars = ± 



























8.2.8 Evidence from microarray data that valproate affects both cholinergic and 
GABAergic neurotransmission 
 
After looking at the phenotypes and finding that valproate could be paralysing sma-6 
mutants by either increasing cholinergic neurotransmission or by decreasing 
GABAergic neurotransmission, I then looked at the expression profile of valproate 
exposure to see whether that would also support the same hypothesis. The expression 
profile positively correlated with valproate show that it would cause quick termination 
of action potentials but the negatively correlated expression profile shows that 
cholinergic neurotransmission is increased on exposure to valproate and GABAergic 
neurotransmission is diminished.  
 
8.2.9 Expression signature positively correlated tovalproate exposure on neuronal 
function 
 
There were several genes positively correlated with valproate, which are involved in 
neuronal function that shows it would cause a quick termination of action potential 
(Figure 93). These include eat-2 which codes for a ligand gated ion channel subunit 
closely related to nicotinic acetylcholine receptor that works post synaptically on 





exchangers positively correlated with valproate help to restore Ca
2+
 concentrations after 
an action potential. kqt-2 and twk-1 codes for K
+
 channels which help to restore resting 
membrane potential after an action potential. snf-8, snf-7, snf-10, snf-5 and snf-4code 
for members of sodium: neurotransmitter symporter family, which reuptake released 
neurotransmitters from the synaptic cleft. Up-regulation of these genes would result in 
the quick termination of action potentials. snb-5 and snb-2 codes for synaptobrevin 
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which is part of the SNARE complex that facilitates binding of vesicles to presynaptic 
membrane on exocytosis in neurotransmission.  
 
Figure 93Expression profile Positively correlated with valproate  on neuronal function. Numbers across top of 
heatmap indicates valproate concentration. The degree of expression  indicated with a red to green scale where 
the higher expression is given by red. 
 
 
8.2.10 Expression signature negatively correlated to valproate on neuronal 
function 
 
Several genes involved in neuronal function are down-regulated on exposure to 
valproate which shows an increase of cholinergic neurotransmission and decrease in 
GABAergic neurotransmission (Figure 94, page 238). lev-8 and acr-17 encode nAChR 
subunits. The protein coded by lev-8 is required for egg laying and muscle contraction. 
Expression of this protein is strongest in the anterior, consistent with increased 
levamisole resistance of head and anterior muscles of lev-8 mutants. ric-3 is  required 
for the maturation and function of four nicotinic acetylcholine receptor types. ace-3 and 
ace-1 encodes two of the four C.elegans’ acetylcholine esterases. This indicates that 
Alkaline ceramidase 
 


















exposure to valproate would decrease nicotinic acetylcholine receptors but increase 
acetylcholine level in the synaptic cleft.  
dgk-4 encodes a diacylglycerol kinase which converts DAG to phosphatidic acid. DAG 
binds to C1 domain of unc-13 which primes vesicle binding to presynaptic membrane 
by forming SNARE complex. Down regulation of dgk-4 would result in an enhanced 
synaptic transmission. unc-10 encodes a protein which is probably involved in the 
priming of presynaptic vesicles.  
unc-30 encodes a transcription factor which controls terminal differentiation of all 19 
type D-GABA-ergic motor neurones by directly regulating the expression of unc-25 
which codes for GAD which synthesises GABA and unc-47 , which codes for VGAT, 
the protein which loads GABA into synaptic vesicles. Therefore valproate is expected to 
decrease GABA inhibitory neurotransmission.  
 
8.2.11 Expression profiling suggests a decrease in dopaminergic and serotonergic 
neurotransmission on exposure to valproate 
 
After showing that valproate affects cholinergic neurotransmission and GABAergic 
neurotransmission, I then assessed its effects on other neurotransmitters. I found both 
serotonergic neurotransmission and dopaminergic neurotransmission to be decreased as 
a result of valproate exposure.  
ast-1 encodes a transcription factor which is required for maintenance of dopamine 
neuronal fate. It positively regulates the expression of several dopamine neuron specific 
genes such as dat-1 and cat-2 which encodes dopamine transporter and tyrosine 
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hydroxylase respectively. This shows that exposure to valproate may decrease 
dopamine neurotransmission.  
unc-86 encodes a transcription factor that is required for fate determination and 
differentiation in diverse neuronal lineages and is also required for the expression of 
tph-1 and cat-1 in seretonergic neurones. TPH-1 catalyzes the rate limiting step of 
serotonin biosynthesis and interacts with TGF-β and insulin like signalling pathways. 
cat-1 codes for a synaptic vesicular monoamine transporter that is required for the 
presence of serotonin and dopamine in nerve terminals. Therefore in addition to 
dopamine neurotransmission, serotonergic neurotransmission is also expected to 
decrease on valproate exposure.  
 
 
Figure 94 Down-regulated expression profile of valproate exposure on neuronal function. Numbers across top 
of heatmap indicates valproate concentration. The degree of expression  indicated with a red to green scale 





Priming of presynaptic  vesicles 
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8.2.12 Sodium valproate acts on both cholinergic and GABAergic 
neurotransmission 
 
After showing that valproate exposure profile also suggest a down regulation of 
GABAergic neurotransmission and an increase in cholinergic neurotransmission, we 
then checked whether that could explain the observed paralysis phenotypes on exposure 
to valproate.  
Sodium valproate can increase paralysis observed in wild type C.elegans treated with 
saturation concentration of Aldicarb(Figure 95, page 240). Therefore, sodium valproate 
should be causing paralysis in a different mechanism other than, or in addition to, 
paralysis by build-up of acetylcholine in the synaptic cleft. The paralysis caused by 
treatment of wild type with Aldicarb and sodium valproate is similar to the paralysis 
observed on unc-25 treated with Aldicarb. Therefore, valproate may be acting similar to 
unc-25 mutation by inhibiting GABAergic neurotransmission. Sodium Valproate does 
not increase paralysis of unc-25 by Aldicarb further and this could be explained by the 
fact that acetylcholine esterase is fully inhibited by the saturation concentration of 
Aldicarb and inhibitory effect of GABA is relieved by unc-25 mutation. This shows that 
valproate causes paralysis via either or both of these two mechanisms. Therefore, 
increase of paralysis of untreated unc-25 mutant by sodium valproate should be due to 
build-up of acetylcholine in the synaptic cleft. Also the increased paralysis of Aldicarb 
treated wild type by sodium valproate should be due to inhibition of GABA mediated 
inhibitory neurotransmission. Aldicarb is more potent than sodium valproate on 
paralysing unc-25.  
Wild type C.elegans does not get paralysed by sodium valproate. nAchR mutant unc-38 
is also resistant to Aldicarb but treatment of Aldicarb treated unc-38 with sodium 
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valproate causes paralysis (Figure 96). The paralysis of unc-38 with and without 
Aldicarb treatment could be explained by decrease of GABA mediated 
neurotransmission by sodium valproate. Wild type C.elegans may be resistant to 
valproate effect on decrease of GABA because its acetylcholine mediated excitatory 
neurotransmission is intact.  
 
 
Figure 95 Synergistic effect of Valproate on Aldicarb seen in wild type C.elegans but not in unc-25 mutant. 
Wild type (N2) or unc-25 mutants were treated with 1mM Aldicarb or 15mM Sodium Valproate (VPA) or 




























Figure 96Sodium valproate has a positive synergistic effect with Aldicarb on unc-38 mutant. Acetylcholine 
receptor mutant unc-38 were treated with either 1mM Aldicarb or 15mM Sodium Valproate (VPA) or both. 




8.2. 13 SMA-6 has a regulatory role in excitatory neurotransmission 
 
After showing that sma-6 has a neuronal phenotype and sma-6 is post synaptic, I then 
tried to develop a model which could explain the observed phenotypes. I hypothesise 
that the function of SMA-6 would be to inactivate acetylcholine bound receptor.  
sma-6mutant is hypersensitive to both Aldicarb and levamisole (Figure 97, page 242) 
SMA-6 is a membrane protein (Greer et al., 2008) and considering the tissues it is 
expressed in it is found to be postsynaptic as explained earlier. sma-6 mutant is more 
sensitive to levamisole than to Aldicarb when compared with unc-25 mutant, which is 
more sensitive to Aldicarb than to levamisole. Treatment with levamisole  as well as 
Aldicarb causes paralysis by activating acetylcholine receptor. The only difference is 
























to reverse the acetylcholine bound receptor back to normal. But there will be no 
mechanism to convert levamisole bound receptor back to the original state. If it is 
something to do with the muscle after receptor, both should have the mechanisms to 
convert back to the original state in equal level. Therefore, the only possible thing that 
can cause paralysis more intensely in sma-6 treated with levamisole is the inability of 
the receptor to convert back to its "unbound" original state. Therefore sma-6 should be 
coding for something that facilitates conversion of acetylcholine bound receptor back to 
the original state. Considering the location of SMA-6 and its kinase activity the most 
probable model is that SMA-6 inactivates acetylcholine bound receptor. Therefore lack 
of SMA-6 would make the nematode hypersensitive to both Aldicarb and levamisole 
but will be more prone to levamisole induced paralysis. sma-6 mutant without any 
treatment may not show any paralysis due to the presence of other mechanisms such as 
the presence of choline esterase to inactivate acetylcholine.   
 
Figure 97sma-6 mutant is hypersensitive to both Aldicarb and Levamisole. Wild type (N2) or TGF-β Sma/Mad 
pathway mutant sma-6were treated with either 100µM acetylcholine receptor agonist Levamisole or the 1mM 


























In The present study, I looked at the paralysis of TGF-β Sma/Mad pathway type I 
receptor mutant sma-6by Sodium Valproate. The paralysis assays performed goes in 
line with a novel neuronal function for SMA-6 where SMA-6 acts post synaptically to 
inactivate acetylcholine bound receptor probably via phosphorylation.  
Valproate does not paralyse wildtype C.elegans but it does paralyse sma-6 mutant. sma-
6 null mutant wk-7 is nicotine hypersensitive (Almedom et al., 2009) and Almedom et 
al have suggested this to be due to a cuticle defect considering the short time taken for 
paralysis.  But my results suggest it to have a neuronal function. This is confirmed by 
the finding that sma-6 is hypersensitive to the acetylcholine receptor agonist levamisole  
and acetylcholine esterase inhibitor Aldicarb.  
SMA-6 has not co-purified with nicotinic acetylcholine receptor extracts (Gottschalk et 
al., 2005). A membrane component is shown to cause aggregation of acetylcholine 
receptors and acetylcholine esterase (Wallace et al., 1985). This suggest that SMA-6 
may not be directly associated with acetylcholine receptor or acetylcholine esterase. But 
it may fascilitate this aggregation probably via phosphorylation to inactivate activated 
acetylcholine receptor (Figure 98, page 244).sma-6 mutants and wild type C.elegans 
treated with sodium valproate show sinusoidal movement of the body on locomotion. 
sma-6 mutants treated with Sodium Valproate gets shortened indicating a contraction of 
muscles of both sides of the body, an observation also made in animals lacking D-type 
neurones which release GABA. Like sma-6 mutants, these nematodes lacking D-type 
neurones also show sinusoidal body movement(Jorgensen, 2005). This also goes in line 
with the hypothesis that SMA-6 has an inhibitory effect on excitatory 
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neurotransmission.SMA-6 is a membrane protein with kinase activity. DBL-1, the 
ligand of TGF-β Sma/Mad pathway is secreted from cholinergic neurones (Duerr et al., 
2008). Hypersensitivity of muscle cells to levamisole and Aldicarb is caused by 
mutations which increase acetylcholine secretion or decrease inhibitory GABAergic 
synaptic signalling (Gumienny and Savage-Dunn, 2013). Loss of  the ligand of SMA-6, 
DBL-1 cause defects in pre and post GABAergic synapses indicating that this 
hypersensitivity is due to a defect in GABAergic neurotransmission (Vashlishan et al., 
2008). Therefore, the hypersensitivity of sma-6 mutants for these drugs also could be 
attributed to a defect in GABAergic neurotransmission or some other inhibitory 
neurotransmission effect.  GABA also serves a metabolic role in the citric acid 
cycle(Jorgensen, 2005) and these findings suggest SMA-6 to be a key link between 
neuronal regulation and metabolism. 
 
Figure 98 Diagram showing the possible mechanisms of SMA-6 neuronal function in the neuromuscular 
junction. SMA-6 acts post synaptically and inactivate acetylcholine receptor which is bound to its ligand. This 
could be either via phosphorylation of activated acetylcholine receptor or by fascilitation of aggregation of 
acetylcholine esterase to activated acetylcholine receptor. 
 
To explain the paralysis of sma-6 on Sodium Valproate, I looked at the expression 
profile of C.elegans on valproate exposure. Sodium valproate increase Acetylcholine 
level in synaptic cleft by decreasing transcription of Acetyclcholine Esterases. It also 
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decreases GABA inhibitory neurotransmission by acting on unc-30.  Valproate could 
induce the paralysis of sma-6 mutants due to inability to decrease cholinergic 





















There is a marked decrease in nuclear components on valproate exposure probably via 
vab-3. In addition, valproate increases lipid in a dose dependent manner up to 15mM. 
Plateau effect seen in dose response of lipid accumulation suggests valproate to induce 
lipid accumulation via a receptor mediated pathway where saturation leads to the 
plateau effect.  Transcription profile following valproate exposure suggest itaffects both 
lipid synthesis and degradation pathways. Valproate induced lipid accumulation is 
found to be partially dependent on DAF-16, DAF-2  and TGF-β Sma/Mab pathways.  
Valproate may decrease lipid accumulation by increasing β-oxidation of fatty acids.  
But It may increase cholesterol and other steroid synthesis, glycosphingolipid, 
glycophospholipids and phosphatidylcholine biosynthesis resulting in an overall 
accumulation of lipids.  
DAF-16 dependent expression profile of valproate  exposure  is expected to be involved 
in steroid synthesis, fatty acid elongation, prostaglandin D synthesis, fatty acid uptake 
and acylated ethanol amine production. It is also expected to increase insulin secretion 
by decreasing the expression of  bbs-5 resulting in lipid synthesis.  These genes are 
down regulated in thedaf-16 mutant resulting in an inhibitor effect by DAF-16 on lipid 
accumulation by valproate exposure. Therefore, the plateau effect of lipid mass on high 
valproate exposure could be due to the over expression of daf-16. Therefore, valproate 
induced lipid accumulation is partially dependent on DAF-16.  It also reveals 
prostaglandin synthesis to be positively correlated with valproate and phosphatidate 
formation to be negatively correlated with valproate in a DAF-2 dependent manner. 
TGF-β Sma/Mab pathway may be responsible for the glycerophospholipid synthesis.  
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Decrease of lipid mass by valproate in daf-2 and sma-6 mutants could be due to a 
decrease in prostaglandin synthesis and glycerophospholipid synthesis respectively.  
During the phenotypic analysis to see whether sma-6 plays a role in valproate induced 
lipid accumulation, I found valproate to cause paralysis of sma-6 mutants. In the last 
chapter, I have developed a model to explain this neuronal function and suggest a model 
in whichsma-6 may act postsynaptically to inhibit acetylcholine receptors, which could 




















10.0 FUTURE WORK 
 
During this study I have performed phenotypic analysis and expression profiling to 
develop several hypothesis to explain the valproate induced lipid accumulation and 
paralysis of sma-6 mutants. These hypotheses now need to be tested experimentally. For 
example, in a future study the expression profile of thevab-3 mutant on exposure to 
valproate could be compared with the negatively correlated expression profile of wild 
type C.elegans following valproate exposure to confirm the role played by vab-3 in 
down-regulating nuclear components on valproate exposure. Also, lipid profiling of 
mutants of the insulin signalling pathway and TGF-β pathway, as well as wild type on 
valproate exposure would confirm the predictions made on insulin dependent and 
independent components of valproate induced lipid accumulation of valproate exposure. 
Solvent extraction of lipids followed by assaying for different lipid types would confirm 
how valproate affects the levels of different lipid types. This could be done by assaying 
a given number of age-synchronized worms on valproate plates. Biosynthesis of lipid 





P on valproate plates could be use to study phospholipid synthesis. 
Profiling lipids and fatty acids in human blood could test applicability of these findings 
to human. Characterization of proteins that are phosphorylated by SMA-6 would 
support the hypothesis developed for the neuronal phenotype of SMA-6. Separating 
proteins of sma-6 mutants followed by analysis of phosphorylation by Mass 
Spectrometry and comparing with the wild type could do this. Also proteins that interact 
with SMA-6 should be identified. Determination of structure of the wild type and 
mutant acetylcholine receptor in wild type and sma-6 mutant would reveal any 
molecular changes, which would be predicted if the given hypothesis is valid. Since 
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sma-6 mutants show a paralysis phenotype on exposure to valproate, any toxic effect of 
valproate on the people mutant for sma-6 homologue, born morphogenic protein, should 
be tested. 
In addition to these, repeat of the lipid assay tests by performing a different assay for 
lipid quantification such as Oil RedO method or Sudan Black assay would validate the 
results. Microarray data too could validate by performing QPCR for a selected number 
of genes. 
In addition to these findings, I also found that MSG and exercise decrease lipid level.  
When the interaction between exercise and MSG was studied, it is found that exercise 
could further decrease the lipid level decreased due to MSG.  It is possible to find 
whether MSG and exercise decrease lipid level via the same or different mechanisms by 
identifying the highest MSG concentration that would bring the minimum lipid level 
and letting those worms exercise to see whether it could further decrease the lipid level. 
If exercise can further decrease the lipid level, that indicates that exercise and MSG act 
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